id	sid	tid	token	lemma	pos
admet-352	1	1	manuscript	manuscript	PROPN
admet-352	1	2	doi	doi	PROPN
admet-352	1	3	:	:	PUNCT
admet-352	1	4	10.5599	10.5599	NUM
admet-352	1	5	/	/	SYM
admet-352	1	6	admet.5.1.352	admet.5.1.352	PROPN
admet-352	1	7	1	1	NUM
admet-352	1	8	admet	admet	X
admet-352	1	9	&	&	CCONJ
admet-352	1	10	dmpk	dmpk	PROPN
admet-352	1	11	5(1	5(1	NUM
admet-352	1	12	)	)	PUNCT
admet-352	1	13	(	(	PUNCT
admet-352	1	14	2017	2017	NUM
admet-352	1	15	)	)	PUNCT
admet-352	1	16	1	1	NUM
admet-352	1	17	-	-	SYM
admet-352	1	18	8	8	NUM
admet-352	1	19	;	;	PUNCT
admet-352	1	20	doi	doi	NOUN
admet-352	1	21	:	:	PUNCT
admet-352	1	22	10.5599	10.5599	NUM
admet-352	1	23	/	/	SYM
admet-352	1	24	admet.5.1.352	admet.5.1.352	NOUN
admet-352	1	25	open	open	ADJ
admet-352	1	26	access	access	NOUN
admet-352	1	27	:	:	PUNCT
admet-352	1	28	issn	issn	PROPN
admet-352	1	29	:	:	PUNCT
admet-352	1	30	1848	1848	NUM
admet-352	1	31	-	-	SYM
admet-352	1	32	7718	7718	NUM
admet-352	1	33	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-352	1	34	mini	mini	NOUN
admet-352	1	35	review	review	NOUN
admet-352	1	36	tyrosine	tyrosine	NOUN
admet-352	1	37	kinase	kinase	PROPN
admet-352	1	38	inhibitors	inhibitor	NOUN
admet-352	1	39	:	:	PUNCT
admet-352	1	40	new	new	ADJ
admet-352	1	41	molecules	molecule	NOUN
admet-352	1	42	in	in	ADP
admet-352	1	43	non	non	ADJ
admet-352	1	44	-	-	ADJ
admet-352	1	45	small	small	ADJ
admet-352	1	46	cell	cell	NOUN
admet-352	1	47	lung	lung	NOUN
admet-352	1	48	cancer	cancer	NOUN
admet-352	1	49	(	(	PUNCT
admet-352	1	50	egfr	egfr	NOUN
admet-352	1	51	and	and	CCONJ
admet-352	1	52	alk	alk	PROPN
admet-352	1	53	)	)	PUNCT
admet-352	1	54	fernando	fernando	PROPN
admet-352	1	55	franco	franco	PROPN
admet-352	1	56	,	,	PUNCT
admet-352	1	57	míriam	míriam	PROPN
admet-352	1	58	méndez	méndez	PROPN
admet-352	1	59	*	*	PROPN
admet-352	1	60	,	,	PUNCT
admet-352	1	61	lourdes	lourdes	PROPN
admet-352	1	62	gutierrez	gutierrez	PROPN
admet-352	1	63	,	,	PUNCT
admet-352	1	64	mariano	mariano	PROPN
admet-352	1	65	provencio	provencio	PROPN
admet-352	1	66	puerta	puerta	PROPN
admet-352	1	67	de	de	PROPN
admet-352	1	68	hierro	hierro	PROPN
admet-352	1	69	universitary	universitary	ADJ
admet-352	1	70	hospital	hospital	NOUN
admet-352	1	71	,	,	PUNCT
admet-352	1	72	madrid	madrid	PROPN
admet-352	1	73	,	,	PUNCT
admet-352	1	74	spain	spain	PROPN
admet-352	1	75	*	*	PUNCT
admet-352	1	76	corresponding	correspond	VERB
admet-352	1	77	author	author	NOUN
admet-352	1	78	:	:	PUNCT
admet-352	1	79	e	e	NOUN
admet-352	1	80	-	-	NOUN
admet-352	1	81	mail	mail	NOUN
admet-352	1	82	:	:	PUNCT
admet-352	2	1	mirimega@hotmail.com	mirimega@hotmail.com	X
admet-352	2	2	.	.	PROPN
admet-352	2	3	received	receive	VERB
admet-352	2	4	:	:	PUNCT
admet-352	2	5	october	october	PROPN
admet-352	2	6	25	25	NUM
admet-352	2	7	,	,	PUNCT
admet-352	2	8	2016	2016	NUM
admet-352	2	9	;	;	PUNCT
admet-352	2	10	revised	revise	VERB
admet-352	2	11	:	:	PUNCT
admet-352	2	12	february	february	PROPN
admet-352	2	13	22	22	NUM
admet-352	2	14	,	,	PUNCT
admet-352	2	15	2017	2017	NUM
admet-352	2	16	;	;	PUNCT
admet-352	2	17	published	publish	VERB
admet-352	2	18	:	:	PUNCT
admet-352	2	19	march	march	PROPN
admet-352	2	20	25	25	NUM
admet-352	2	21	,	,	PUNCT
admet-352	2	22	2017	2017	NUM
admet-352	2	23	abstract	abstract	ADJ
admet-352	2	24	lung	lung	NOUN
admet-352	2	25	cancer	cancer	NOUN
admet-352	2	26	is	be	AUX
admet-352	2	27	a	a	DET
admet-352	2	28	tumor	tumor	NOUN
admet-352	2	29	pathology	pathology	NOUN
admet-352	2	30	that	that	PRON
admet-352	2	31	includes	include	VERB
admet-352	2	32	a	a	DET
admet-352	2	33	group	group	NOUN
admet-352	2	34	of	of	ADP
admet-352	2	35	neoplasms	neoplasm	NOUN
admet-352	2	36	with	with	ADP
admet-352	2	37	different	different	ADJ
admet-352	2	38	biological	biological	ADJ
admet-352	2	39	characteristics	characteristic	NOUN
admet-352	2	40	,	,	PUNCT
admet-352	2	41	which	which	PRON
admet-352	2	42	determine	determine	VERB
admet-352	2	43	the	the	DET
admet-352	2	44	course	course	NOUN
admet-352	2	45	of	of	ADP
admet-352	2	46	the	the	DET
admet-352	2	47	disease	disease	NOUN
admet-352	2	48	and	and	CCONJ
admet-352	2	49	the	the	DET
admet-352	2	50	potential	potential	ADJ
admet-352	2	51	treatment	treatment	NOUN
admet-352	2	52	response	response	NOUN
admet-352	2	53	depending	depend	VERB
admet-352	2	54	on	on	ADP
admet-352	2	55	the	the	DET
admet-352	2	56	subtype	subtype	NOUN
admet-352	2	57	diagnosed	diagnose	VERB
admet-352	2	58	.	.	PUNCT
admet-352	3	1	non	non	ADJ
admet-352	3	2	-	-	ADJ
admet-352	3	3	small	small	ADJ
admet-352	3	4	lung	lung	NOUN
admet-352	3	5	carcinoma	carcinoma	NOUN
admet-352	3	6	corresponds	correspond	VERB
admet-352	3	7	to	to	ADP
admet-352	3	8	85	85	NUM
admet-352	3	9	%	%	NOUN
admet-352	3	10	of	of	ADP
admet-352	3	11	all	all	DET
admet-352	3	12	lung	lung	NOUN
admet-352	3	13	cancers	cancer	NOUN
admet-352	3	14	.	.	PUNCT
admet-352	4	1	adenocarcinoma	adenocarcinoma	NOUN
admet-352	4	2	is	be	AUX
admet-352	4	3	the	the	DET
admet-352	4	4	most	most	ADV
admet-352	4	5	common	common	ADJ
admet-352	4	6	histologic	histologic	ADJ
admet-352	4	7	subtype	subtype	NOUN
admet-352	4	8	of	of	ADP
admet-352	4	9	this	this	DET
admet-352	4	10	group	group	NOUN
admet-352	4	11	.	.	PUNCT
admet-352	5	1	in	in	ADP
admet-352	5	2	the	the	DET
admet-352	5	3	united	united	PROPN
admet-352	5	4	states	states	PROPN
admet-352	5	5	approximately	approximately	ADV
admet-352	5	6	130,000	130,000	NUM
admet-352	5	7	new	new	ADJ
admet-352	5	8	cases	case	NOUN
admet-352	5	9	a	a	DET
admet-352	5	10	year	year	NOUN
admet-352	5	11	are	be	AUX
admet-352	5	12	diagnosed	diagnose	VERB
admet-352	5	13	and	and	CCONJ
admet-352	5	14	in	in	ADP
admet-352	5	15	the	the	DET
admet-352	5	16	world	world	NOUN
admet-352	5	17	around	around	ADP
admet-352	5	18	a	a	DET
admet-352	5	19	million	million	NUM
admet-352	5	20	.	.	PUNCT
admet-352	6	1	adenocarcinoma	adenocarcinoma	NOUN
admet-352	6	2	is	be	AUX
admet-352	6	3	the	the	DET
admet-352	6	4	most	most	ADV
admet-352	6	5	likely	likely	ADJ
admet-352	6	6	subtype	subtype	NOUN
admet-352	6	7	,	,	PUNCT
admet-352	6	8	with	with	ADP
admet-352	6	9	possible	possible	ADJ
admet-352	6	10	molecular	molecular	ADJ
admet-352	6	11	alterations	alteration	NOUN
admet-352	6	12	(	(	PUNCT
admet-352	6	13	egfr	egfr	ADJ
admet-352	6	14	mutations	mutation	NOUN
admet-352	6	15	and	and	CCONJ
admet-352	6	16	translocations	translocation	NOUN
admet-352	6	17	in	in	ADP
admet-352	6	18	alk	alk	PROPN
admet-352	6	19	)	)	PUNCT
admet-352	6	20	,	,	PUNCT
admet-352	6	21	which	which	PRON
admet-352	6	22	are	be	AUX
admet-352	6	23	a	a	DET
admet-352	6	24	therapeutic	therapeutic	ADJ
admet-352	6	25	target	target	NOUN
admet-352	6	26	.	.	PUNCT
admet-352	7	1	knowledge	knowledge	NOUN
admet-352	7	2	of	of	ADP
admet-352	7	3	the	the	DET
admet-352	7	4	molecular	molecular	ADJ
admet-352	7	5	profile	profile	NOUN
admet-352	7	6	of	of	ADP
admet-352	7	7	the	the	DET
admet-352	7	8	tumor	tumor	NOUN
admet-352	7	9	and	and	CCONJ
admet-352	7	10	its	its	PRON
admet-352	7	11	biology	biology	NOUN
admet-352	7	12	has	have	AUX
admet-352	7	13	led	lead	VERB
admet-352	7	14	us	we	PRON
admet-352	7	15	to	to	PART
admet-352	7	16	identify	identify	VERB
admet-352	7	17	therapeutic	therapeutic	ADJ
admet-352	7	18	targets	target	NOUN
admet-352	7	19	as	as	ADP
admet-352	7	20	protein	protein	NOUN
admet-352	7	21	tyrosine	tyrosine	NOUN
admet-352	7	22	kinase	kinase	PROPN
admet-352	7	23	,	,	PUNCT
admet-352	7	24	whose	whose	DET
admet-352	7	25	inhibition	inhibition	NOUN
admet-352	7	26	have	have	AUX
admet-352	7	27	demonstrated	demonstrate	VERB
admet-352	7	28	impact	impact	NOUN
admet-352	7	29	in	in	ADP
admet-352	7	30	terms	term	NOUN
admet-352	7	31	of	of	ADP
admet-352	7	32	survival	survival	NOUN
admet-352	7	33	and	and	CCONJ
admet-352	7	34	quality	quality	NOUN
admet-352	7	35	of	of	ADP
admet-352	7	36	life	life	NOUN
admet-352	7	37	for	for	ADP
admet-352	7	38	patients	patient	NOUN
admet-352	7	39	with	with	ADP
admet-352	7	40	these	these	DET
admet-352	7	41	molecular	molecular	ADJ
admet-352	7	42	alterations	alteration	NOUN
admet-352	7	43	.	.	PUNCT
admet-352	8	1	however	however	ADV
admet-352	8	2	,	,	PUNCT
admet-352	8	3	the	the	DET
admet-352	8	4	complex	complex	ADJ
admet-352	8	5	biology	biology	NOUN
admet-352	8	6	of	of	ADP
admet-352	8	7	non	non	ADJ
admet-352	8	8	-	-	ADJ
admet-352	8	9	small	small	ADJ
admet-352	8	10	cell	cell	NOUN
admet-352	8	11	lung	lung	NOUN
admet-352	8	12	carcinoma	carcinoma	NOUN
admet-352	8	13	gives	give	VERB
admet-352	8	14	the	the	DET
admet-352	8	15	malignant	malignant	ADJ
admet-352	8	16	cell	cell	NOUN
admet-352	8	17	the	the	DET
admet-352	8	18	ability	ability	NOUN
admet-352	8	19	to	to	PART
admet-352	8	20	generate	generate	VERB
admet-352	8	21	mechanisms	mechanism	NOUN
admet-352	8	22	of	of	ADP
admet-352	8	23	resistance	resistance	NOUN
admet-352	8	24	to	to	ADP
admet-352	8	25	these	these	DET
admet-352	8	26	drugs	drug	NOUN
admet-352	8	27	and	and	CCONJ
admet-352	8	28	has	have	AUX
admet-352	8	29	forced	force	VERB
admet-352	8	30	us	we	PRON
admet-352	8	31	to	to	PART
admet-352	8	32	extend	extend	VERB
admet-352	8	33	the	the	DET
admet-352	8	34	studies	study	NOUN
admet-352	8	35	to	to	PART
admet-352	8	36	control	control	VERB
admet-352	8	37	the	the	DET
admet-352	8	38	disease	disease	NOUN
admet-352	8	39	by	by	ADP
admet-352	8	40	blocking	block	VERB
admet-352	8	41	these	these	DET
admet-352	8	42	mechanisms	mechanism	NOUN
admet-352	8	43	.	.	PUNCT
admet-352	9	1	keywords	keyword	VERB
admet-352	9	2	lung	lung	NOUN
admet-352	9	3	cancer	cancer	NOUN
admet-352	9	4	;	;	PUNCT
admet-352	9	5	egfr	egfr	ADJ
admet-352	9	6	inhibitors	inhibitor	NOUN
admet-352	9	7	,	,	PUNCT
admet-352	9	8	alk	alk	VERB
admet-352	9	9	inhibitors	inhibitor	NOUN
admet-352	9	10	introduction	introduction	NOUN
admet-352	9	11	non	non	ADJ
admet-352	9	12	-	-	ADJ
admet-352	9	13	small	small	ADJ
admet-352	9	14	lung	lung	NOUN
admet-352	9	15	carcinoma	carcinoma	NOUN
admet-352	9	16	corresponds	correspond	VERB
admet-352	9	17	to	to	ADP
admet-352	9	18	85	85	NUM
admet-352	9	19	%	%	NOUN
admet-352	9	20	of	of	ADP
admet-352	9	21	lung	lung	NOUN
admet-352	9	22	cancers	cancer	NOUN
admet-352	9	23	.	.	PUNCT
admet-352	10	1	adenocarcinoma	adenocarcinoma	NOUN
admet-352	10	2	is	be	AUX
admet-352	10	3	the	the	DET
admet-352	10	4	most	most	ADV
admet-352	10	5	common	common	ADJ
admet-352	10	6	histologic	histologic	ADJ
admet-352	10	7	subtype	subtype	NOUN
admet-352	10	8	.	.	PUNCT
admet-352	11	1	in	in	ADP
admet-352	11	2	the	the	DET
admet-352	11	3	united	united	PROPN
admet-352	11	4	states	states	PROPN
admet-352	11	5	approximately	approximately	ADV
admet-352	11	6	130,000	130,000	NUM
admet-352	11	7	new	new	ADJ
admet-352	11	8	cases	case	NOUN
admet-352	11	9	are	be	AUX
admet-352	11	10	reported	report	VERB
admet-352	11	11	per	per	ADP
admet-352	11	12	year	year	NOUN
admet-352	11	13	[	[	X
admet-352	11	14	1	1	NUM
admet-352	11	15	]	]	PUNCT
admet-352	11	16	.	.	PUNCT
admet-352	12	1	patients	patient	NOUN
admet-352	12	2	with	with	ADP
admet-352	12	3	advanced	advanced	ADJ
admet-352	12	4	non	non	ADJ
admet-352	12	5	-	-	ADJ
admet-352	12	6	small	small	ADJ
admet-352	12	7	cell	cell	NOUN
admet-352	12	8	lung	lung	NOUN
admet-352	12	9	cancer	cancer	NOUN
admet-352	12	10	(	(	PUNCT
admet-352	12	11	nsclc	nsclc	NOUN
admet-352	12	12	)	)	PUNCT
admet-352	12	13	usually	usually	ADV
admet-352	12	14	receive	receive	VERB
admet-352	12	15	systemic	systemic	ADJ
admet-352	12	16	therapy	therapy	NOUN
admet-352	12	17	.	.	PUNCT
admet-352	13	1	after	after	ADP
admet-352	13	2	histopathological	histopathological	ADJ
admet-352	13	3	diagnosis	diagnosis	NOUN
admet-352	13	4	,	,	PUNCT
admet-352	13	5	an	an	DET
admet-352	13	6	extensive	extensive	ADJ
admet-352	13	7	molecular	molecular	ADJ
admet-352	13	8	study	study	NOUN
admet-352	13	9	is	be	AUX
admet-352	13	10	required	require	VERB
admet-352	13	11	to	to	PART
admet-352	13	12	characterize	characterize	VERB
admet-352	13	13	the	the	DET
admet-352	13	14	tumor	tumor	NOUN
admet-352	13	15	.	.	PUNCT
admet-352	14	1	regardless	regardless	ADV
admet-352	14	2	of	of	ADP
admet-352	14	3	the	the	DET
admet-352	14	4	clinical	clinical	ADJ
admet-352	14	5	characteristics	characteristic	NOUN
admet-352	14	6	of	of	ADP
admet-352	14	7	the	the	DET
admet-352	14	8	patient	patient	NOUN
admet-352	14	9	,	,	PUNCT
admet-352	14	10	at	at	ADP
admet-352	14	11	least	least	ADJ
admet-352	14	12	the	the	DET
admet-352	14	13	mutational	mutational	ADJ
admet-352	14	14	status	status	NOUN
admet-352	14	15	of	of	ADP
admet-352	14	16	the	the	DET
admet-352	14	17	epidermal	epidermal	ADJ
admet-352	14	18	growth	growth	NOUN
admet-352	14	19	factor	factor	NOUN
admet-352	14	20	receptor	receptor	NOUN
admet-352	14	21	(	(	PUNCT
admet-352	14	22	egfr	egfr	X
admet-352	14	23	)	)	PUNCT
admet-352	14	24	and	and	CCONJ
admet-352	14	25	alk	alk	VERB
admet-352	14	26	should	should	AUX
admet-352	14	27	be	be	AUX
admet-352	14	28	analyzed	analyze	VERB
admet-352	14	29	[	[	PUNCT
admet-352	14	30	2	2	NUM
admet-352	14	31	-	-	SYM
admet-352	14	32	4	4	NUM
admet-352	14	33	]	]	PUNCT
admet-352	14	34	.	.	PUNCT
admet-352	15	1	activating	activate	VERB
admet-352	15	2	mutations	mutation	NOUN
admet-352	15	3	in	in	ADP
admet-352	15	4	egfr	egfr	ADJ
admet-352	15	5	tyrosine	tyrosine	PROPN
admet-352	15	6	kinase	kinase	PROPN
admet-352	15	7	are	be	AUX
admet-352	15	8	observed	observe	VERB
admet-352	15	9	in	in	ADP
admet-352	15	10	approximately	approximately	ADV
admet-352	15	11	15	15	NUM
admet-352	15	12	percent	percent	NOUN
admet-352	15	13	of	of	ADP
admet-352	15	14	nsclc	nsclc	NOUN
admet-352	15	15	adenocarcinoma	adenocarcinoma	NOUN
admet-352	15	16	in	in	ADP
admet-352	15	17	the	the	DET
admet-352	15	18	united	united	PROPN
admet-352	15	19	states	states	PROPN
admet-352	15	20	and	and	CCONJ
admet-352	15	21	occur	occur	VERB
admet-352	15	22	more	more	ADV
admet-352	15	23	frequently	frequently	ADV
admet-352	15	24	in	in	ADP
admet-352	15	25	nonsmokers	nonsmoker	NOUN
admet-352	15	26	[	[	X
admet-352	15	27	5	5	NUM
admet-352	15	28	]	]	PUNCT
admet-352	15	29	.	.	PUNCT
admet-352	16	1	in	in	ADP
admet-352	16	2	asian	asian	ADJ
admet-352	16	3	populations	population	NOUN
admet-352	16	4	,	,	PUNCT
admet-352	16	5	the	the	DET
admet-352	16	6	incidence	incidence	NOUN
admet-352	16	7	of	of	ADP
admet-352	16	8	these	these	DET
admet-352	16	9	egfr	egfr	ADJ
admet-352	16	10	mutations	mutation	NOUN
admet-352	16	11	is	be	AUX
admet-352	16	12	substantially	substantially	ADV
admet-352	16	13	higher	high	ADJ
admet-352	16	14	,	,	PUNCT
admet-352	16	15	up	up	ADP
admet-352	16	16	to	to	PART
admet-352	16	17	62	62	NUM
admet-352	16	18	percent	percent	NOUN
admet-352	16	19	[	[	X
admet-352	16	20	6	6	NUM
admet-352	16	21	]	]	PUNCT
admet-352	16	22	.	.	PUNCT
admet-352	17	1	in	in	ADP
admet-352	17	2	unselected	unselected	ADJ
admet-352	17	3	nsclc	nsclc	NOUN
admet-352	17	4	populations	population	NOUN
admet-352	17	5	,	,	PUNCT
admet-352	17	6	the	the	DET
admet-352	17	7	alk	alk	NOUN
admet-352	17	8	rearrangement	rearrangement	NOUN
admet-352	17	9	is	be	AUX
admet-352	17	10	a	a	DET
admet-352	17	11	relatively	relatively	ADV
admet-352	17	12	rare	rare	ADJ
admet-352	17	13	event	event	NOUN
admet-352	17	14	.	.	PUNCT
admet-352	18	1	the	the	DET
admet-352	18	2	overall	overall	ADJ
admet-352	18	3	incidence	incidence	NOUN
admet-352	18	4	of	of	ADP
admet-352	18	5	alk	alk	NOUN
admet-352	18	6	gene	gene	NOUN
admet-352	18	7	rearrangements	rearrangement	NOUN
admet-352	18	8	has	have	AUX
admet-352	18	9	been	be	AUX
admet-352	18	10	about	about	ADV
admet-352	18	11	4	4	NUM
admet-352	18	12	percent	percent	NOUN
admet-352	18	13	.	.	PUNCT
admet-352	19	1	the	the	DET
admet-352	19	2	presence	presence	NOUN
admet-352	19	3	of	of	ADP
admet-352	19	4	alk	alk	NOUN
admet-352	19	5	gene	gene	NOUN
admet-352	19	6	rearrangements	rearrangement	NOUN
admet-352	19	7	in	in	ADP
admet-352	19	8	nsclc	nsclc	NOUN
admet-352	19	9	tumors	tumor	NOUN
admet-352	19	10	tends	tend	VERB
admet-352	19	11	to	to	PART
admet-352	19	12	occur	occur	VERB
admet-352	19	13	independently	independently	ADV
admet-352	19	14	of	of	ADP
admet-352	19	15	egfr	egfr	ADJ
admet-352	19	16	mutations	mutation	NOUN
admet-352	19	17	.	.	PUNCT
admet-352	20	1	similar	similar	ADJ
admet-352	20	2	frequencies	frequency	NOUN
admet-352	20	3	of	of	ADP
admet-352	20	4	alk	alk	NOUN
admet-352	20	5	gene	gene	NOUN
admet-352	20	6	rearrangements	rearrangement	NOUN
admet-352	20	7	have	have	AUX
admet-352	20	8	been	be	AUX
admet-352	20	9	reported	report	VERB
admet-352	20	10	in	in	ADP
admet-352	20	11	asian	asian	ADJ
admet-352	20	12	and	and	CCONJ
admet-352	20	13	western	western	ADJ
admet-352	20	14	populations	population	NOUN
admet-352	20	15	.	.	PUNCT
admet-352	21	1	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	PROPN
admet-352	21	2	m.	m.	PROPN
admet-352	21	3	mendez	mendez	PROPN
admet-352	21	4	et	et	PROPN
admet-352	21	5	al	al	PROPN
admet-352	21	6	.	.	PROPN
admet-352	21	7	admet	admet	PROPN
admet-352	21	8	&	&	CCONJ
admet-352	21	9	dmpk	dmpk	PROPN
admet-352	21	10	5(1	5(1	NUM
admet-352	21	11	)	)	PUNCT
admet-352	21	12	(	(	PUNCT
admet-352	21	13	2017	2017	NUM
admet-352	21	14	)	)	PUNCT
admet-352	21	15	1	1	NUM
admet-352	21	16	-	-	SYM
admet-352	21	17	8	8	NUM
admet-352	21	18	2	2	NUM
admet-352	21	19	egfr	egfr	NOUN
admet-352	21	20	inhibitors	inhibitor	NOUN
admet-352	21	21	first	first	ADV
admet-352	21	22	and	and	CCONJ
admet-352	21	23	second	second	ADJ
admet-352	21	24	generation	generation	NOUN
admet-352	21	25	of	of	ADP
admet-352	21	26	egfr	egfr	ADJ
admet-352	21	27	inhibitors	inhibitor	NOUN
admet-352	21	28	patients	patient	NOUN
admet-352	21	29	with	with	ADP
admet-352	21	30	molecular	molecular	ADJ
admet-352	21	31	alterations	alteration	NOUN
admet-352	21	32	constitute	constitute	VERB
admet-352	21	33	a	a	DET
admet-352	21	34	subpopulation	subpopulation	NOUN
admet-352	21	35	with	with	ADP
admet-352	21	36	clinical	clinical	ADJ
admet-352	21	37	characteristics	characteristic	NOUN
admet-352	21	38	,	,	PUNCT
admet-352	21	39	prognosis	prognosis	NOUN
admet-352	21	40	and	and	CCONJ
admet-352	21	41	response	response	NOUN
admet-352	21	42	to	to	ADP
admet-352	21	43	different	different	ADJ
admet-352	21	44	treatment	treatment	NOUN
admet-352	21	45	(	(	PUNCT
admet-352	21	46	chemotherapy	chemotherapy	NOUN
admet-352	21	47	vs	vs	ADP
admet-352	21	48	tyrosine	tyrosine	NOUN
admet-352	21	49	kinase	kinase	PROPN
admet-352	21	50	inhibitors	inhibitor	NOUN
admet-352	21	51	)	)	PUNCT
admet-352	22	1	[	[	X
admet-352	22	2	5,7	5,7	NUM
admet-352	22	3	-	-	SYM
admet-352	22	4	9	9	NUM
admet-352	22	5	]	]	PUNCT
admet-352	22	6	.	.	PUNCT
admet-352	23	1	first	first	ADJ
admet-352	23	2	-	-	PUNCT
admet-352	23	3	generation	generation	NOUN
admet-352	23	4	egfr	egfr	NOUN
admet-352	23	5	tkis	tkis	NOUN
admet-352	23	6	(	(	PUNCT
admet-352	23	7	including	include	VERB
admet-352	23	8	gefitinib	gefitinib	NOUN
admet-352	23	9	and	and	CCONJ
admet-352	23	10	erlotinib	erlotinib	NOUN
admet-352	23	11	)	)	PUNCT
admet-352	23	12	selectively	selectively	ADV
admet-352	23	13	target	target	VERB
admet-352	23	14	the	the	DET
admet-352	23	15	receptor	receptor	NOUN
admet-352	23	16	,	,	PUNCT
admet-352	23	17	through	through	ADP
admet-352	23	18	a	a	DET
admet-352	23	19	competitive	competitive	ADJ
admet-352	23	20	,	,	PUNCT
admet-352	23	21	reversible	reversible	ADJ
admet-352	23	22	binding	binding	NOUN
admet-352	23	23	at	at	ADP
admet-352	23	24	the	the	DET
admet-352	23	25	tyrosine	tyrosine	NOUN
admet-352	23	26	kinase	kinase	PROPN
admet-352	23	27	domain	domain	PROPN
admet-352	23	28	.	.	PUNCT
admet-352	24	1	however	however	ADV
admet-352	24	2	,	,	PUNCT
admet-352	24	3	despite	despite	SCONJ
admet-352	24	4	good	good	ADJ
admet-352	24	5	response	response	NOUN
admet-352	24	6	there	there	PRON
admet-352	24	7	is	be	VERB
admet-352	24	8	evidence	evidence	NOUN
admet-352	24	9	that	that	SCONJ
admet-352	24	10	after	after	ADP
admet-352	24	11	a	a	DET
admet-352	24	12	variable	variable	ADJ
admet-352	24	13	period	period	NOUN
admet-352	24	14	of	of	ADP
admet-352	24	15	time	time	NOUN
admet-352	24	16	(	(	PUNCT
admet-352	24	17	5	5	NUM
admet-352	24	18	-	-	SYM
admet-352	24	19	13	13	NUM
admet-352	24	20	months	month	NOUN
admet-352	24	21	)	)	PUNCT
admet-352	24	22	,	,	PUNCT
admet-352	24	23	the	the	DET
admet-352	24	24	patients	patient	NOUN
admet-352	24	25	develop	develop	VERB
admet-352	24	26	acquired	acquire	VERB
admet-352	24	27	resistance	resistance	NOUN
admet-352	24	28	to	to	ADP
admet-352	24	29	egfr	egfr	ADJ
admet-352	24	30	-	-	PUNCT
admet-352	24	31	tki	tki	NOUN
admet-352	24	32	therapy	therapy	NOUN
admet-352	24	33	that	that	PRON
admet-352	24	34	negatively	negatively	ADV
admet-352	24	35	impacts	impact	VERB
admet-352	24	36	their	their	PRON
admet-352	24	37	survival	survival	NOUN
admet-352	24	38	.	.	PUNCT
admet-352	25	1	second	second	ADJ
admet-352	25	2	generation	generation	NOUN
admet-352	25	3	tkis	tkis	NOUN
admet-352	25	4	(	(	PUNCT
admet-352	25	5	afatinib	afatinib	NOUN
admet-352	25	6	,	,	PUNCT
admet-352	25	7	dacomitinib	dacomitinib	NOUN
admet-352	25	8	)	)	PUNCT
admet-352	25	9	differ	differ	VERB
admet-352	25	10	from	from	ADP
admet-352	25	11	first	first	ADJ
admet-352	25	12	generation	generation	NOUN
admet-352	25	13	egfr	egfr	NOUN
admet-352	25	14	-	-	PUNCT
admet-352	25	15	tkis	tkis	NOUN
admet-352	25	16	because	because	SCONJ
admet-352	25	17	they	they	PRON
admet-352	25	18	form	form	VERB
admet-352	25	19	an	an	DET
admet-352	25	20	irreversible	irreversible	ADJ
admet-352	25	21	link	link	NOUN
admet-352	25	22	to	to	ADP
admet-352	25	23	the	the	DET
admet-352	25	24	egfr	egfr	ADJ
admet-352	25	25	kinase	kinase	PROPN
admet-352	25	26	domain	domain	PROPN
admet-352	25	27	and	and	CCONJ
admet-352	25	28	inhibit	inhibit	NOUN
admet-352	25	29	receptors	receptor	NOUN
admet-352	25	30	as	as	ADP
admet-352	25	31	her2	her2	PROPN
admet-352	25	32	and	and	CCONJ
admet-352	25	33	her4	her4	PROPN
admet-352	25	34	and	and	CCONJ
admet-352	25	35	are	be	AUX
admet-352	25	36	active	active	ADJ
admet-352	25	37	agents	agent	NOUN
admet-352	25	38	particularly	particularly	ADV
admet-352	25	39	in	in	ADP
admet-352	25	40	those	those	PRON
admet-352	25	41	with	with	ADP
admet-352	25	42	exon	exon	NOUN
admet-352	25	43	19	19	NUM
admet-352	25	44	deletion	deletion	NOUN
admet-352	25	45	.	.	PUNCT
admet-352	26	1	the	the	DET
admet-352	26	2	increasing	increase	VERB
admet-352	26	3	knowledge	knowledge	NOUN
admet-352	26	4	in	in	ADP
admet-352	26	5	tumor	tumor	NOUN
admet-352	26	6	biology	biology	NOUN
admet-352	26	7	and	and	CCONJ
admet-352	26	8	the	the	DET
admet-352	26	9	mechanisms	mechanism	NOUN
admet-352	26	10	,	,	PUNCT
admet-352	26	11	by	by	ADP
admet-352	26	12	which	which	PRON
admet-352	26	13	resistance	resistance	NOUN
admet-352	26	14	develops	develop	VERB
admet-352	26	15	,	,	PUNCT
admet-352	26	16	have	have	AUX
admet-352	26	17	helped	help	VERB
admet-352	26	18	to	to	PART
admet-352	26	19	develop	develop	VERB
admet-352	26	20	new	new	ADJ
admet-352	26	21	molecules	molecule	NOUN
admet-352	26	22	that	that	PRON
admet-352	26	23	have	have	AUX
admet-352	26	24	already	already	ADV
admet-352	26	25	demonstrated	demonstrate	VERB
admet-352	26	26	a	a	DET
admet-352	26	27	positive	positive	ADJ
admet-352	26	28	impact	impact	NOUN
admet-352	26	29	on	on	ADP
admet-352	26	30	response	response	NOUN
admet-352	26	31	rates	rate	NOUN
admet-352	26	32	and	and	CCONJ
admet-352	26	33	survival	survival	NOUN
admet-352	27	1	[	[	X
admet-352	27	2	9	9	NUM
admet-352	27	3	-	-	SYM
admet-352	27	4	11	11	NUM
admet-352	27	5	]	]	PUNCT
admet-352	27	6	.	.	PUNCT
admet-352	28	1	third	third	ADJ
admet-352	28	2	generation	generation	NOUN
admet-352	28	3	of	of	ADP
admet-352	28	4	egfr	egfr	ADJ
admet-352	28	5	inhibitors	inhibitor	NOUN
admet-352	28	6	the	the	DET
admet-352	28	7	t790	t790	NUM
admet-352	28	8	m	m	NUM
admet-352	28	9	egfr	egfr	ADJ
admet-352	28	10	mutation	mutation	NOUN
admet-352	28	11	is	be	AUX
admet-352	28	12	present	present	ADJ
admet-352	28	13	in	in	ADP
admet-352	28	14	over	over	ADP
admet-352	28	15	60	60	NUM
admet-352	28	16	%	%	NOUN
admet-352	28	17	of	of	ADP
admet-352	28	18	cases	case	NOUN
admet-352	28	19	of	of	ADP
admet-352	28	20	resistance	resistance	NOUN
admet-352	28	21	to	to	ADP
admet-352	28	22	tkis	tkis	NOUN
admet-352	28	23	first	first	ADJ
admet-352	28	24	and	and	CCONJ
admet-352	28	25	second	second	ADJ
admet-352	28	26	generation	generation	NOUN
admet-352	28	27	.	.	PUNCT
admet-352	29	1	it	it	PRON
admet-352	29	2	is	be	AUX
admet-352	29	3	the	the	DET
admet-352	29	4	resistance	resistance	NOUN
admet-352	29	5	mechanism	mechanism	NOUN
admet-352	29	6	of	of	ADP
admet-352	29	7	egfr	egfr	NOUN
admet-352	29	8	most	most	ADV
admet-352	29	9	commonly	commonly	ADV
admet-352	29	10	known	know	VERB
admet-352	29	11	.	.	PUNCT
admet-352	30	1	this	this	DET
admet-352	30	2	acquired	acquire	VERB
admet-352	30	3	resistance	resistance	NOUN
admet-352	30	4	is	be	AUX
admet-352	30	5	mediated	mediate	VERB
admet-352	30	6	by	by	ADP
admet-352	30	7	a	a	DET
admet-352	30	8	threonine	threonine	NOUN
admet-352	30	9	-	-	PUNCT
admet-352	30	10	to	to	ADP
admet-352	30	11	-	-	PUNCT
admet-352	30	12	methionine	methionine	NOUN
admet-352	30	13	mutation	mutation	NOUN
admet-352	30	14	in	in	ADP
admet-352	30	15	egfr	egfr	NOUN
admet-352	30	16	at	at	ADP
admet-352	30	17	position	position	NOUN
admet-352	30	18	790	790	NUM
admet-352	30	19	(	(	PUNCT
admet-352	30	20	egfr	egfr	NOUN
admet-352	30	21	t790	t790	NUM
admet-352	30	22	m	m	NOUN
admet-352	30	23	)	)	PUNCT
admet-352	30	24	,	,	PUNCT
admet-352	30	25	activation	activation	NOUN
admet-352	30	26	of	of	ADP
admet-352	30	27	a	a	DET
admet-352	30	28	bypass	bypass	NOUN
admet-352	30	29	-	-	PUNCT
admet-352	30	30	signalling	signal	VERB
admet-352	30	31	pathway	pathway	NOUN
admet-352	30	32	such	such	ADJ
admet-352	30	33	as	as	ADP
admet-352	30	34	mesenchymal	mesenchymal	ADJ
admet-352	30	35	-	-	ADJ
admet-352	30	36	epithelial	epithelial	ADJ
admet-352	30	37	transition	transition	NOUN
admet-352	30	38	(	(	PUNCT
admet-352	30	39	met	meet	VERB
admet-352	30	40	)	)	PUNCT
admet-352	30	41	pathway	pathway	NOUN
admet-352	30	42	,	,	PUNCT
admet-352	30	43	human	human	ADJ
admet-352	30	44	epidermal	epidermal	ADJ
admet-352	30	45	growth	growth	NOUN
admet-352	30	46	factor	factor	NOUN
admet-352	30	47	2	2	NUM
admet-352	30	48	(	(	PUNCT
admet-352	30	49	her2	her2	PROPN
admet-352	30	50	)	)	PUNCT
admet-352	30	51	,	,	PUNCT
admet-352	30	52	or	or	CCONJ
admet-352	30	53	mitogen	mitogen	NOUN
admet-352	30	54	-	-	PUNCT
admet-352	30	55	activated	activate	VERB
admet-352	30	56	protein	protein	NOUN
admet-352	30	57	kinase	kinase	NOUN
admet-352	30	58	1	1	NUM
admet-352	30	59	(	(	PUNCT
admet-352	30	60	mapk1	mapk1	NOUN
admet-352	30	61	)	)	PUNCT
admet-352	30	62	amplification	amplification	NOUN
admet-352	30	63	,	,	PUNCT
admet-352	30	64	and	and	CCONJ
admet-352	30	65	histologic	histologic	ADJ
admet-352	30	66	transformation	transformation	NOUN
admet-352	30	67	to	to	ADP
admet-352	30	68	small	small	ADJ
admet-352	30	69	-	-	PUNCT
admet-352	30	70	cell	cell	NOUN
admet-352	30	71	lung	lung	NOUN
admet-352	30	72	cancer	cancer	NOUN
admet-352	30	73	or	or	CCONJ
admet-352	30	74	an	an	DET
admet-352	30	75	epithelial	epithelial	NOUN
admet-352	30	76	-	-	PUNCT
admet-352	30	77	to	to	ADP
admet-352	30	78	-	-	PUNCT
admet-352	30	79	mesenchymal	mesenchymal	NOUN
admet-352	30	80	transition	transition	NOUN
admet-352	31	1	[	[	X
admet-352	31	2	12	12	NUM
admet-352	31	3	-	-	SYM
admet-352	31	4	15	15	NUM
admet-352	31	5	]	]	PUNCT
admet-352	31	6	.	.	PUNCT
admet-352	32	1	following	follow	VERB
admet-352	32	2	the	the	DET
admet-352	32	3	acquisition	acquisition	NOUN
admet-352	32	4	of	of	ADP
admet-352	32	5	the	the	DET
admet-352	32	6	mutation	mutation	NOUN
admet-352	32	7	,	,	PUNCT
admet-352	32	8	the	the	DET
admet-352	32	9	median	median	ADJ
admet-352	32	10	survival	survival	NOUN
admet-352	32	11	is	be	AUX
admet-352	32	12	less	less	ADJ
admet-352	32	13	than	than	ADP
admet-352	32	14	two	two	NUM
admet-352	32	15	years	year	NOUN
admet-352	32	16	,	,	PUNCT
admet-352	32	17	so	so	CCONJ
admet-352	32	18	there	there	PRON
admet-352	32	19	is	be	VERB
admet-352	32	20	a	a	DET
admet-352	32	21	need	need	NOUN
admet-352	32	22	to	to	PART
admet-352	32	23	develop	develop	VERB
admet-352	32	24	new	new	ADJ
admet-352	32	25	drugs	drug	NOUN
admet-352	32	26	that	that	PRON
admet-352	32	27	will	will	AUX
admet-352	32	28	control	control	VERB
admet-352	32	29	tumor	tumor	NOUN
admet-352	32	30	growth	growth	NOUN
admet-352	32	31	in	in	ADP
admet-352	32	32	patients	patient	NOUN
admet-352	32	33	positive	positive	ADJ
admet-352	32	34	egfr	egfr	NOUN
admet-352	32	35	t790	t790	NUM
admet-352	32	36	m.	m.	NOUN
admet-352	32	37	osimertinib	osimertinib	NOUN
admet-352	32	38	(	(	PUNCT
admet-352	32	39	azd9291	azd9291	ADJ
admet-352	32	40	)	)	PUNCT
admet-352	32	41	azd9291	azd9291	NOUN
admet-352	32	42	approved	approve	VERB
admet-352	32	43	by	by	ADP
admet-352	32	44	the	the	DET
admet-352	32	45	fda	fda	PROPN
admet-352	32	46	in	in	ADP
admet-352	32	47	november	november	PROPN
admet-352	32	48	2015	2015	NUM
admet-352	32	49	,	,	PUNCT
admet-352	32	50	is	be	AUX
admet-352	32	51	a	a	DET
admet-352	32	52	new	new	ADJ
admet-352	32	53	molecule	molecule	NOUN
admet-352	32	54	tki	tki	X
admet-352	32	55	third	third	ADJ
admet-352	32	56	generation	generation	NOUN
admet-352	32	57	,	,	PUNCT
admet-352	32	58	which	which	PRON
admet-352	32	59	binds	bind	VERB
admet-352	32	60	irreversibly	irreversibly	ADV
admet-352	32	61	to	to	ADP
admet-352	32	62	the	the	DET
admet-352	32	63	residue	residue	NOUN
admet-352	32	64	kinase	kinase	NOUN
admet-352	32	65	egfr	egfr	NOUN
admet-352	32	66	at	at	ADP
admet-352	32	67	the	the	DET
admet-352	32	68	site	site	NOUN
admet-352	32	69	of	of	ADP
admet-352	32	70	atp	atp	PROPN
admet-352	32	71	binding	bind	VERB
admet-352	32	72	by	by	ADP
admet-352	32	73	covalent	covalent	NOUN
admet-352	32	74	bond	bond	NOUN
admet-352	32	75	formation	formation	NOUN
admet-352	32	76	,	,	PUNCT
admet-352	32	77	in	in	ADP
admet-352	32	78	patients	patient	NOUN
admet-352	32	79	who	who	PRON
admet-352	32	80	have	have	AUX
admet-352	32	81	acquired	acquire	VERB
admet-352	32	82	t790	t790	NUM
admet-352	32	83	m	m	NOUN
admet-352	32	84	mutation	mutation	NOUN
admet-352	32	85	.	.	PUNCT
admet-352	33	1	after	after	ADP
admet-352	33	2	oral	oral	ADJ
admet-352	33	3	administration	administration	NOUN
admet-352	33	4	,	,	PUNCT
admet-352	33	5	it	it	PRON
admet-352	33	6	is	be	AUX
admet-352	33	7	metabolized	metabolize	VERB
admet-352	33	8	azd9291	azd9291	NOUN
admet-352	33	9	that	that	PRON
admet-352	33	10	has	have	VERB
admet-352	33	11	two	two	NUM
admet-352	33	12	pharmacologically	pharmacologically	ADV
admet-352	33	13	active	active	ADJ
admet-352	33	14	forms	form	NOUN
admet-352	33	15	az5104	az5104	NOUN
admet-352	33	16	and	and	CCONJ
admet-352	33	17	az7550	az7550	PROPN
admet-352	33	18	.	.	PUNCT
admet-352	34	1	az7550	az7550	PROPN
admet-352	34	2	showed	show	VERB
admet-352	34	3	a	a	DET
admet-352	34	4	comparable	comparable	ADJ
admet-352	34	5	potency	potency	NOUN
admet-352	34	6	and	and	CCONJ
admet-352	34	7	selectivity	selectivity	NOUN
admet-352	34	8	profile	profile	NOUN
admet-352	34	9	similar	similar	ADJ
admet-352	34	10	to	to	ADP
admet-352	34	11	osimertinib	osimertinib	NOUN
admet-352	34	12	,	,	PUNCT
admet-352	34	13	whereas	whereas	SCONJ
admet-352	34	14	az5104	az5104	PROPN
admet-352	34	15	in	in	ADP
admet-352	34	16	addition	addition	NOUN
admet-352	34	17	exhibited	exhibit	VERB
admet-352	34	18	greater	great	ADJ
admet-352	34	19	potency	potency	NOUN
admet-352	34	20	against	against	ADP
admet-352	34	21	exon	exon	NOUN
admet-352	34	22	19	19	NUM
admet-352	34	23	deletion	deletion	NOUN
admet-352	34	24	and	and	CCONJ
admet-352	34	25	t790	t790	NUM
admet-352	34	26	m	m	NOUN
admet-352	34	27	mutants	mutant	NOUN
admet-352	34	28	and	and	CCONJ
admet-352	34	29	wild	wild	ADJ
admet-352	34	30	-	-	PUNCT
admet-352	34	31	type	type	NOUN
admet-352	34	32	egfr	egfr	NOUN
admet-352	34	33	.	.	PUNCT
admet-352	35	1	the	the	DET
admet-352	35	2	first	first	ADJ
admet-352	35	3	phase	phase	NOUN
admet-352	35	4	i	i	PRON
admet-352	35	5	dose	dose	VERB
admet-352	35	6	escalation	escalation	NOUN
admet-352	35	7	study	study	NOUN
admet-352	35	8	was	be	AUX
admet-352	35	9	the	the	DET
admet-352	35	10	aura	aura	NOUN
admet-352	35	11	,	,	PUNCT
admet-352	35	12	made	make	VERB
admet-352	35	13	with	with	ADP
admet-352	35	14	egfr	egfr	NOUN
admet-352	35	15	mutated	mutate	VERB
admet-352	35	16	patients	patient	NOUN
admet-352	35	17	in	in	ADP
admet-352	35	18	progression	progression	NOUN
admet-352	35	19	with	with	ADP
admet-352	35	20	gefitinib	gefitinib	NOUN
admet-352	35	21	or	or	CCONJ
admet-352	35	22	erlotinib	erlotinib	NOUN
admet-352	35	23	treatment	treatment	NOUN
admet-352	35	24	[	[	X
admet-352	35	25	11	11	NUM
admet-352	35	26	,	,	PUNCT
admet-352	35	27	16	16	NUM
admet-352	35	28	-	-	SYM
admet-352	35	29	18	18	NUM
admet-352	35	30	]	]	PUNCT
admet-352	35	31	.	.	PUNCT
admet-352	36	1	the	the	DET
admet-352	36	2	doses	dose	NOUN
admet-352	36	3	used	use	VERB
admet-352	36	4	were	be	AUX
admet-352	36	5	between	between	ADP
admet-352	36	6	20	20	NUM
admet-352	36	7	and	and	CCONJ
admet-352	36	8	240	240	NUM
admet-352	36	9	mg	mg	NOUN
admet-352	36	10	per	per	ADP
admet-352	36	11	day	day	NOUN
admet-352	36	12	.	.	PUNCT
admet-352	37	1	in	in	ADP
admet-352	37	2	the	the	DET
admet-352	37	3	expansion	expansion	NOUN
admet-352	37	4	phase	phase	NOUN
admet-352	37	5	,	,	PUNCT
admet-352	37	6	the	the	DET
admet-352	37	7	analysis	analysis	NOUN
admet-352	37	8	of	of	ADP
admet-352	37	9	the	the	DET
admet-352	37	10	t790	t790	NUM
admet-352	37	11	m	m	NOUN
admet-352	37	12	mutation	mutation	NOUN
admet-352	37	13	patients	patient	NOUN
admet-352	37	14	demonstrated	demonstrate	VERB
admet-352	37	15	an	an	DET
admet-352	37	16	objective	objective	ADJ
admet-352	37	17	response	response	NOUN
admet-352	37	18	rate	rate	NOUN
admet-352	37	19	of	of	ADP
admet-352	37	20	67	67	NUM
admet-352	37	21	%	%	NOUN
admet-352	37	22	(	(	PUNCT
admet-352	37	23	95	95	NUM
admet-352	37	24	%	%	NOUN
admet-352	37	25	ci	ci	NOUN
admet-352	37	26	52	52	NUM
admet-352	37	27	-	-	SYM
admet-352	37	28	70	70	NUM
admet-352	37	29	%	%	NOUN
admet-352	37	30	)	)	PUNCT
admet-352	37	31	compared	compare	VERB
admet-352	37	32	to	to	ADP
admet-352	37	33	21	21	NUM
admet-352	37	34	%	%	NOUN
admet-352	37	35	in	in	ADP
admet-352	37	36	patients	patient	NOUN
admet-352	37	37	without	without	ADP
admet-352	37	38	the	the	DET
admet-352	37	39	mutation	mutation	NOUN
admet-352	37	40	.	.	PUNCT
admet-352	38	1	the	the	DET
admet-352	38	2	rate	rate	NOUN
admet-352	38	3	of	of	ADP
admet-352	38	4	disease	disease	NOUN
admet-352	38	5	control	control	NOUN
admet-352	38	6	in	in	ADP
admet-352	38	7	the	the	DET
admet-352	38	8	overall	overall	ADJ
admet-352	38	9	analysis	analysis	NOUN
admet-352	38	10	of	of	ADP
admet-352	38	11	all	all	DET
admet-352	38	12	aura	aura	NOUN
admet-352	38	13	studies	study	NOUN
admet-352	38	14	was	be	AUX
admet-352	38	15	91	91	NUM
admet-352	38	16	%	%	NOUN
admet-352	38	17	.	.	PUNCT
admet-352	39	1	the	the	DET
admet-352	39	2	median	median	ADJ
admet-352	39	3	progression	progression	NOUN
admet-352	39	4	-	-	PUNCT
admet-352	39	5	free	free	ADJ
admet-352	39	6	survival	survival	NOUN
admet-352	39	7	was	be	AUX
admet-352	39	8	9.6	9.6	NUM
admet-352	39	9	months	month	NOUN
admet-352	39	10	versus	versus	ADP
admet-352	39	11	3	3	NUM
admet-352	39	12	months	month	NOUN
admet-352	39	13	in	in	ADP
admet-352	39	14	patients	patient	NOUN
admet-352	39	15	without	without	ADP
admet-352	39	16	the	the	DET
admet-352	39	17	mutation	mutation	NOUN
admet-352	39	18	.	.	PUNCT
admet-352	40	1	the	the	DET
admet-352	40	2	profile	profile	NOUN
admet-352	40	3	of	of	ADP
admet-352	40	4	side	side	NOUN
admet-352	40	5	events	event	NOUN
admet-352	40	6	is	be	AUX
admet-352	40	7	favourable	favourable	ADJ
admet-352	40	8	,	,	PUNCT
admet-352	40	9	since	since	SCONJ
admet-352	40	10	they	they	PRON
admet-352	40	11	are	be	AUX
admet-352	40	12	few	few	ADJ
admet-352	40	13	and	and	CCONJ
admet-352	40	14	mostly	mostly	ADV
admet-352	40	15	grades	grade	NOUN
admet-352	40	16	1	1	NUM
admet-352	40	17	and	and	CCONJ
admet-352	40	18	2	2	NUM
admet-352	40	19	.	.	X
admet-352	41	1	the	the	DET
admet-352	41	2	most	most	ADV
admet-352	41	3	frequent	frequent	ADJ
admet-352	41	4	were	be	AUX
admet-352	41	5	rash	rash	ADJ
admet-352	41	6	,	,	PUNCT
admet-352	41	7	diarrhea	diarrhea	NOUN
admet-352	41	8	and	and	CCONJ
admet-352	41	9	nausea	nausea	NOUN
admet-352	41	10	.	.	PUNCT
admet-352	42	1	since	since	SCONJ
admet-352	42	2	no	no	DET
admet-352	42	3	significant	significant	ADJ
admet-352	42	4	difference	difference	NOUN
admet-352	42	5	in	in	ADP
admet-352	42	6	response	response	NOUN
admet-352	42	7	to	to	ADP
admet-352	42	8	higher	high	ADJ
admet-352	42	9	doses	dose	NOUN
admet-352	42	10	was	be	AUX
admet-352	42	11	observed	observe	VERB
admet-352	42	12	,	,	PUNCT
admet-352	42	13	80	80	NUM
admet-352	42	14	mg	mg	NUM
admet-352	42	15	/	/	SYM
admet-352	42	16	day	day	NOUN
admet-352	42	17	is	be	AUX
admet-352	42	18	recommended	recommend	VERB
admet-352	42	19	until	until	ADP
admet-352	42	20	disease	disease	NOUN
admet-352	42	21	progression	progression	NOUN
admet-352	42	22	or	or	CCONJ
admet-352	42	23	unacceptable	unacceptable	ADJ
admet-352	42	24	toxicity	toxicity	NOUN
admet-352	42	25	[	[	X
admet-352	42	26	16	16	NUM
admet-352	42	27	-	-	SYM
admet-352	42	28	18	18	NUM
admet-352	42	29	]	]	PUNCT
admet-352	42	30	.	.	PUNCT
admet-352	43	1	if	if	SCONJ
admet-352	43	2	it	it	PRON
admet-352	43	3	is	be	AUX
admet-352	43	4	necessary	necessary	ADJ
admet-352	43	5	to	to	PART
admet-352	43	6	reduce	reduce	VERB
admet-352	43	7	the	the	DET
admet-352	43	8	dose	dose	NOUN
admet-352	43	9	,	,	PUNCT
admet-352	43	10	this	this	PRON
admet-352	43	11	should	should	AUX
admet-352	43	12	be	be	AUX
admet-352	43	13	done	do	VERB
admet-352	43	14	at	at	ADP
admet-352	43	15	40	40	NUM
admet-352	43	16	mg	mg	NOUN
admet-352	43	17	per	per	ADP
admet-352	43	18	day	day	NOUN
admet-352	43	19	,	,	PUNCT
admet-352	43	20	since	since	SCONJ
admet-352	43	21	tablets	tablet	NOUN
admet-352	43	22	are	be	AUX
admet-352	43	23	40	40	NUM
admet-352	43	24	and	and	CCONJ
admet-352	43	25	80	80	NUM
admet-352	43	26	mg	mg	NUM
admet-352	43	27	.	.	PUNCT
admet-352	44	1	its	its	PRON
admet-352	44	2	elimination	elimination	NOUN
admet-352	44	3	is	be	AUX
admet-352	44	4	mainly	mainly	ADV
admet-352	44	5	hepatic	hepatic	ADJ
admet-352	44	6	and	and	CCONJ
admet-352	44	7	has	have	AUX
admet-352	44	8	not	not	PART
admet-352	44	9	been	be	AUX
admet-352	44	10	studied	study	VERB
admet-352	44	11	in	in	ADP
admet-352	44	12	patients	patient	NOUN
admet-352	44	13	with	with	ADP
admet-352	44	14	renal	renal	ADJ
admet-352	44	15	insufficiency	insufficiency	NOUN
admet-352	44	16	[	[	X
admet-352	44	17	16	16	NUM
admet-352	44	18	]	]	PUNCT
admet-352	44	19	.	.	PUNCT
admet-352	45	1	current	current	ADJ
admet-352	45	2	studies	study	NOUN
admet-352	45	3	of	of	ADP
admet-352	45	4	liquid	liquid	ADJ
admet-352	45	5	biopsy	biopsy	NOUN
admet-352	45	6	are	be	AUX
admet-352	45	7	presented	present	VERB
admet-352	45	8	as	as	ADP
admet-352	45	9	an	an	DET
admet-352	45	10	option	option	NOUN
admet-352	45	11	for	for	ADP
admet-352	45	12	detection	detection	NOUN
admet-352	45	13	of	of	ADP
admet-352	45	14	mutations	mutation	NOUN
admet-352	45	15	in	in	ADP
admet-352	45	16	peripheral	peripheral	ADJ
admet-352	45	17	blood	blood	NOUN
admet-352	45	18	.	.	PUNCT
admet-352	46	1	this	this	PRON
admet-352	46	2	probably	probably	ADV
admet-352	46	3	serves	serve	VERB
admet-352	46	4	not	not	PART
admet-352	46	5	only	only	ADV
admet-352	46	6	for	for	ADP
admet-352	46	7	diagnosis	diagnosis	NOUN
admet-352	46	8	but	but	CCONJ
admet-352	46	9	also	also	ADV
admet-352	46	10	for	for	ADP
admet-352	46	11	monitoring	monitoring	NOUN
admet-352	46	12	;	;	PUNCT
admet-352	46	13	however	however	ADV
admet-352	46	14	,	,	PUNCT
admet-352	46	15	more	more	ADJ
admet-352	46	16	studies	study	NOUN
admet-352	46	17	are	be	AUX
admet-352	46	18	needed	need	VERB
admet-352	46	19	in	in	ADP
admet-352	46	20	this	this	DET
admet-352	46	21	line	line	NOUN
admet-352	46	22	.	.	PUNCT
admet-352	47	1	admet	admet	PROPN
admet-352	47	2	&	&	CCONJ
admet-352	47	3	dmpk	dmpk	PROPN
admet-352	47	4	5(1	5(1	NUM
admet-352	47	5	)	)	PUNCT
admet-352	47	6	(	(	PUNCT
admet-352	47	7	2017	2017	NUM
admet-352	47	8	)	)	PUNCT
admet-352	47	9	1	1	NUM
admet-352	47	10	-	-	SYM
admet-352	47	11	8	8	NUM
admet-352	47	12	tkis	tkis	NOUN
admet-352	47	13	in	in	ADP
admet-352	47	14	non	non	ADJ
admet-352	47	15	-	-	ADJ
admet-352	47	16	small	small	ADJ
admet-352	47	17	cell	cell	NOUN
admet-352	47	18	lung	lung	NOUN
admet-352	47	19	cancer	cancer	NOUN
admet-352	47	20	doi	doi	NOUN
admet-352	47	21	:	:	PUNCT
admet-352	47	22	10.5599	10.5599	NUM
admet-352	47	23	/	/	SYM
admet-352	47	24	admet.5.1.352	admet.5.1.352	NOUN
admet-352	47	25	3	3	NUM
admet-352	47	26	rociletinib	rociletinib	NOUN
admet-352	47	27	(	(	PUNCT
admet-352	47	28	co-16086	co-16086	ADJ
admet-352	47	29	)	)	PUNCT
admet-352	47	30	rociletinib	rociletinib	NOUN
admet-352	47	31	,	,	PUNCT
admet-352	47	32	is	be	AUX
admet-352	47	33	a	a	DET
admet-352	47	34	new	new	ADJ
admet-352	47	35	oral	oral	ADJ
admet-352	47	36	selective	selective	ADJ
admet-352	47	37	covalent	covalent	NOUN
admet-352	47	38	molecule	molecule	NOUN
admet-352	47	39	egfr	egfr	NOUN
admet-352	47	40	inhibitor	inhibitor	NOUN
admet-352	47	41	,	,	PUNCT
admet-352	47	42	with	with	ADP
admet-352	47	43	demonstrated	demonstrate	VERB
admet-352	47	44	activity	activity	NOUN
admet-352	47	45	against	against	ADP
admet-352	47	46	the	the	DET
admet-352	47	47	t790	t790	NUM
admet-352	47	48	m	m	NOUN
admet-352	47	49	mutation	mutation	NOUN
admet-352	47	50	,	,	PUNCT
admet-352	47	51	deletionn	deletionn	NOUN
admet-352	47	52	19	19	NUM
admet-352	47	53	and	and	CCONJ
admet-352	47	54	l858r	l858r	NOUN
admet-352	48	1	[	[	X
admet-352	48	2	19	19	NUM
admet-352	48	3	-	-	SYM
admet-352	48	4	20	20	NUM
admet-352	48	5	]	]	PUNCT
admet-352	48	6	.	.	PUNCT
admet-352	49	1	initial	initial	ADJ
admet-352	49	2	studies	study	NOUN
admet-352	49	3	were	be	AUX
admet-352	49	4	performed	perform	VERB
admet-352	49	5	in	in	ADP
admet-352	49	6	patients	patient	NOUN
admet-352	49	7	with	with	ADP
admet-352	49	8	acquired	acquire	VERB
admet-352	49	9	resistance	resistance	NOUN
admet-352	49	10	to	to	ADP
admet-352	49	11	gefitinib	gefitinib	NOUN
admet-352	49	12	and	and	CCONJ
admet-352	49	13	erlotinib	erlotinib	NOUN
admet-352	49	14	.	.	PUNCT
admet-352	50	1	the	the	DET
admet-352	50	2	subsequent	subsequent	ADJ
admet-352	50	3	inclusion	inclusion	NOUN
admet-352	50	4	of	of	ADP
admet-352	50	5	patients	patient	NOUN
admet-352	50	6	with	with	ADP
admet-352	50	7	mutation	mutation	NOUN
admet-352	50	8	t790	t790	NUM
admet-352	50	9	m	m	NOUN
admet-352	50	10	has	have	AUX
admet-352	50	11	shown	show	VERB
admet-352	50	12	the	the	DET
admet-352	50	13	particular	particular	ADJ
admet-352	50	14	activity	activity	NOUN
admet-352	50	15	of	of	ADP
admet-352	50	16	the	the	DET
admet-352	50	17	drug	drug	NOUN
admet-352	50	18	in	in	ADP
admet-352	50	19	this	this	DET
admet-352	50	20	subgroup	subgroup	NOUN
admet-352	50	21	of	of	ADP
admet-352	50	22	patients	patient	NOUN
admet-352	50	23	.	.	PUNCT
admet-352	51	1	partial	partial	ADJ
admet-352	51	2	results	result	NOUN
admet-352	51	3	of	of	ADP
admet-352	51	4	studies	study	NOUN
admet-352	51	5	of	of	ADP
admet-352	51	6	a	a	DET
admet-352	51	7	phase	phase	NOUN
admet-352	51	8	ii	ii	NOUN
admet-352	51	9	study	study	NOUN
admet-352	51	10	presented	present	VERB
admet-352	51	11	at	at	ADP
admet-352	51	12	asco	asco	PROPN
admet-352	51	13	2015	2015	NUM
admet-352	51	14	reflect	reflect	VERB
admet-352	51	15	an	an	DET
admet-352	51	16	objective	objective	ADJ
admet-352	51	17	response	response	NOUN
admet-352	51	18	rate	rate	NOUN
admet-352	51	19	in	in	ADP
admet-352	51	20	this	this	DET
admet-352	51	21	subgroup	subgroup	NOUN
admet-352	51	22	of	of	ADP
admet-352	51	23	59	59	NUM
admet-352	51	24	%	%	NOUN
admet-352	51	25	(	(	PUNCT
admet-352	51	26	95	95	NUM
admet-352	51	27	%	%	NOUN
admet-352	51	28	ci	ci	NOUN
admet-352	51	29	45	45	NUM
admet-352	51	30	-	-	SYM
admet-352	51	31	73	73	NUM
admet-352	51	32	)	)	PUNCT
admet-352	51	33	and	and	CCONJ
admet-352	51	34	rates	rate	NOUN
admet-352	51	35	of	of	ADP
admet-352	51	36	disease	disease	NOUN
admet-352	51	37	control	control	VERB
admet-352	51	38	85	85	NUM
admet-352	51	39	%	%	NOUN
admet-352	51	40	.	.	PUNCT
admet-352	52	1	however	however	ADV
admet-352	52	2	,	,	PUNCT
admet-352	52	3	new	new	ADJ
admet-352	52	4	combined	combine	VERB
admet-352	52	5	analyses	analysis	NOUN
admet-352	52	6	of	of	ADP
admet-352	52	7	the	the	DET
admet-352	52	8	tiger	tiger	NOUN
admet-352	52	9	-	-	PUNCT
admet-352	52	10	x	x	NOUN
admet-352	52	11	and	and	CCONJ
admet-352	52	12	tiger-2	tiger-2	NUM
admet-352	52	13	studies	study	NOUN
admet-352	52	14	have	have	AUX
admet-352	52	15	shown	show	VERB
admet-352	52	16	that	that	SCONJ
admet-352	52	17	the	the	DET
admet-352	52	18	actual	actual	ADJ
admet-352	52	19	response	response	NOUN
admet-352	52	20	rate	rate	NOUN
admet-352	52	21	is	be	AUX
admet-352	52	22	only	only	ADV
admet-352	52	23	around	around	ADV
admet-352	52	24	30	30	NUM
admet-352	52	25	%	%	NOUN
admet-352	52	26	.	.	PUNCT
admet-352	53	1	among	among	ADP
admet-352	53	2	the	the	DET
admet-352	53	3	most	most	ADV
admet-352	53	4	common	common	ADJ
admet-352	53	5	adverse	adverse	ADJ
admet-352	53	6	events	event	NOUN
admet-352	53	7	are	be	AUX
admet-352	53	8	diarrhea	diarrhea	NOUN
admet-352	53	9	and	and	CCONJ
admet-352	53	10	skin	skin	NOUN
admet-352	53	11	toxicity	toxicity	NOUN
admet-352	53	12	,	,	PUNCT
admet-352	53	13	most	most	ADJ
admet-352	53	14	of	of	ADP
admet-352	53	15	them	they	PRON
admet-352	53	16	in	in	ADP
admet-352	53	17	grades	grade	NOUN
admet-352	53	18	1	1	NUM
admet-352	53	19	and	and	CCONJ
admet-352	53	20	2	2	NUM
admet-352	53	21	[	[	X
admet-352	53	22	21	21	NUM
admet-352	53	23	]	]	PUNCT
admet-352	53	24	.	.	PUNCT
admet-352	54	1	cases	case	NOUN
admet-352	54	2	of	of	ADP
admet-352	54	3	hyperglycemia	hyperglycemia	NOUN
admet-352	54	4	and	and	CCONJ
admet-352	54	5	qt	qt	NOUN
admet-352	54	6	prolongation	prolongation	NOUN
admet-352	54	7	(	(	PUNCT
admet-352	54	8	>	>	X
admet-352	54	9	10	10	NUM
admet-352	54	10	%	%	NOUN
admet-352	54	11	)	)	PUNCT
admet-352	54	12	were	be	AUX
admet-352	54	13	frequently	frequently	ADV
admet-352	54	14	presented	present	VERB
admet-352	54	15	,	,	PUNCT
admet-352	54	16	in	in	ADP
admet-352	54	17	the	the	DET
admet-352	54	18	latter	latter	ADJ
admet-352	54	19	case	case	NOUN
admet-352	54	20	without	without	ADP
admet-352	54	21	reaching	reach	VERB
admet-352	54	22	documented	document	VERB
admet-352	54	23	arrhythmias	arrhythmia	NOUN
admet-352	54	24	.	.	PUNCT
admet-352	55	1	dose	dose	NOUN
admet-352	55	2	reductions	reduction	NOUN
admet-352	55	3	occurred	occur	VERB
admet-352	55	4	in	in	ADP
admet-352	55	5	51	51	NUM
admet-352	55	6	%	%	NOUN
admet-352	55	7	of	of	ADP
admet-352	55	8	patients	patient	NOUN
admet-352	55	9	,	,	PUNCT
admet-352	55	10	most	most	ADV
admet-352	55	11	commonly	commonly	ADV
admet-352	55	12	due	due	ADJ
admet-352	55	13	to	to	ADP
admet-352	55	14	hyperglycemia	hyperglycemia	NOUN
admet-352	55	15	(	(	PUNCT
admet-352	55	16	22	22	NUM
admet-352	55	17	%	%	NOUN
admet-352	55	18	)	)	PUNCT
admet-352	55	19	and	and	CCONJ
admet-352	55	20	qtc	qtc	PROPN
admet-352	55	21	prolongation	prolongation	NOUN
admet-352	55	22	(	(	PUNCT
admet-352	55	23	11	11	NUM
admet-352	55	24	%	%	NOUN
admet-352	55	25	)	)	PUNCT
admet-352	55	26	.	.	PUNCT
admet-352	56	1	fifty	fifty	NUM
admet-352	56	2	-	-	PUNCT
admet-352	56	3	seven	seven	NUM
admet-352	56	4	percent	percent	NOUN
admet-352	56	5	of	of	ADP
admet-352	56	6	patients	patient	NOUN
admet-352	56	7	had	have	AUX
admet-352	56	8	dose	dose	VERB
admet-352	56	9	interruptions	interruption	NOUN
admet-352	56	10	,	,	PUNCT
admet-352	56	11	which	which	PRON
admet-352	56	12	were	be	AUX
admet-352	56	13	most	most	ADV
admet-352	56	14	often	often	ADV
admet-352	56	15	due	due	ADJ
admet-352	56	16	to	to	ADP
admet-352	56	17	hyperglycemia	hyperglycemia	NOUN
admet-352	56	18	(	(	PUNCT
admet-352	56	19	22	22	NUM
admet-352	56	20	%	%	NOUN
admet-352	56	21	)	)	PUNCT
admet-352	56	22	,	,	PUNCT
admet-352	56	23	qtc	qtc	PROPN
admet-352	56	24	prolongation	prolongation	NOUN
admet-352	56	25	(	(	PUNCT
admet-352	56	26	10	10	NUM
admet-352	56	27	%	%	NOUN
admet-352	56	28	)	)	PUNCT
admet-352	56	29	,	,	PUNCT
admet-352	56	30	and	and	CCONJ
admet-352	56	31	nausea	nausea	NOUN
admet-352	56	32	(	(	PUNCT
admet-352	56	33	10	10	NUM
admet-352	56	34	%	%	NOUN
admet-352	56	35	)	)	PUNCT
admet-352	56	36	.	.	PUNCT
admet-352	57	1	the	the	DET
admet-352	57	2	average	average	ADJ
admet-352	57	3	survival	survival	NOUN
admet-352	57	4	in	in	ADP
admet-352	57	5	patients	patient	NOUN
admet-352	57	6	was	be	AUX
admet-352	57	7	8	8	NUM
admet-352	57	8	months	month	NOUN
admet-352	57	9	with	with	ADP
admet-352	57	10	the	the	DET
admet-352	57	11	t790	t790	NUM
admet-352	57	12	m	m	NOUN
admet-352	57	13	mutation	mutation	NOUN
admet-352	57	14	in	in	ADP
admet-352	57	15	patients	patient	NOUN
admet-352	57	16	where	where	SCONJ
admet-352	57	17	the	the	DET
admet-352	57	18	500	500	NUM
admet-352	57	19	-	-	SYM
admet-352	57	20	650	650	NUM
admet-352	57	21	mg	mg	PROPN
admet-352	57	22	dose	dose	NOUN
admet-352	57	23	was	be	AUX
admet-352	57	24	administered	administer	VERB
admet-352	57	25	.	.	PUNCT
admet-352	58	1	although	although	SCONJ
admet-352	58	2	initially	initially	ADV
admet-352	58	3	seeming	seem	VERB
admet-352	58	4	a	a	DET
admet-352	58	5	promising	promising	ADJ
admet-352	58	6	drug	drug	NOUN
admet-352	58	7	,	,	PUNCT
admet-352	58	8	the	the	DET
admet-352	58	9	adverse	adverse	ADJ
admet-352	58	10	event	event	NOUN
admet-352	58	11	profile	profile	NOUN
admet-352	58	12	and	and	CCONJ
admet-352	58	13	response	response	NOUN
admet-352	58	14	rates	rate	NOUN
admet-352	58	15	have	have	AUX
admet-352	58	16	prompted	prompt	VERB
admet-352	58	17	the	the	DET
admet-352	58	18	fda	fda	PROPN
admet-352	58	19	to	to	PART
admet-352	58	20	give	give	VERB
admet-352	58	21	a	a	DET
admet-352	58	22	negative	negative	ADJ
admet-352	58	23	opinion	opinion	NOUN
admet-352	58	24	for	for	ADP
admet-352	58	25	accelerated	accelerated	ADJ
admet-352	58	26	approval	approval	NOUN
admet-352	58	27	of	of	ADP
admet-352	58	28	the	the	DET
admet-352	58	29	drug	drug	NOUN
admet-352	58	30	[	[	X
admet-352	58	31	21	21	NUM
admet-352	58	32	-	-	SYM
admet-352	58	33	22	22	NUM
admet-352	58	34	]	]	PUNCT
admet-352	58	35	.	.	PUNCT
admet-352	59	1	hm61713	hm61713	PROPN
admet-352	59	2	(	(	PUNCT
admet-352	59	3	bi	bi	NOUN
admet-352	59	4	1482694	1482694	NUM
admet-352	59	5	)	)	PUNCT
admet-352	59	6	hm61713	hm61713	NOUN
admet-352	59	7	is	be	AUX
admet-352	59	8	an	an	DET
admet-352	59	9	irreversible	irreversible	ADJ
admet-352	59	10	kinase	kinase	NOUN
admet-352	59	11	inhibitor	inhibitor	NOUN
admet-352	59	12	that	that	PRON
admet-352	59	13	binds	bind	VERB
admet-352	59	14	to	to	ADP
admet-352	59	15	a	a	DET
admet-352	59	16	cysteine	cysteine	NOUN
admet-352	59	17	residue	residue	NOUN
admet-352	59	18	near	near	ADP
admet-352	59	19	the	the	DET
admet-352	59	20	egfr	egfr	ADJ
admet-352	59	21	kinase	kinase	PROPN
admet-352	59	22	domain	domain	PROPN
admet-352	59	23	.	.	PUNCT
admet-352	60	1	preliminary	preliminary	ADJ
admet-352	60	2	studies	study	NOUN
admet-352	60	3	in	in	ADP
admet-352	60	4	cell	cell	NOUN
admet-352	60	5	lines	line	NOUN
admet-352	60	6	,	,	PUNCT
admet-352	60	7	has	have	AUX
admet-352	60	8	shown	show	VERB
admet-352	60	9	activity	activity	NOUN
admet-352	60	10	against	against	ADP
admet-352	60	11	t790	t790	NUM
admet-352	60	12	m	m	NOUN
admet-352	60	13	mutations	mutation	NOUN
admet-352	60	14	and	and	CCONJ
admet-352	60	15	l858r	l858r	NOUN
admet-352	60	16	.	.	PUNCT
admet-352	61	1	studies	study	NOUN
admet-352	61	2	are	be	AUX
admet-352	61	3	currently	currently	ADV
admet-352	61	4	underway	underway	ADJ
admet-352	61	5	with	with	ADP
admet-352	61	6	phase	phase	NOUN
admet-352	61	7	i	i	PROPN
admet-352	61	8	/	/	SYM
admet-352	61	9	ii	ii	PROPN
admet-352	61	10	with	with	ADP
admet-352	61	11	a	a	DET
admet-352	61	12	dose	dose	NOUN
admet-352	61	13	of	of	ADP
admet-352	61	14	800	800	NUM
admet-352	61	15	mg	mg	NUM
admet-352	61	16	/	/	SYM
admet-352	61	17	day	day	NOUN
admet-352	61	18	in	in	ADP
admet-352	61	19	patients	patient	NOUN
admet-352	61	20	with	with	ADP
admet-352	61	21	t790	t790	NUM
admet-352	61	22	m	m	NOUN
admet-352	61	23	mutation	mutation	NOUN
admet-352	61	24	.	.	PUNCT
admet-352	62	1	initial	initial	ADJ
admet-352	62	2	results	result	NOUN
admet-352	62	3	show	show	VERB
admet-352	62	4	an	an	DET
admet-352	62	5	overall	overall	ADJ
admet-352	62	6	response	response	NOUN
admet-352	62	7	rate	rate	NOUN
admet-352	62	8	of	of	ADP
admet-352	62	9	62	62	NUM
admet-352	62	10	%	%	NOUN
admet-352	62	11	in	in	ADP
admet-352	62	12	this	this	DET
admet-352	62	13	subgroup	subgroup	NOUN
admet-352	62	14	of	of	ADP
admet-352	62	15	patients	patient	NOUN
admet-352	62	16	.	.	PUNCT
admet-352	63	1	disease	disease	NOUN
admet-352	63	2	control	control	NOUN
admet-352	63	3	rate	rate	NOUN
admet-352	63	4	was	be	AUX
admet-352	63	5	91	91	NUM
admet-352	63	6	%	%	NOUN
admet-352	63	7	by	by	ADP
admet-352	63	8	independent	independent	ADJ
admet-352	63	9	assessment	assessment	NOUN
admet-352	63	10	.	.	PUNCT
admet-352	64	1	the	the	DET
admet-352	64	2	most	most	ADV
admet-352	64	3	common	common	ADJ
admet-352	64	4	treatment	treatment	NOUN
admet-352	64	5	-	-	PUNCT
admet-352	64	6	related	relate	VERB
admet-352	64	7	adverse	adverse	ADJ
admet-352	64	8	events	event	NOUN
admet-352	64	9	included	include	VERB
admet-352	64	10	diarrhoea	diarrhoea	NOUN
admet-352	64	11	(	(	PUNCT
admet-352	64	12	55	55	NUM
admet-352	64	13	%	%	NOUN
admet-352	64	14	)	)	PUNCT
admet-352	64	15	,	,	PUNCT
admet-352	64	16	nausea	nausea	NOUN
admet-352	64	17	(	(	PUNCT
admet-352	64	18	37	37	NUM
admet-352	64	19	%	%	NOUN
admet-352	64	20	)	)	PUNCT
admet-352	64	21	,	,	PUNCT
admet-352	64	22	rash	rash	NOUN
admet-352	64	23	(	(	PUNCT
admet-352	64	24	38	38	NUM
admet-352	64	25	%	%	NOUN
admet-352	64	26	)	)	PUNCT
admet-352	64	27	and	and	CCONJ
admet-352	64	28	pruritus	pruritus	PROPN
admet-352	64	29	(	(	PUNCT
admet-352	64	30	36	36	NUM
admet-352	64	31	%	%	NOUN
admet-352	64	32	)	)	PUNCT
admet-352	64	33	,	,	PUNCT
admet-352	64	34	the	the	DET
admet-352	64	35	majority	majority	NOUN
admet-352	64	36	were	be	AUX
admet-352	64	37	mild	mild	ADJ
admet-352	64	38	-	-	PUNCT
admet-352	64	39	to	to	ADP
admet-352	64	40	-	-	PUNCT
admet-352	64	41	moderate	moderate	ADJ
admet-352	64	42	[	[	X
admet-352	64	43	23	23	NUM
admet-352	64	44	]	]	PUNCT
admet-352	64	45	.	.	PUNCT
admet-352	65	1	it	it	PRON
admet-352	65	2	seems	seem	VERB
admet-352	65	3	a	a	DET
admet-352	65	4	promising	promising	ADJ
admet-352	65	5	agent	agent	NOUN
admet-352	65	6	;	;	PUNCT
admet-352	65	7	however	however	ADV
admet-352	65	8	further	further	ADJ
admet-352	65	9	studies	study	NOUN
admet-352	65	10	to	to	PART
admet-352	65	11	confirm	confirm	VERB
admet-352	65	12	therapeutic	therapeutic	ADJ
admet-352	65	13	activity	activity	NOUN
admet-352	65	14	are	be	AUX
admet-352	65	15	needed	need	VERB
admet-352	65	16	.	.	PUNCT
admet-352	66	1	eluxa	eluxa	NOUN
admet-352	66	2	1	1	NUM
admet-352	66	3	is	be	AUX
admet-352	66	4	an	an	DET
admet-352	66	5	ongoing	ongoing	ADJ
admet-352	66	6	pivotal	pivotal	ADJ
admet-352	66	7	phase	phase	NOUN
admet-352	66	8	ii	ii	NOUN
admet-352	66	9	clinical	clinical	ADJ
admet-352	66	10	trial	trial	NOUN
admet-352	66	11	,	,	PUNCT
admet-352	66	12	designed	design	VERB
admet-352	66	13	to	to	PART
admet-352	66	14	further	far	ADV
admet-352	66	15	investigate	investigate	VERB
admet-352	66	16	the	the	DET
admet-352	66	17	efficacy	efficacy	NOUN
admet-352	66	18	and	and	CCONJ
admet-352	66	19	safety	safety	NOUN
admet-352	66	20	of	of	ADP
admet-352	66	21	bi	bi	NOUN
admet-352	66	22	1482694	1482694	NUM
admet-352	66	23	in	in	ADP
admet-352	66	24	patients	patient	NOUN
admet-352	66	25	with	with	ADP
admet-352	66	26	nsclc	nsclc	NOUN
admet-352	66	27	whose	whose	DET
admet-352	66	28	tumours	tumour	NOUN
admet-352	66	29	acquired	acquire	VERB
admet-352	66	30	t790m	t790m	PROPN
admet-352	66	31	-	-	PUNCT
admet-352	66	32	mediated	mediate	VERB
admet-352	66	33	resistance	resistance	NOUN
admet-352	66	34	after	after	ADP
admet-352	66	35	first	first	ADJ
admet-352	66	36	-	-	PUNCT
admet-352	66	37	line	line	NOUN
admet-352	66	38	egfr	egfr	NOUN
admet-352	66	39	tkis	tkis	PROPN
admet-352	66	40	.	.	PUNCT
admet-352	67	1	asp8273	asp8273	PROPN
admet-352	67	2	asp8273	asp8273	PROPN
admet-352	67	3	is	be	AUX
admet-352	67	4	another	another	DET
admet-352	67	5	small	small	ADJ
admet-352	67	6	molecule	molecule	NOUN
admet-352	67	7	,	,	PUNCT
admet-352	67	8	irreversible	irreversible	ADJ
admet-352	67	9	egfr	egfr	NOUN
admet-352	67	10	tk	tk	PROPN
admet-352	67	11	inhibitor	inhibitor	NOUN
admet-352	67	12	targeting	target	VERB
admet-352	67	13	egfr	egfr	ADJ
admet-352	67	14	mutations	mutation	NOUN
admet-352	67	15	including	include	VERB
admet-352	67	16	t790	t790	NUM
admet-352	67	17	m.	m.	NOUN
admet-352	67	18	in	in	ADP
admet-352	67	19	mouse	mouse	NOUN
admet-352	67	20	xenograft	xenograft	NOUN
admet-352	67	21	models	model	NOUN
admet-352	67	22	,	,	PUNCT
admet-352	67	23	asp8273	asp8273	ADV
admet-352	67	24	achieved	achieve	VERB
admet-352	67	25	complete	complete	ADJ
admet-352	67	26	remission	remission	NOUN
admet-352	67	27	of	of	ADP
admet-352	67	28	tumors	tumor	NOUN
admet-352	67	29	after	after	ADP
admet-352	67	30	14	14	NUM
admet-352	67	31	days	day	NOUN
admet-352	67	32	of	of	ADP
admet-352	67	33	treatment	treatment	NOUN
admet-352	67	34	.	.	PUNCT
admet-352	68	1	phase	phase	NOUN
admet-352	68	2	i	i	PRON
admet-352	68	3	/	/	SYM
admet-352	68	4	ii	ii	PROPN
admet-352	68	5	studies	study	NOUN
admet-352	68	6	have	have	AUX
admet-352	68	7	established	establish	VERB
admet-352	68	8	400	400	NUM
admet-352	68	9	mg	mg	NOUN
admet-352	68	10	/	/	SYM
admet-352	68	11	day	day	NOUN
admet-352	68	12	as	as	ADP
admet-352	68	13	the	the	DET
admet-352	68	14	optimal	optimal	ADJ
admet-352	68	15	dose	dose	NOUN
admet-352	68	16	.	.	PUNCT
admet-352	69	1	the	the	DET
admet-352	69	2	most	most	ADV
admet-352	69	3	common	common	ADJ
admet-352	69	4	adverse	adverse	ADJ
admet-352	69	5	events	event	NOUN
admet-352	69	6	were	be	AUX
admet-352	69	7	gastrointestinal	gastrointestinal	ADJ
admet-352	69	8	toxicity	toxicity	NOUN
admet-352	69	9	and	and	CCONJ
admet-352	69	10	thrombocytopenia	thrombocytopenia	PROPN
admet-352	69	11	.	.	PUNCT
admet-352	70	1	dose	dose	NOUN
admet-352	70	2	-	-	PUNCT
admet-352	70	3	limiting	limit	VERB
admet-352	70	4	toxicities	toxicity	NOUN
admet-352	70	5	were	be	AUX
admet-352	70	6	reported	report	VERB
admet-352	70	7	at	at	ADP
admet-352	70	8	levels	level	NOUN
admet-352	70	9	higher	high	ADJ
admet-352	70	10	doses	dose	NOUN
admet-352	70	11	(	(	PUNCT
admet-352	70	12	400	400	NUM
admet-352	70	13	-	-	SYM
admet-352	70	14	600	600	NUM
admet-352	70	15	mg	mg	NUM
admet-352	70	16	)	)	PUNCT
admet-352	70	17	.	.	PUNCT
admet-352	71	1	maximum	maximum	ADJ
admet-352	71	2	tolerated	tolerate	VERB
admet-352	71	3	dose	dose	NOUN
admet-352	71	4	was	be	AUX
admet-352	71	5	established	establish	VERB
admet-352	71	6	as	as	ADP
admet-352	71	7	300	300	NUM
admet-352	71	8	mg	mg	NOUN
admet-352	71	9	.	.	PUNCT
admet-352	72	1	the	the	DET
admet-352	72	2	objective	objective	ADJ
admet-352	72	3	response	response	NOUN
admet-352	72	4	rate	rate	NOUN
admet-352	72	5	in	in	ADP
admet-352	72	6	patients	patient	NOUN
admet-352	72	7	with	with	ADP
admet-352	72	8	t790	t790	NUM
admet-352	72	9	m	m	NOUN
admet-352	72	10	was	be	AUX
admet-352	72	11	25	25	NUM
admet-352	72	12	%	%	NOUN
admet-352	72	13	[	[	X
admet-352	72	14	24	24	NUM
admet-352	72	15	-	-	SYM
admet-352	72	16	25	25	NUM
admet-352	72	17	]	]	PUNCT
admet-352	72	18	.	.	PUNCT
admet-352	73	1	pf-06747775	pf-06747775	NOUN
admet-352	73	2	and	and	CCONJ
admet-352	73	3	egf816	egf816	PROPN
admet-352	73	4	they	they	PRON
admet-352	73	5	are	be	AUX
admet-352	73	6	other	other	ADJ
admet-352	73	7	new	new	ADJ
admet-352	73	8	small	small	ADJ
admet-352	73	9	molecules	molecule	NOUN
admet-352	73	10	that	that	PRON
admet-352	73	11	inhibit	inhibit	VERB
admet-352	73	12	t790	t790	NUM
admet-352	73	13	m	m	NOUN
admet-352	73	14	;	;	PUNCT
admet-352	73	15	however	however	ADV
admet-352	73	16	,	,	PUNCT
admet-352	73	17	they	they	PRON
admet-352	73	18	are	be	AUX
admet-352	73	19	in	in	ADP
admet-352	73	20	early	early	ADJ
admet-352	73	21	stages	stage	NOUN
admet-352	73	22	of	of	ADP
admet-352	73	23	study	study	NOUN
admet-352	73	24	and	and	CCONJ
admet-352	73	25	results	result	NOUN
admet-352	73	26	are	be	AUX
admet-352	73	27	expected	expect	VERB
admet-352	73	28	to	to	PART
admet-352	73	29	verify	verify	VERB
admet-352	73	30	their	their	PRON
admet-352	73	31	antitumor	antitumor	NOUN
admet-352	73	32	activity	activity	NOUN
admet-352	73	33	in	in	ADP
admet-352	73	34	the	the	DET
admet-352	73	35	clinic	clinic	NOUN
admet-352	74	1	[	[	X
admet-352	74	2	26	26	NUM
admet-352	74	3	-	-	SYM
admet-352	74	4	30	30	NUM
admet-352	74	5	]	]	PUNCT
admet-352	74	6	.	.	PUNCT
admet-352	75	1	similarly	similarly	ADV
admet-352	75	2	,	,	PUNCT
admet-352	75	3	there	there	PRON
admet-352	75	4	are	be	VERB
admet-352	75	5	clinical	clinical	ADJ
admet-352	75	6	phase	phase	NOUN
admet-352	75	7	i	i	PRON
admet-352	75	8	-	-	PUNCT
admet-352	75	9	ii	ii	PROPN
admet-352	75	10	trials	trial	NOUN
admet-352	75	11	to	to	PART
admet-352	75	12	evaluate	evaluate	VERB
admet-352	75	13	the	the	DET
admet-352	75	14	effectiveness	effectiveness	NOUN
admet-352	75	15	of	of	ADP
admet-352	75	16	combinations	combination	NOUN
admet-352	75	17	of	of	ADP
admet-352	75	18	third	third	ADJ
admet-352	75	19	generation	generation	NOUN
admet-352	75	20	tkis	tkis	NOUN
admet-352	75	21	with	with	ADP
admet-352	75	22	various	various	ADJ
admet-352	75	23	molecules	molecule	NOUN
admet-352	75	24	,	,	PUNCT
admet-352	75	25	including	include	VERB
admet-352	75	26	met	meet	VERB
admet-352	75	27	and	and	CCONJ
admet-352	75	28	mek	mek	PROPN
admet-352	75	29	inhibitors	inhibitor	NOUN
admet-352	75	30	,	,	PUNCT
admet-352	75	31	as	as	ADV
admet-352	75	32	well	well	ADV
admet-352	75	33	as	as	ADP
admet-352	75	34	immunotherapy	immunotherapy	NOUN
admet-352	75	35	,	,	PUNCT
admet-352	75	36	among	among	ADP
admet-352	75	37	others	other	NOUN
admet-352	75	38	.	.	PUNCT
admet-352	76	1	m.	m.	NOUN
admet-352	76	2	mendez	mendez	PROPN
admet-352	76	3	et	et	PROPN
admet-352	76	4	al	al	PROPN
admet-352	76	5	.	.	PROPN
admet-352	76	6	admet	admet	PROPN
admet-352	76	7	&	&	CCONJ
admet-352	76	8	dmpk	dmpk	PROPN
admet-352	76	9	5(1	5(1	NUM
admet-352	76	10	)	)	PUNCT
admet-352	76	11	(	(	PUNCT
admet-352	76	12	2017	2017	NUM
admet-352	76	13	)	)	PUNCT
admet-352	76	14	1	1	NUM
admet-352	76	15	-	-	SYM
admet-352	76	16	8	8	NUM
admet-352	76	17	4	4	NUM
admet-352	76	18	alk	alk	NOUN
admet-352	76	19	inhibitors	inhibitor	NOUN
admet-352	76	20	anaplastic	anaplastic	ADJ
admet-352	76	21	lymphoma	lymphoma	NOUN
admet-352	76	22	kinase	kinase	PROPN
admet-352	76	23	(	(	PUNCT
admet-352	76	24	alk	alk	PROPN
admet-352	76	25	)	)	PUNCT
admet-352	76	26	is	be	AUX
admet-352	76	27	a	a	DET
admet-352	76	28	member	member	NOUN
admet-352	76	29	of	of	ADP
admet-352	76	30	the	the	DET
admet-352	76	31	insulin	insulin	NOUN
admet-352	76	32	receptor	receptor	NOUN
admet-352	76	33	tyrosine	tyrosine	PROPN
admet-352	76	34	kinase	kinase	PROPN
admet-352	76	35	family	family	PROPN
admet-352	76	36	(	(	PUNCT
admet-352	76	37	rtk	rtk	PROPN
admet-352	76	38	)	)	PUNCT
admet-352	76	39	.	.	PUNCT
admet-352	77	1	the	the	DET
admet-352	77	2	echinoderm	echinoderm	NOUN
admet-352	77	3	microtubule	microtubule	NOUN
admet-352	77	4	-	-	PUNCT
admet-352	77	5	associated	associate	VERB
admet-352	77	6	protein	protein	NOUN
admet-352	77	7	-	-	PUNCT
admet-352	77	8	like	like	ADJ
admet-352	77	9	4	4	NUM
admet-352	77	10	-	-	ADJ
admet-352	77	11	anaplastic	anaplastic	ADJ
admet-352	77	12	lymphoma	lymphoma	NOUN
admet-352	77	13	kinase	kinase	PROPN
admet-352	77	14	(	(	PUNCT
admet-352	77	15	eml4	eml4	PROPN
admet-352	77	16	-	-	PUNCT
admet-352	77	17	alk	alk	PROPN
admet-352	77	18	)	)	PUNCT
admet-352	77	19	fusion	fusion	NOUN
admet-352	77	20	oncogene	oncogene	NOUN
admet-352	77	21	arises	arise	VERB
admet-352	77	22	from	from	ADP
admet-352	77	23	an	an	DET
admet-352	77	24	inversion	inversion	NOUN
admet-352	77	25	on	on	ADP
admet-352	77	26	the	the	DET
admet-352	77	27	short	short	ADJ
admet-352	77	28	arm	arm	NOUN
admet-352	77	29	of	of	ADP
admet-352	77	30	chromosome	chromosome	NOUN
admet-352	77	31	2	2	NUM
admet-352	77	32	that	that	PRON
admet-352	77	33	joins	join	VERB
admet-352	77	34	eml4	eml4	PROPN
admet-352	77	35	to	to	PART
admet-352	77	36	alk	alk	VERB
admet-352	77	37	.	.	PUNCT
admet-352	78	1	the	the	DET
admet-352	78	2	resulting	result	VERB
admet-352	78	3	chimeric	chimeric	ADJ
admet-352	78	4	protein	protein	NOUN
admet-352	78	5	,	,	PUNCT
admet-352	78	6	eml4	eml4	PROPN
admet-352	78	7	-	-	PUNCT
admet-352	78	8	alk	alk	PROPN
admet-352	78	9	,	,	PUNCT
admet-352	78	10	contains	contain	VERB
admet-352	78	11	an	an	DET
admet-352	78	12	n	n	CCONJ
admet-352	78	13	-	-	PUNCT
admet-352	78	14	terminus	terminus	NOUN
admet-352	78	15	derived	derive	VERB
admet-352	78	16	from	from	ADP
admet-352	78	17	eml4	eml4	PROPN
admet-352	78	18	and	and	CCONJ
admet-352	78	19	a	a	DET
admet-352	78	20	c	c	NOUN
admet-352	78	21	-	-	PUNCT
admet-352	78	22	terminus	terminus	NOUN
admet-352	78	23	containing	contain	VERB
admet-352	78	24	the	the	DET
admet-352	78	25	entire	entire	ADJ
admet-352	78	26	intracellular	intracellular	ADJ
admet-352	78	27	tyrosine	tyrosine	NOUN
admet-352	78	28	kinase	kinase	NOUN
admet-352	78	29	domain	domain	PROPN
admet-352	78	30	of	of	ADP
admet-352	78	31	alk	alk	PROPN
admet-352	78	32	.	.	PUNCT
admet-352	79	1	alk	alk	PROPN
admet-352	79	2	rearrangements	rearrangement	NOUN
admet-352	79	3	occur	occur	VERB
admet-352	79	4	in	in	ADP
admet-352	79	5	3–7	3–7	NUM
admet-352	79	6	%	%	NOUN
admet-352	79	7	of	of	ADP
admet-352	79	8	patients	patient	NOUN
admet-352	79	9	with	with	ADP
admet-352	79	10	nsclc	nsclc	NOUN
admet-352	79	11	and	and	CCONJ
admet-352	79	12	are	be	AUX
admet-352	79	13	more	more	ADV
admet-352	79	14	common	common	ADJ
admet-352	79	15	among	among	ADP
admet-352	79	16	patients	patient	NOUN
admet-352	79	17	with	with	ADP
admet-352	79	18	a	a	DET
admet-352	79	19	non	non	ADJ
admet-352	79	20	/	/	SYM
admet-352	79	21	light	light	ADJ
admet-352	79	22	smoking	smoking	NOUN
admet-352	79	23	history	history	NOUN
admet-352	79	24	,	,	PUNCT
admet-352	79	25	adenocarcinoma	adenocarcinoma	NOUN
admet-352	79	26	histology	histology	NOUN
admet-352	79	27	,	,	PUNCT
admet-352	79	28	a	a	DET
admet-352	79	29	younger	young	ADJ
admet-352	79	30	age	age	NOUN
admet-352	79	31	,	,	PUNCT
admet-352	79	32	female	female	ADJ
admet-352	79	33	gender	gender	NOUN
admet-352	79	34	and	and	CCONJ
admet-352	79	35	in	in	ADP
admet-352	79	36	tumours	tumours	PROPN
admet-352	79	37	wild	wild	ADJ
admet-352	79	38	type	type	NOUN
admet-352	79	39	for	for	ADP
admet-352	79	40	egfr	egfr	NOUN
admet-352	79	41	and	and	CCONJ
admet-352	79	42	kras	kra	NOUN
admet-352	80	1	[	[	X
admet-352	80	2	31	31	NUM
admet-352	80	3	]	]	PUNCT
admet-352	80	4	.	.	PUNCT
admet-352	81	1	anaplastic	anaplastic	ADJ
admet-352	81	2	lymphoma	lymphoma	NOUN
admet-352	81	3	kinase	kinase	PROPN
admet-352	81	4	(	(	PUNCT
admet-352	81	5	alk	alk	PROPN
admet-352	81	6	)	)	PUNCT
admet-352	81	7	gene	gene	NOUN
admet-352	81	8	rearrangements	rearrangement	NOUN
admet-352	81	9	may	may	AUX
admet-352	81	10	be	be	AUX
admet-352	81	11	detected	detect	VERB
admet-352	81	12	using	use	VERB
admet-352	81	13	fluorescence	fluorescence	NOUN
admet-352	81	14	in	in	ADP
admet-352	81	15	situ	situ	ADJ
admet-352	81	16	hybridization	hybridization	NOUN
admet-352	81	17	(	(	PUNCT
admet-352	81	18	fish	fish	NOUN
admet-352	81	19	)	)	PUNCT
admet-352	81	20	or	or	CCONJ
admet-352	81	21	immunohistochemistry	immunohistochemistry	NOUN
admet-352	81	22	(	(	PUNCT
admet-352	81	23	ihc	ihc	PROPN
admet-352	81	24	)	)	PUNCT
admet-352	81	25	.	.	PUNCT
admet-352	82	1	the	the	DET
admet-352	82	2	gold	gold	ADJ
admet-352	82	3	standard	standard	NOUN
admet-352	82	4	assay	assay	VERB
admet-352	82	5	for	for	ADP
admet-352	82	6	diagnosing	diagnosing	NOUN
admet-352	82	7	is	be	AUX
admet-352	82	8	fish	fish	NOUN
admet-352	82	9	.	.	PUNCT
admet-352	83	1	to	to	PART
admet-352	83	2	be	be	AUX
admet-352	83	3	declared	declare	VERB
admet-352	83	4	alk	alk	NOUN
admet-352	83	5	positive	positive	ADJ
admet-352	83	6	,	,	PUNCT
admet-352	83	7	at	at	ADV
admet-352	83	8	least	least	ADV
admet-352	83	9	15	15	NUM
admet-352	83	10	%	%	NOUN
admet-352	83	11	of	of	ADP
admet-352	83	12	50	50	NUM
admet-352	83	13	evaluated	evaluated	ADJ
admet-352	83	14	tumor	tumor	NOUN
admet-352	83	15	cells	cell	NOUN
admet-352	83	16	must	must	AUX
admet-352	83	17	harbour	harbour	VERB
admet-352	83	18	split	split	ADJ
admet-352	83	19	signals	signal	NOUN
admet-352	83	20	.	.	PUNCT
admet-352	84	1	ihc	ihc	PROPN
admet-352	84	2	may	may	AUX
admet-352	84	3	be	be	AUX
admet-352	84	4	a	a	DET
admet-352	84	5	more	more	ADV
admet-352	84	6	practical	practical	ADJ
admet-352	84	7	approach	approach	NOUN
admet-352	84	8	to	to	ADP
admet-352	84	9	detecting	detect	VERB
admet-352	84	10	alk	alk	VERB
admet-352	84	11	-	-	PUNCT
admet-352	84	12	positive	positive	ADJ
admet-352	84	13	nsclc	nsclc	NOUN
admet-352	84	14	.	.	PUNCT
admet-352	85	1	moreover	moreover	ADV
admet-352	85	2	,	,	PUNCT
admet-352	85	3	the	the	DET
admet-352	85	4	absence	absence	NOUN
admet-352	85	5	of	of	ADP
admet-352	85	6	alk	alk	NOUN
admet-352	85	7	expression	expression	NOUN
admet-352	85	8	in	in	ADP
admet-352	85	9	normal	normal	ADJ
admet-352	85	10	lung	lung	NOUN
admet-352	85	11	tissue	tissue	NOUN
admet-352	85	12	makes	make	VERB
admet-352	85	13	ihc	ihc	PROPN
admet-352	85	14	less	less	ADV
admet-352	85	15	cumbersome	cumbersome	ADJ
admet-352	85	16	to	to	PART
admet-352	85	17	interpret	interpret	VERB
admet-352	85	18	than	than	ADP
admet-352	85	19	fish	fish	NOUN
admet-352	85	20	.	.	PUNCT
admet-352	86	1	in	in	ADP
admet-352	86	2	2015	2015	NUM
admet-352	86	3	,	,	PUNCT
admet-352	86	4	an	an	DET
admet-352	86	5	ihc	ihc	PROPN
admet-352	86	6	test	test	NOUN
admet-352	86	7	using	use	VERB
admet-352	86	8	the	the	DET
admet-352	86	9	d5f3	d5f3	NOUN
admet-352	86	10	alk	alk	NOUN
admet-352	86	11	antibody	antibody	NOUN
admet-352	86	12	(	(	PUNCT
admet-352	86	13	ventana	ventana	PROPN
admet-352	86	14	)	)	PUNCT
admet-352	86	15	was	be	AUX
admet-352	86	16	approved	approve	VERB
admet-352	86	17	after	after	ADP
admet-352	86	18	demonstration	demonstration	NOUN
admet-352	86	19	of	of	ADP
admet-352	86	20	concordance	concordance	NOUN
admet-352	86	21	with	with	ADP
admet-352	86	22	the	the	DET
admet-352	86	23	break	break	NOUN
admet-352	86	24	apart	apart	ADP
admet-352	86	25	fish	fish	NOUN
admet-352	86	26	test	test	NOUN
admet-352	86	27	,	,	PUNCT
admet-352	86	28	with	with	ADP
admet-352	86	29	94	94	NUM
admet-352	86	30	%	%	NOUN
admet-352	86	31	overall	overall	ADJ
admet-352	86	32	agreement	agreement	NOUN
admet-352	86	33	[	[	X
admet-352	86	34	32	32	NUM
admet-352	86	35	]	]	PUNCT
admet-352	86	36	.	.	PUNCT
admet-352	87	1	first	first	ADJ
admet-352	87	2	generation	generation	NOUN
admet-352	87	3	of	of	ADP
admet-352	87	4	alk	alk	NOUN
admet-352	87	5	inhibitors	inhibitor	NOUN
admet-352	87	6	crizotinib	crizotinib	NOUN
admet-352	87	7	(	(	PUNCT
admet-352	87	8	pf-02341066	pf-02341066	NOUN
admet-352	87	9	,	,	PUNCT
admet-352	87	10	xalkori	xalkori	PROPN
admet-352	87	11	)	)	PUNCT
admet-352	88	1	crizotinib	crizotinib	NOUN
admet-352	88	2	is	be	AUX
admet-352	88	3	the	the	DET
admet-352	88	4	first	first	ADJ
admet-352	88	5	-	-	PUNCT
admet-352	88	6	generation	generation	NOUN
admet-352	88	7	alk	alk	NOUN
admet-352	88	8	inhibitor	inhibitor	NOUN
admet-352	88	9	approved	approve	VERB
admet-352	88	10	for	for	ADP
admet-352	88	11	alk	alk	NOUN
admet-352	88	12	-	-	PUNCT
admet-352	88	13	positive	positive	ADJ
admet-352	88	14	nsclc	nsclc	NOUN
admet-352	88	15	(	(	PUNCT
admet-352	88	16	4	4	NUM
admet-352	88	17	)	)	PUNCT
admet-352	88	18	.	.	PUNCT
admet-352	89	1	it	it	PRON
admet-352	89	2	also	also	ADV
admet-352	89	3	has	have	VERB
admet-352	89	4	activity	activity	NOUN
admet-352	89	5	against	against	ADP
admet-352	89	6	c	c	NOUN
admet-352	89	7	-	-	PUNCT
admet-352	89	8	met	meet	VERB
admet-352	89	9	and	and	CCONJ
admet-352	89	10	ros1	ros1	PROPN
admet-352	89	11	tyrosine	tyrosine	NOUN
admet-352	89	12	kinases	kinase	NOUN
admet-352	89	13	.	.	PUNCT
admet-352	90	1	it	it	PRON
admet-352	90	2	was	be	AUX
admet-352	90	3	approved	approve	VERB
admet-352	90	4	in	in	ADP
admet-352	90	5	first	first	ADJ
admet-352	90	6	line	line	NOUN
admet-352	90	7	and	and	CCONJ
admet-352	90	8	in	in	ADP
admet-352	90	9	pretreated	pretreate	VERB
admet-352	90	10	alk	alk	NOUN
admet-352	90	11	positive	positive	ADJ
admet-352	90	12	nsclc	nsclc	NOUN
admet-352	90	13	patients	patient	NOUN
admet-352	90	14	[	[	X
admet-352	90	15	33	33	NUM
admet-352	90	16	-	-	SYM
admet-352	90	17	34	34	NUM
admet-352	90	18	]	]	PUNCT
admet-352	90	19	.	.	PUNCT
admet-352	91	1	response	response	NOUN
admet-352	91	2	rates	rate	NOUN
admet-352	91	3	to	to	PART
admet-352	91	4	crizotinib	crizotinib	VERB
admet-352	91	5	are	be	AUX
admet-352	91	6	approximately	approximately	ADV
admet-352	91	7	60	60	NUM
admet-352	91	8	%	%	NOUN
admet-352	91	9	,	,	PUNCT
admet-352	91	10	which	which	PRON
admet-352	91	11	means	mean	VERB
admet-352	91	12	there	there	PRON
admet-352	91	13	are	be	VERB
admet-352	91	14	a	a	DET
admet-352	91	15	40	40	NUM
admet-352	91	16	%	%	NOUN
admet-352	91	17	of	of	ADP
admet-352	91	18	primary	primary	ADJ
admet-352	91	19	resistances	resistance	NOUN
admet-352	91	20	.	.	PUNCT
admet-352	92	1	one	one	NUM
admet-352	92	2	reason	reason	NOUN
admet-352	92	3	is	be	AUX
admet-352	92	4	because	because	SCONJ
admet-352	92	5	some	some	DET
admet-352	92	6	alk	alk	NOUN
admet-352	92	7	translocations	translocation	NOUN
admet-352	92	8	may	may	AUX
admet-352	92	9	not	not	PART
admet-352	92	10	generate	generate	VERB
admet-352	92	11	functional	functional	ADJ
admet-352	92	12	rearrangements	rearrangement	NOUN
admet-352	92	13	in	in	ADP
admet-352	92	14	all	all	DET
admet-352	92	15	patients	patient	NOUN
admet-352	92	16	[	[	X
admet-352	92	17	35	35	NUM
admet-352	92	18	]	]	PUNCT
admet-352	92	19	.	.	PUNCT
admet-352	93	1	there	there	PRON
admet-352	93	2	are	be	VERB
admet-352	93	3	secondary	secondary	ADJ
admet-352	93	4	causes	cause	NOUN
admet-352	93	5	of	of	ADP
admet-352	93	6	resistance	resistance	NOUN
admet-352	93	7	thought	think	VERB
admet-352	93	8	alk	alk	VERB
admet-352	93	9	kinase	kinase	PROPN
admet-352	93	10	mutations	mutation	NOUN
admet-352	94	1	and	and	CCONJ
admet-352	94	2	it	it	PRON
admet-352	94	3	may	may	AUX
admet-352	94	4	occur	occur	VERB
admet-352	94	5	in	in	ADP
admet-352	94	6	30	30	NUM
admet-352	94	7	%	%	NOUN
admet-352	94	8	of	of	ADP
admet-352	94	9	the	the	DET
admet-352	94	10	cases	case	NOUN
admet-352	94	11	:	:	PUNCT
admet-352	94	12	l1196	l1196	NUM
admet-352	94	13	m	m	NOUN
admet-352	94	14	,	,	PUNCT
admet-352	94	15	f1174l	f1174l	NOUN
admet-352	94	16	,	,	PUNCT
admet-352	94	17	and	and	CCONJ
admet-352	94	18	g1202r	g1202r	PROPN
admet-352	94	19	or	or	CCONJ
admet-352	94	20	c1156y	c1156y	PROPN
admet-352	94	21	mutation	mutation	NOUN
admet-352	94	22	[	[	X
admet-352	94	23	36	36	NUM
admet-352	94	24	]	]	PUNCT
admet-352	94	25	activation	activation	NOUN
admet-352	94	26	of	of	ADP
admet-352	94	27	other	other	ADJ
admet-352	94	28	oncogenes	oncogene	NOUN
admet-352	94	29	resulting	result	VERB
admet-352	94	30	in	in	ADP
admet-352	94	31	bypass	bypass	NOUN
admet-352	94	32	signaling	signal	VERB
admet-352	94	33	cascades	cascade	NOUN
admet-352	94	34	such	such	ADJ
admet-352	94	35	as	as	ADP
admet-352	94	36	egfr	egfr	NOUN
admet-352	94	37	,	,	PUNCT
admet-352	94	38	ckit	ckit	NOUN
admet-352	94	39	and	and	CCONJ
admet-352	94	40	kras	kra	NOUN
admet-352	94	41	or	or	CCONJ
admet-352	94	42	copy	copy	VERB
admet-352	94	43	number	number	NOUN
admet-352	94	44	gains	gain	NOUN
admet-352	94	45	of	of	ADP
admet-352	94	46	the	the	DET
admet-352	94	47	alk	alk	NOUN
admet-352	94	48	fusion	fusion	NOUN
admet-352	94	49	gene	gene	NOUN
admet-352	94	50	[	[	X
admet-352	94	51	37	37	NUM
admet-352	94	52	]	]	PUNCT
admet-352	94	53	and	and	CCONJ
admet-352	94	54	pharmacokinetic	pharmacokinetic	ADJ
admet-352	94	55	failings	failing	NOUN
admet-352	94	56	of	of	ADP
admet-352	94	57	the	the	DET
admet-352	94	58	drug	drug	NOUN
admet-352	94	59	itself	itself	PRON
admet-352	94	60	due	due	ADP
admet-352	94	61	to	to	ADP
admet-352	94	62	inadequate	inadequate	ADJ
admet-352	94	63	systemic	systemic	ADJ
admet-352	94	64	levels	level	NOUN
admet-352	94	65	or	or	CCONJ
admet-352	94	66	poor	poor	ADJ
admet-352	94	67	cns	cns	NOUN
admet-352	94	68	penetration	penetration	NOUN
admet-352	94	69	and	and	CCONJ
admet-352	94	70	about	about	ADV
admet-352	94	71	50	50	NUM
admet-352	94	72	%	%	NOUN
admet-352	94	73	of	of	ADP
admet-352	94	74	patients	patient	NOUN
admet-352	94	75	develop	develop	VERB
admet-352	94	76	cns	cns	NOUN
admet-352	94	77	metastases	metastasis	NOUN
admet-352	94	78	during	during	ADP
admet-352	94	79	treatment	treatment	NOUN
admet-352	94	80	with	with	ADP
admet-352	94	81	crizotinib	crizotinib	NOUN
admet-352	95	1	[	[	X
admet-352	95	2	38	38	NUM
admet-352	95	3	-	-	SYM
admet-352	95	4	39	39	NUM
admet-352	95	5	]	]	PUNCT
admet-352	95	6	and	and	CCONJ
admet-352	95	7	in	in	ADP
admet-352	95	8	many	many	ADJ
admet-352	95	9	cases	case	NOUN
admet-352	95	10	,	,	PUNCT
admet-352	95	11	no	no	DET
admet-352	95	12	definitive	definitive	ADJ
admet-352	95	13	resistance	resistance	NOUN
admet-352	95	14	mutation	mutation	NOUN
admet-352	95	15	can	can	AUX
admet-352	95	16	be	be	AUX
admet-352	95	17	identified	identify	VERB
admet-352	95	18	[	[	PUNCT
admet-352	95	19	40	40	NUM
admet-352	95	20	]	]	PUNCT
admet-352	95	21	.	.	PUNCT
admet-352	96	1	second	second	ADJ
admet-352	96	2	generation	generation	NOUN
admet-352	96	3	of	of	ADP
admet-352	96	4	alk	alk	NOUN
admet-352	96	5	inhibitors	inhibitor	NOUN
admet-352	96	6	these	these	DET
admet-352	96	7	drugs	drug	NOUN
admet-352	96	8	were	be	AUX
admet-352	96	9	developed	develop	VERB
admet-352	96	10	to	to	PART
admet-352	96	11	overcome	overcome	VERB
admet-352	96	12	crizotinib	crizotinib	ADJ
admet-352	96	13	-	-	PUNCT
admet-352	96	14	resistant	resistant	ADJ
admet-352	96	15	mutations	mutation	NOUN
admet-352	96	16	and	and	CCONJ
admet-352	96	17	to	to	PART
admet-352	96	18	improve	improve	VERB
admet-352	96	19	activity	activity	NOUN
admet-352	96	20	in	in	ADP
admet-352	96	21	cns	cns	NOUN
admet-352	96	22	disease	disease	NOUN
admet-352	96	23	(	(	PUNCT
admet-352	96	24	table	table	NOUN
admet-352	96	25	1	1	NUM
admet-352	96	26	)	)	PUNCT
admet-352	96	27	.	.	PUNCT
admet-352	97	1	ceritinib	ceritinib	PROPN
admet-352	97	2	ceritinib	ceritinib	PROPN
admet-352	97	3	is	be	AUX
admet-352	97	4	20	20	NUM
admet-352	97	5	-	-	NUM
admet-352	97	6	fold	fold	VERB
admet-352	97	7	more	more	ADV
admet-352	97	8	potent	potent	ADJ
admet-352	97	9	than	than	SCONJ
admet-352	97	10	crizotinib	crizotinib	VERB
admet-352	97	11	in	in	ADP
admet-352	97	12	terms	term	NOUN
admet-352	97	13	of	of	ADP
admet-352	97	14	alk	alk	NOUN
admet-352	97	15	selectivity	selectivity	NOUN
admet-352	97	16	[	[	X
admet-352	97	17	41	41	NUM
admet-352	97	18	]	]	PUNCT
admet-352	97	19	.	.	PUNCT
admet-352	98	1	it	it	PRON
admet-352	98	2	strongly	strongly	ADV
admet-352	98	3	inhibits	inhibit	VERB
admet-352	98	4	resistance	resistance	NOUN
admet-352	98	5	mutations	mutation	NOUN
admet-352	98	6	,	,	PUNCT
admet-352	98	7	and	and	CCONJ
admet-352	98	8	especially	especially	ADV
admet-352	98	9	l1196	l1196	PROPN
admet-352	98	10	m	m	PROPN
admet-352	98	11	,	,	PUNCT
admet-352	98	12	g1269a	g1269a	PROPN
admet-352	98	13	,	,	PUNCT
admet-352	98	14	i1171	i1171	PROPN
admet-352	98	15	t	t	PROPN
admet-352	98	16	and	and	CCONJ
admet-352	98	17	s1206y	s1206y	ADV
admet-352	98	18	mutations	mutation	NOUN
admet-352	98	19	.	.	PUNCT
admet-352	99	1	however	however	ADV
admet-352	99	2	,	,	PUNCT
admet-352	99	3	ceritinib	ceritinib	PROPN
admet-352	99	4	was	be	AUX
admet-352	99	5	not	not	PART
admet-352	99	6	effective	effective	ADJ
admet-352	99	7	against	against	ADP
admet-352	99	8	g1202r	g1202r	NOUN
admet-352	99	9	and	and	CCONJ
admet-352	99	10	f1174c	f1174c	PROPN
admet-352	99	11	crizotinib	crizotinib	ADV
admet-352	99	12	-	-	PUNCT
admet-352	99	13	resistant	resistant	ADJ
admet-352	99	14	mutations	mutation	NOUN
admet-352	99	15	.	.	PUNCT
admet-352	100	1	the	the	DET
admet-352	100	2	updated	update	VERB
admet-352	100	3	ascend-1	ascend-1	ADP
admet-352	100	4	report	report	NOUN
admet-352	100	5	on	on	ADP
admet-352	100	6	the	the	DET
admet-352	100	7	evaluation	evaluation	NOUN
admet-352	100	8	of	of	ADP
admet-352	100	9	the	the	DET
admet-352	100	10	efficacy	efficacy	NOUN
admet-352	100	11	of	of	ADP
admet-352	100	12	ceritinib	ceritinib	PROPN
admet-352	100	13	at	at	ADP
admet-352	100	14	a	a	DET
admet-352	100	15	daily	daily	ADJ
admet-352	100	16	dose	dose	NOUN
admet-352	100	17	of	of	ADP
admet-352	100	18	750	750	NUM
admet-352	100	19	mg	mg	NOUN
admet-352	100	20	was	be	AUX
admet-352	100	21	recently	recently	ADV
admet-352	100	22	presented	present	VERB
admet-352	100	23	.	.	PUNCT
admet-352	101	1	a	a	DET
admet-352	101	2	total	total	NOUN
admet-352	101	3	of	of	ADP
admet-352	101	4	246	246	NUM
admet-352	101	5	patients	patient	NOUN
admet-352	101	6	with	with	ADP
admet-352	101	7	alk+	alk+	NOUN
admet-352	101	8	nsclc	nsclc	NOUN
admet-352	101	9	were	be	AUX
admet-352	101	10	enrolled	enrol	VERB
admet-352	101	11	,	,	PUNCT
admet-352	101	12	including	include	VERB
admet-352	101	13	163	163	NUM
admet-352	101	14	pretreated	pretreate	VERB
admet-352	101	15	with	with	ADP
admet-352	101	16	an	an	DET
admet-352	101	17	alk	alk	NOUN
admet-352	101	18	inhibitor	inhibitor	NOUN
admet-352	101	19	(	(	PUNCT
admet-352	101	20	crizotinib	crizotinib	VERB
admet-352	101	21	or	or	CCONJ
admet-352	101	22	alectinib	alectinib	NOUN
admet-352	101	23	)	)	PUNCT
admet-352	101	24	and	and	CCONJ
admet-352	101	25	83	83	NUM
admet-352	101	26	alk	alk	NOUN
admet-352	101	27	inhibitor	inhibitor	NOUN
admet-352	101	28	naïve	naïve	ADJ
admet-352	101	29	patients	patient	NOUN
admet-352	101	30	.	.	PUNCT
admet-352	102	1	the	the	DET
admet-352	102	2	overall	overall	ADJ
admet-352	102	3	rate	rate	NOUN
admet-352	102	4	responses	response	NOUN
admet-352	102	5	(	(	PUNCT
admet-352	102	6	orrs	orr	NOUN
admet-352	102	7	)	)	PUNCT
admet-352	102	8	were	be	AUX
admet-352	102	9	56.4	56.4	NUM
admet-352	102	10	%	%	NOUN
admet-352	102	11	,	,	PUNCT
admet-352	102	12	72.3	72.3	NUM
admet-352	102	13	%	%	NOUN
admet-352	102	14	and	and	CCONJ
admet-352	102	15	61.8	61.8	NUM
admet-352	102	16	%	%	NOUN
admet-352	102	17	and	and	CCONJ
admet-352	102	18	the	the	DET
admet-352	102	19	median	median	NOUN
admet-352	102	20	of	of	ADP
admet-352	102	21	progression	progression	NOUN
admet-352	102	22	free	free	ADJ
admet-352	102	23	survival	survival	NOUN
admet-352	102	24	(	(	PUNCT
admet-352	102	25	pfs	pfs	PROPN
admet-352	102	26	)	)	PUNCT
admet-352	102	27	was	be	AUX
admet-352	102	28	18.4	18.4	NUM
admet-352	102	29	,	,	PUNCT
admet-352	102	30	9.0	9.0	NUM
admet-352	102	31	and	and	CCONJ
admet-352	102	32	6.9	6.9	NUM
admet-352	102	33	months	month	NOUN
admet-352	102	34	in	in	ADP
admet-352	102	35	the	the	DET
admet-352	102	36	group	group	NOUN
admet-352	102	37	pretreated	pretreate	VERB
admet-352	102	38	with	with	ADP
admet-352	102	39	an	an	DET
admet-352	102	40	alk	alk	NOUN
admet-352	102	41	inhibitor	inhibitor	NOUN
admet-352	102	42	,	,	PUNCT
admet-352	102	43	alk	alk	VERB
admet-352	102	44	inhibitor	inhibitor	NOUN
admet-352	102	45	-	-	PUNCT
admet-352	102	46	naive	naive	ADJ
admet-352	102	47	patients	patient	NOUN
admet-352	102	48	and	and	CCONJ
admet-352	102	49	the	the	DET
admet-352	102	50	overall	overall	ADJ
admet-352	102	51	population	population	NOUN
admet-352	102	52	,	,	PUNCT
admet-352	102	53	respectively	respectively	ADV
admet-352	102	54	.	.	PUNCT
admet-352	103	1	124	124	NUM
admet-352	103	2	patients	patient	NOUN
admet-352	103	3	had	have	VERB
admet-352	103	4	measurable	measurable	ADJ
admet-352	103	5	brain	brain	NOUN
admet-352	103	6	metastases	metastasis	NOUN
admet-352	103	7	at	at	ADP
admet-352	103	8	baseline	baseline	NOUN
admet-352	103	9	:	:	PUNCT
admet-352	103	10	28	28	NUM
admet-352	103	11	patients	patient	NOUN
admet-352	103	12	pretreated	pretreate	VERB
admet-352	103	13	with	with	ADP
admet-352	103	14	an	an	DET
admet-352	103	15	alk	alk	NOUN
admet-352	103	16	inhibitor	inhibitor	NOUN
admet-352	103	17	and	and	CCONJ
admet-352	103	18	8	8	NUM
admet-352	103	19	admet	admet	X
admet-352	103	20	&	&	CCONJ
admet-352	103	21	dmpk	dmpk	PROPN
admet-352	103	22	5(1	5(1	NUM
admet-352	103	23	)	)	PUNCT
admet-352	103	24	(	(	PUNCT
admet-352	103	25	2017	2017	NUM
admet-352	103	26	)	)	PUNCT
admet-352	103	27	1	1	NUM
admet-352	103	28	-	-	SYM
admet-352	103	29	8	8	NUM
admet-352	103	30	tkis	tkis	NOUN
admet-352	103	31	in	in	ADP
admet-352	103	32	non	non	ADJ
admet-352	103	33	-	-	ADJ
admet-352	103	34	small	small	ADJ
admet-352	103	35	cell	cell	NOUN
admet-352	103	36	lung	lung	NOUN
admet-352	103	37	cancer	cancer	NOUN
admet-352	103	38	doi	doi	NOUN
admet-352	103	39	:	:	PUNCT
admet-352	103	40	10.5599	10.5599	NUM
admet-352	103	41	/	/	SYM
admet-352	103	42	admet.5.1.352	admet.5.1.352	NOUN
admet-352	103	43	5	5	NUM
admet-352	103	44	patients	patient	NOUN
admet-352	103	45	in	in	ADP
admet-352	103	46	the	the	DET
admet-352	103	47	alk	alk	NOUN
admet-352	103	48	inhibitor	inhibitor	NOUN
admet-352	103	49	naive	naive	ADJ
admet-352	103	50	group	group	NOUN
admet-352	103	51	.	.	PUNCT
admet-352	104	1	the	the	DET
admet-352	104	2	intracranial	intracranial	ADJ
admet-352	104	3	orrs	orr	NOUN
admet-352	104	4	were	be	AUX
admet-352	104	5	36	36	NUM
admet-352	104	6	%	%	NOUN
admet-352	104	7	(	(	PUNCT
admet-352	104	8	95	95	NUM
admet-352	104	9	%	%	NOUN
admet-352	104	10	ci	ci	NOUN
admet-352	104	11	19–56	19–56	NUM
admet-352	104	12	%	%	NOUN
admet-352	104	13	)	)	PUNCT
admet-352	104	14	in	in	ADP
admet-352	104	15	patients	patient	NOUN
admet-352	104	16	pretreated	pretreate	VERB
admet-352	104	17	with	with	ADP
admet-352	104	18	an	an	DET
admet-352	104	19	alk	alk	NOUN
admet-352	104	20	inhibitor	inhibitor	NOUN
admet-352	104	21	and	and	CCONJ
admet-352	104	22	63	63	NUM
admet-352	104	23	%	%	NOUN
admet-352	104	24	(	(	PUNCT
admet-352	104	25	95	95	NUM
admet-352	104	26	%	%	NOUN
admet-352	104	27	ci	ci	NOUN
admet-352	104	28	25–92	25–92	NUM
admet-352	104	29	%	%	NOUN
admet-352	104	30	)	)	PUNCT
admet-352	104	31	in	in	ADP
admet-352	104	32	the	the	DET
admet-352	104	33	alk	alk	NOUN
admet-352	104	34	inhibitor	inhibitor	NOUN
admet-352	104	35	-	-	PUNCT
admet-352	104	36	naive	naive	ADJ
admet-352	104	37	group	group	NOUN
admet-352	104	38	[	[	X
admet-352	104	39	33,34	33,34	NOUN
admet-352	104	40	]	]	X
admet-352	104	41	.	.	PUNCT
admet-352	105	1	the	the	DET
admet-352	105	2	ascend-3	ascend-3	NUM
admet-352	105	3	trial	trial	NOUN
admet-352	105	4	enrolled	enrol	VERB
admet-352	105	5	124	124	NUM
admet-352	105	6	patients	patient	NOUN
admet-352	105	7	,	,	PUNCT
admet-352	105	8	40.3	40.3	NUM
admet-352	105	9	%	%	NOUN
admet-352	105	10	with	with	ADP
admet-352	105	11	brain	brain	NOUN
admet-352	105	12	metastases	metastasis	NOUN
admet-352	105	13	,	,	PUNCT
admet-352	105	14	46	46	NUM
admet-352	105	15	%	%	NOUN
admet-352	105	16	of	of	ADP
admet-352	105	17	whom	whom	PRON
admet-352	105	18	had	have	VERB
admet-352	105	19	no	no	DET
admet-352	105	20	prior	prior	ADJ
admet-352	105	21	brt	brt	PROPN
admet-352	105	22	(	(	PUNCT
admet-352	105	23	brain	brain	NOUN
admet-352	105	24	radiotherapy	radiotherapy	NOUN
admet-352	105	25	)	)	PUNCT
admet-352	105	26	.	.	PUNCT
admet-352	106	1	the	the	DET
admet-352	106	2	orr	orr	PROPN
admet-352	106	3	was	be	AUX
admet-352	106	4	63.7	63.7	NUM
admet-352	106	5	%	%	NOUN
admet-352	106	6	(	(	PUNCT
admet-352	106	7	95	95	NUM
admet-352	106	8	%	%	NOUN
admet-352	106	9	ci54.6–72.2	ci54.6–72.2	NOUN
admet-352	106	10	%	%	NOUN
admet-352	106	11	)	)	PUNCT
admet-352	106	12	.	.	PUNCT
admet-352	107	1	the	the	DET
admet-352	107	2	intracranial	intracranial	ADJ
admet-352	107	3	orr	orr	PROPN
admet-352	107	4	was	be	AUX
admet-352	107	5	20	20	NUM
admet-352	107	6	%	%	NOUN
admet-352	107	7	(	(	PUNCT
admet-352	107	8	95	95	NUM
admet-352	107	9	%	%	NOUN
admet-352	107	10	ci	ci	NOUN
admet-352	107	11	2.5	2.5	NUM
admet-352	107	12	–	–	PUNCT
admet-352	107	13	55.6	55.6	NUM
admet-352	107	14	%	%	NOUN
admet-352	107	15	)	)	PUNCT
admet-352	108	1	[	[	X
admet-352	108	2	35	35	NUM
admet-352	108	3	]	]	PUNCT
admet-352	108	4	.	.	PUNCT
admet-352	109	1	two	two	NUM
admet-352	109	2	randomized	randomize	VERB
admet-352	109	3	phase	phase	NOUN
admet-352	109	4	iii	iii	NUM
admet-352	109	5	trials	trial	NOUN
admet-352	109	6	are	be	AUX
admet-352	109	7	currently	currently	ADV
admet-352	109	8	open	open	ADJ
admet-352	109	9	to	to	PART
admet-352	109	10	evaluate	evaluate	VERB
admet-352	109	11	ceritinib	ceritinib	NOUN
admet-352	109	12	versus	versus	ADP
admet-352	109	13	first	first	ADJ
admet-352	109	14	-	-	PUNCT
admet-352	109	15	line	line	NOUN
admet-352	109	16	chemotherapy	chemotherapy	NOUN
admet-352	109	17	(	(	PUNCT
admet-352	109	18	ascend-4	ascend-4	NUM
admet-352	109	19	)	)	PUNCT
admet-352	109	20	and	and	CCONJ
admet-352	109	21	second	second	ADJ
admet-352	109	22	-	-	PUNCT
admet-352	109	23	line	line	NOUN
admet-352	109	24	chemotherapy	chemotherapy	NOUN
admet-352	109	25	(	(	PUNCT
admet-352	109	26	ascend-5	ascend-5	PROPN
admet-352	109	27	)	)	PUNCT
admet-352	109	28	.	.	PUNCT
admet-352	110	1	alectinib	alectinib	PROPN
admet-352	110	2	alectinib	alectinib	PROPN
admet-352	110	3	is	be	AUX
admet-352	110	4	a	a	DET
admet-352	110	5	highly	highly	ADV
admet-352	110	6	selective	selective	ADJ
admet-352	110	7	alk	alk	NOUN
admet-352	110	8	inhibitor	inhibitor	NOUN
admet-352	110	9	,	,	PUNCT
admet-352	110	10	in	in	ADP
admet-352	110	11	preclinical	preclinical	ADJ
admet-352	110	12	studies	study	NOUN
admet-352	110	13	it	it	PRON
admet-352	110	14	showed	show	VERB
admet-352	110	15	activity	activity	NOUN
admet-352	110	16	against	against	ADP
admet-352	110	17	crizotinibresistant	crizotinibresistant	NOUN
admet-352	110	18	alk	alk	NOUN
admet-352	110	19	mutations	mutation	NOUN
admet-352	110	20	(	(	PUNCT
admet-352	110	21	l1196	l1196	NOUN
admet-352	110	22	m	m	NOUN
admet-352	110	23	,	,	PUNCT
admet-352	110	24	c1156y	c1156y	NOUN
admet-352	110	25	and	and	CCONJ
admet-352	110	26	f1174l	f1174l	NOUN
admet-352	110	27	)	)	PUNCT
admet-352	110	28	and	and	CCONJ
admet-352	110	29	ret	ret	NOUN
admet-352	110	30	but	but	CCONJ
admet-352	110	31	not	not	PART
admet-352	110	32	against	against	ADP
admet-352	110	33	insr	insr	NOUN
admet-352	110	34	,	,	PUNCT
admet-352	110	35	igf	igf	PROPN
admet-352	110	36	-	-	ADJ
admet-352	110	37	r1	r1	PROPN
admet-352	110	38	and	and	CCONJ
admet-352	110	39	ros1	ros1	PROPN
admet-352	110	40	.	.	PUNCT
admet-352	111	1	japan	japan	PROPN
admet-352	111	2	was	be	AUX
admet-352	111	3	the	the	DET
admet-352	111	4	first	first	ADJ
admet-352	111	5	country	country	NOUN
admet-352	111	6	to	to	PART
admet-352	111	7	approve	approve	VERB
admet-352	111	8	alectinib	alectinib	NOUN
admet-352	111	9	in	in	ADP
admet-352	111	10	patients	patient	NOUN
admet-352	111	11	with	with	ADP
admet-352	111	12	advanced	advanced	ADJ
admet-352	111	13	alk	alk	NOUN
admet-352	111	14	-	-	PUNCT
admet-352	111	15	rearranged	rearrange	VERB
admet-352	111	16	nsclc	nsclc	NOUN
admet-352	111	17	,	,	PUNCT
admet-352	111	18	based	base	VERB
admet-352	111	19	on	on	ADP
admet-352	111	20	the	the	DET
admet-352	111	21	results	result	NOUN
admet-352	111	22	of	of	ADP
admet-352	111	23	the	the	DET
admet-352	111	24	phase	phase	NOUN
admet-352	111	25	i	i	PROPN
admet-352	111	26	/	/	SYM
admet-352	111	27	ii	ii	PROPN
admet-352	111	28	af-001jp	af-001jp	PROPN
admet-352	111	29	trial	trial	NOUN
admet-352	111	30	targeting	target	VERB
admet-352	111	31	patients	patient	NOUN
admet-352	111	32	with	with	ADP
admet-352	111	33	alk+	alk+	NOUN
admet-352	111	34	nsclc	nsclc	NOUN
admet-352	111	35	who	who	PRON
admet-352	111	36	had	have	AUX
admet-352	111	37	not	not	PART
admet-352	111	38	previously	previously	ADV
admet-352	111	39	been	be	AUX
admet-352	111	40	treated	treat	VERB
admet-352	111	41	with	with	ADP
admet-352	111	42	crizotinib	crizotinib	NOUN
admet-352	111	43	or	or	CCONJ
admet-352	111	44	other	other	ADJ
admet-352	111	45	alk	alk	NOUN
admet-352	111	46	inhibitors	inhibitor	NOUN
admet-352	111	47	[	[	X
admet-352	111	48	42,43	42,43	VERB
admet-352	111	49	]	]	X
admet-352	111	50	.	.	PUNCT
admet-352	112	1	in	in	ADP
admet-352	112	2	the	the	DET
admet-352	112	3	phase	phase	NOUN
admet-352	112	4	ii	ii	NOUN
admet-352	112	5	trial	trial	NOUN
admet-352	112	6	,	,	PUNCT
admet-352	112	7	46	46	NUM
admet-352	112	8	patients	patient	NOUN
admet-352	112	9	were	be	AUX
admet-352	112	10	treated	treat	VERB
admet-352	112	11	and	and	CCONJ
admet-352	112	12	43	43	NUM
admet-352	112	13	of	of	ADP
admet-352	112	14	them	they	PRON
admet-352	112	15	(	(	PUNCT
admet-352	112	16	93.5	93.5	NUM
admet-352	112	17	%	%	NOUN
admet-352	112	18	)	)	PUNCT
admet-352	112	19	achieved	achieve	VERB
admet-352	112	20	an	an	DET
admet-352	112	21	orr	orr	NOUN
admet-352	112	22	(	(	PUNCT
admet-352	112	23	95	95	NUM
admet-352	112	24	%	%	NOUN
admet-352	112	25	ci	ci	NOUN
admet-352	112	26	82.1–98.6	82.1–98.6	NUM
admet-352	112	27	)	)	PUNCT
admet-352	112	28	.	.	PUNCT
admet-352	113	1	the	the	DET
admet-352	113	2	2	2	NUM
admet-352	113	3	-	-	PUNCT
admet-352	113	4	year	year	NOUN
admet-352	113	5	pfs	pfs	PROPN
admet-352	113	6	rate	rate	NOUN
admet-352	113	7	was	be	AUX
admet-352	113	8	76	76	NUM
admet-352	113	9	%	%	NOUN
admet-352	113	10	(	(	PUNCT
admet-352	113	11	95	95	NUM
admet-352	113	12	%	%	NOUN
admet-352	113	13	ci	ci	NOUN
admet-352	113	14	60–86	60–86	NUM
admet-352	113	15	%	%	NOUN
admet-352	113	16	)	)	PUNCT
admet-352	113	17	and	and	CCONJ
admet-352	113	18	the	the	DET
admet-352	113	19	2	2	NUM
admet-352	113	20	-	-	PUNCT
admet-352	113	21	year	year	NOUN
admet-352	113	22	os	os	NOUN
admet-352	113	23	was	be	AUX
admet-352	113	24	79	79	NUM
admet-352	113	25	%	%	NOUN
admet-352	113	26	(	(	PUNCT
admet-352	113	27	95	95	NUM
admet-352	113	28	%	%	NOUN
admet-352	113	29	ci	ci	NOUN
admet-352	113	30	63–89	63–89	NUM
admet-352	113	31	%	%	NOUN
admet-352	113	32	)	)	PUNCT
admet-352	113	33	.	.	PUNCT
admet-352	114	1	a	a	DET
admet-352	114	2	phase	phase	NOUN
admet-352	114	3	i	i	NOUN
admet-352	114	4	/	/	SYM
admet-352	114	5	ii	ii	PROPN
admet-352	114	6	trial	trial	NOUN
admet-352	114	7	with	with	ADP
admet-352	114	8	47	47	NUM
admet-352	114	9	alk+	alk+	NOUN
admet-352	114	10	nsclc	nsclc	NOUN
admet-352	114	11	patients	patient	NOUN
admet-352	114	12	who	who	PRON
admet-352	114	13	progressed	progress	VERB
admet-352	114	14	on	on	ADP
admet-352	114	15	or	or	CCONJ
admet-352	114	16	were	be	AUX
admet-352	114	17	intolerant	intolerant	ADJ
admet-352	114	18	to	to	PART
admet-352	114	19	crizotinib	crizotinib	VERB
admet-352	114	20	.	.	PUNCT
admet-352	115	1	the	the	DET
admet-352	115	2	orr	orr	PROPN
admet-352	115	3	was	be	AUX
admet-352	115	4	55	55	NUM
admet-352	115	5	%	%	NOUN
admet-352	115	6	and	and	CCONJ
admet-352	115	7	the	the	DET
admet-352	115	8	subset	subset	ADJ
admet-352	115	9	analysis	analysis	NOUN
admet-352	115	10	of	of	ADP
admet-352	115	11	21	21	NUM
admet-352	115	12	patients	patient	NOUN
admet-352	115	13	with	with	ADP
admet-352	115	14	cns	cns	NOUN
admet-352	115	15	metastases	metastasis	NOUN
admet-352	115	16	at	at	ADP
admet-352	115	17	baseline	baseline	PROPN
admet-352	115	18	showed	show	VERB
admet-352	115	19	a	a	DET
admet-352	115	20	disease	disease	NOUN
admet-352	115	21	control	control	NOUN
admet-352	115	22	rate	rate	NOUN
admet-352	115	23	approximating	approximate	VERB
admet-352	115	24	90	90	NUM
admet-352	115	25	%	%	NOUN
admet-352	115	26	.	.	PUNCT
admet-352	116	1	the	the	DET
admet-352	116	2	recommended	recommend	VERB
admet-352	116	3	dose	dose	NOUN
admet-352	116	4	for	for	ADP
admet-352	116	5	phase	phase	NOUN
admet-352	116	6	ii	ii	PROPN
admet-352	116	7	studies	study	NOUN
admet-352	116	8	was	be	AUX
admet-352	116	9	600	600	NUM
admet-352	116	10	mg	mg	NOUN
admet-352	116	11	bid	bid	VERB
admet-352	116	12	[	[	PUNCT
admet-352	116	13	44	44	NUM
admet-352	116	14	-	-	SYM
admet-352	116	15	46	46	NUM
admet-352	116	16	]	]	PUNCT
admet-352	116	17	.	.	PUNCT
admet-352	117	1	brigatinib	brigatinib	PROPN
admet-352	117	2	brigatinib	brigatinib	PROPN
admet-352	117	3	is	be	AUX
admet-352	117	4	a	a	DET
admet-352	117	5	novel	novel	ADJ
admet-352	117	6	potent	potent	ADJ
admet-352	117	7	oral	oral	ADJ
admet-352	117	8	drug	drug	NOUN
admet-352	117	9	that	that	PRON
admet-352	117	10	has	have	AUX
admet-352	117	11	demonstrated	demonstrate	VERB
admet-352	117	12	ability	ability	NOUN
admet-352	117	13	to	to	PART
admet-352	117	14	overcome	overcome	VERB
admet-352	117	15	crizotinib	crizotinib	ADJ
admet-352	117	16	resistance	resistance	NOUN
admet-352	117	17	mutations	mutation	NOUN
admet-352	117	18	,	,	PUNCT
admet-352	117	19	including	include	VERB
admet-352	117	20	g1202r	g1202r	NOUN
admet-352	117	21	and	and	CCONJ
admet-352	117	22	activity	activity	NOUN
admet-352	117	23	against	against	ADP
admet-352	117	24	ros1	ros1	PROPN
admet-352	117	25	and	and	CCONJ
admet-352	117	26	inhibits	inhibit	VERB
admet-352	117	27	mutant	mutant	ADJ
admet-352	117	28	egfr	egfr	NOUN
admet-352	117	29	,	,	PUNCT
admet-352	117	30	including	include	VERB
admet-352	117	31	t790	t790	NUM
admet-352	117	32	m	m	NOUN
admet-352	117	33	[	[	X
admet-352	117	34	47	47	NUM
admet-352	117	35	-	-	SYM
admet-352	117	36	49	49	NUM
admet-352	117	37	]	]	PUNCT
admet-352	117	38	.	.	PUNCT
admet-352	118	1	brigatinib	brigatinib	NOUN
admet-352	118	2	showed	show	VERB
admet-352	118	3	antitumor	antitumor	PROPN
admet-352	118	4	activity	activity	NOUN
admet-352	118	5	in	in	ADP
admet-352	118	6	patients	patient	NOUN
admet-352	118	7	treated	treat	VERB
admet-352	118	8	with	with	ADP
admet-352	118	9	crizotinib	crizotinib	NOUN
admet-352	118	10	with	with	ADP
admet-352	118	11	an	an	DET
admet-352	118	12	objective	objective	ADJ
admet-352	118	13	response	response	NOUN
admet-352	118	14	rate	rate	NOUN
admet-352	118	15	of	of	ADP
admet-352	118	16	71	71	NUM
admet-352	118	17	%	%	NOUN
admet-352	118	18	and	and	CCONJ
admet-352	118	19	in	in	ADP
admet-352	118	20	crizotinib	crizotinib	ADJ
admet-352	118	21	-	-	ADJ
admet-352	118	22	naive	naive	ADJ
admet-352	118	23	patients	patient	NOUN
admet-352	118	24	of	of	ADP
admet-352	118	25	100	100	NUM
admet-352	118	26	%	%	NOUN
admet-352	118	27	.	.	PUNCT
admet-352	119	1	the	the	DET
admet-352	119	2	median	median	PROPN
admet-352	119	3	pfs	pfs	PROPN
admet-352	119	4	was	be	AUX
admet-352	119	5	13.4	13.4	NUM
admet-352	119	6	months	month	NOUN
admet-352	119	7	in	in	ADP
admet-352	119	8	the	the	DET
admet-352	119	9	subgroup	subgroup	NOUN
admet-352	119	10	with	with	ADP
admet-352	119	11	prior	prior	ADJ
admet-352	119	12	crizotinib	crizotinib	NOUN
admet-352	119	13	therapy	therapy	NOUN
admet-352	119	14	[	[	X
admet-352	119	15	50	50	NUM
admet-352	119	16	]	]	PUNCT
admet-352	119	17	.	.	PUNCT
admet-352	120	1	a	a	DET
admet-352	120	2	pivotal	pivotal	ADJ
admet-352	120	3	,	,	PUNCT
admet-352	120	4	randomized	randomize	VERB
admet-352	120	5	,	,	PUNCT
admet-352	120	6	phase	phase	NOUN
admet-352	120	7	2	2	NUM
admet-352	120	8	trial	trial	NOUN
admet-352	120	9	of	of	ADP
admet-352	120	10	brigatinib	brigatinib	NOUN
admet-352	120	11	in	in	ADP
admet-352	120	12	patients	patient	NOUN
admet-352	120	13	with	with	ADP
admet-352	120	14	crizotinib	crizotinib	ADJ
admet-352	120	15	-	-	ADJ
admet-352	120	16	resistant	resistant	ADJ
admet-352	120	17	alk+	alk+	NOUN
admet-352	120	18	nsclc	nsclc	NOUN
admet-352	120	19	has	have	AUX
admet-352	120	20	completed	complete	VERB
admet-352	120	21	accrual	accrual	ADJ
admet-352	120	22	.	.	PUNCT
admet-352	121	1	entrectinib	entrectinib	NOUN
admet-352	121	2	entrectinib	entrectinib	NOUN
admet-352	121	3	is	be	AUX
admet-352	121	4	a	a	DET
admet-352	121	5	novel	novel	NOUN
admet-352	121	6	,	,	PUNCT
admet-352	121	7	orally	orally	ADV
admet-352	121	8	available	available	ADJ
admet-352	121	9	,	,	PUNCT
admet-352	121	10	selective	selective	ADJ
admet-352	121	11	tyrosine	tyrosine	NOUN
admet-352	121	12	kinase	kinase	PROPN
admet-352	121	13	inhibitor	inhibitor	NOUN
admet-352	121	14	of	of	ADP
admet-352	121	15	the	the	DET
admet-352	121	16	trk	trk	PROPN
admet-352	121	17	family	family	NOUN
admet-352	121	18	of	of	ADP
admet-352	121	19	tyrosine	tyrosine	NOUN
admet-352	121	20	kinases	kinase	NOUN
admet-352	121	21	,	,	PUNCT
admet-352	121	22	ros1	ros1	PROPN
admet-352	121	23	and	and	CCONJ
admet-352	121	24	alk	alk	PROPN
admet-352	121	25	.	.	PUNCT
admet-352	122	1	rearrangements	rearrangement	NOUN
admet-352	122	2	in	in	ADP
admet-352	122	3	ntrk1	ntrk1	NOUN
admet-352	122	4	were	be	AUX
admet-352	122	5	recently	recently	ADV
admet-352	122	6	described	describe	VERB
admet-352	122	7	in	in	ADP
admet-352	122	8	approximately	approximately	ADV
admet-352	122	9	3	3	NUM
admet-352	122	10	%	%	NOUN
admet-352	122	11	of	of	ADP
admet-352	122	12	nsclc	nsclc	NOUN
admet-352	122	13	that	that	PRON
admet-352	122	14	were	be	AUX
admet-352	122	15	negative	negative	ADJ
admet-352	122	16	for	for	ADP
admet-352	122	17	other	other	ADJ
admet-352	122	18	oncogenic	oncogenic	ADJ
admet-352	122	19	driver	driver	NOUN
admet-352	122	20	mutations	mutation	NOUN
admet-352	122	21	[	[	X
admet-352	122	22	51	51	NUM
admet-352	122	23	]	]	PUNCT
admet-352	122	24	.	.	PUNCT
admet-352	123	1	entrectinib	entrectinib	PROPN
admet-352	123	2	has	have	AUX
admet-352	123	3	demonstrated	demonstrate	VERB
admet-352	123	4	in	in	ADP
admet-352	123	5	vitro	vitro	X
admet-352	123	6	and	and	CCONJ
admet-352	123	7	in	in	ADP
admet-352	123	8	vivo	vivo	ADJ
admet-352	123	9	antitumour	antitumour	NOUN
admet-352	123	10	activity	activity	NOUN
admet-352	123	11	against	against	ADP
admet-352	123	12	various	various	ADJ
admet-352	123	13	trk	trk	NOUN
admet-352	123	14	,	,	PUNCT
admet-352	123	15	ros1	ros1	PROPN
admet-352	123	16	or	or	CCONJ
admet-352	123	17	alk	alk	NOUN
admet-352	123	18	-	-	PUNCT
admet-352	123	19	driven	drive	VERB
admet-352	123	20	xenograft	xenograft	NOUN
admet-352	123	21	models	model	NOUN
admet-352	123	22	of	of	ADP
admet-352	123	23	different	different	ADJ
admet-352	123	24	human	human	ADJ
admet-352	123	25	cancers	cancer	NOUN
admet-352	123	26	(	(	PUNCT
admet-352	123	27	npm	npm	NOUN
admet-352	123	28	-	-	PUNCT
admet-352	123	29	alk	alk	NOUN
admet-352	123	30	-	-	PUNCT
admet-352	123	31	driven	drive	VERB
admet-352	123	32	lymphoma	lymphoma	NOUN
admet-352	123	33	and	and	CCONJ
admet-352	123	34	eml4	eml4	PROPN
admet-352	123	35	-	-	PUNCT
admet-352	123	36	alk	alk	NOUN
admet-352	123	37	-	-	PUNCT
admet-352	123	38	driven	drive	VERB
admet-352	123	39	nsclc	nsclc	NOUN
admet-352	123	40	)	)	PUNCT
admet-352	123	41	entrectinib	entrectinib	NOUN
admet-352	123	42	has	have	VERB
admet-352	123	43	adequate	adequate	ADJ
admet-352	123	44	oral	oral	ADJ
admet-352	123	45	bioavailability	bioavailability	NOUN
admet-352	123	46	and	and	CCONJ
admet-352	123	47	can	can	AUX
admet-352	123	48	efficiently	efficiently	ADV
admet-352	123	49	cross	cross	VERB
admet-352	123	50	the	the	DET
admet-352	123	51	blood	blood	NOUN
admet-352	123	52	–	–	PUNCT
admet-352	123	53	brain	brain	NOUN
admet-352	123	54	barrier	barrier	NOUN
admet-352	123	55	in	in	ADP
admet-352	123	56	mice	mouse	NOUN
admet-352	123	57	with	with	ADP
admet-352	123	58	intracranially	intracranially	ADV
admet-352	123	59	injected	inject	VERB
admet-352	123	60	ncih2228	ncih2228	PROPN
admet-352	123	61	eml4	eml4	PROPN
admet-352	123	62	-	-	PUNCT
admet-352	123	63	alk	alk	NOUN
admet-352	123	64	cells	cell	NOUN
admet-352	123	65	[	[	X
admet-352	123	66	52	52	NUM
admet-352	123	67	]	]	PUNCT
admet-352	123	68	.	.	PUNCT
admet-352	124	1	entrectinib	entrectinib	NOUN
admet-352	124	2	400	400	NUM
admet-352	124	3	mg	mg	NOUN
admet-352	124	4	/	/	SYM
admet-352	124	5	m2	m2	PROPN
admet-352	124	6	is	be	AUX
admet-352	124	7	the	the	DET
admet-352	124	8	dose	dose	NOUN
admet-352	124	9	recommended	recommend	VERB
admet-352	124	10	for	for	ADP
admet-352	124	11	the	the	DET
admet-352	124	12	trials	trial	NOUN
admet-352	124	13	phase	phase	NOUN
admet-352	124	14	ii	ii	NOUN
admet-352	125	1	[	[	X
admet-352	125	2	53	53	NUM
admet-352	125	3	]	]	PUNCT
admet-352	125	4	.	.	PUNCT
admet-352	126	1	third	third	ADJ
admet-352	126	2	generation	generation	NOUN
admet-352	126	3	of	of	ADP
admet-352	126	4	alk	alk	NOUN
admet-352	126	5	inhibitors	inhibitor	NOUN
admet-352	126	6	lorlatinib	lorlatinib	NOUN
admet-352	126	7	(	(	PUNCT
admet-352	126	8	pf-06463922	pf-06463922	ADJ
admet-352	126	9	)	)	PUNCT
admet-352	126	10	lorlatinib	lorlatinib	NOUN
admet-352	126	11	has	have	AUX
admet-352	126	12	been	be	AUX
admet-352	126	13	identified	identify	VERB
admet-352	126	14	as	as	ADP
admet-352	126	15	an	an	DET
admet-352	126	16	orally	orally	ADV
admet-352	126	17	novel	novel	ADJ
admet-352	126	18	reversible	reversible	ADJ
admet-352	126	19	available	available	ADJ
admet-352	126	20	atp	atp	NOUN
admet-352	126	21	-	-	PUNCT
admet-352	126	22	competitive	competitive	ADJ
admet-352	126	23	selective	selective	ADJ
admet-352	126	24	targeting	targeting	NOUN
admet-352	126	25	of	of	ADP
admet-352	126	26	a	a	DET
admet-352	126	27	specific	specific	ADJ
admet-352	126	28	residue	residue	NOUN
admet-352	126	29	leucine	leucine	NOUN
admet-352	126	30	at	at	ADP
admet-352	126	31	position	position	NOUN
admet-352	126	32	1198	1198	NUM
admet-352	126	33	(	(	PUNCT
admet-352	126	34	l1198	l1198	PROPN
admet-352	126	35	)	)	PUNCT
admet-352	126	36	detected	detect	VERB
admet-352	126	37	in	in	ADP
admet-352	126	38	only	only	ADV
admet-352	126	39	approximately	approximately	ADV
admet-352	126	40	25	25	NUM
admet-352	126	41	%	%	NOUN
admet-352	126	42	of	of	ADP
admet-352	126	43	kinases	kinase	NOUN
admet-352	126	44	,	,	PUNCT
admet-352	126	45	brain	brain	NOUN
admet-352	126	46	penetrant	penetrant	NOUN
admet-352	126	47	inhibitor	inhibitor	NOUN
admet-352	126	48	of	of	ADP
admet-352	126	49	alk	alk	PROPN
admet-352	126	50	(	(	PUNCT
admet-352	126	51	including	include	VERB
admet-352	126	52	all	all	DET
admet-352	126	53	known	know	VERB
admet-352	126	54	mutations	mutation	NOUN
admet-352	126	55	)	)	PUNCT
admet-352	126	56	and	and	CCONJ
admet-352	126	57	the	the	DET
admet-352	126	58	c	c	NOUN
admet-352	126	59	-	-	PUNCT
admet-352	126	60	ros	ros	PROPN
admet-352	126	61	oncogene	oncogene	NOUN
admet-352	126	62	1	1	NUM
admet-352	126	63	(	(	PUNCT
admet-352	126	64	ros1	ros1	PROPN
admet-352	126	65	)	)	PUNCT
admet-352	126	66	.	.	PUNCT
admet-352	127	1	in	in	ADP
admet-352	127	2	vitro	vitro	X
admet-352	127	3	and	and	CCONJ
admet-352	127	4	preclinical	preclinical	ADJ
admet-352	127	5	studies	study	NOUN
admet-352	127	6	it	it	PRON
admet-352	127	7	is	be	AUX
admet-352	127	8	∼10	∼10	ADJ
admet-352	127	9	-	-	ADJ
admet-352	127	10	fold	fold	VERB
admet-352	127	11	more	more	ADV
admet-352	127	12	potent	potent	ADJ
admet-352	127	13	against	against	ADP
admet-352	127	14	wildtype	wildtype	NOUN
admet-352	127	15	eml4	eml4	PROPN
admet-352	127	16	-	-	PUNCT
admet-352	127	17	alk	alk	PROPN
admet-352	127	18	and	and	CCONJ
admet-352	127	19	∼40	∼40	NOUN
admet-352	127	20	-	-	NOUN
admet-352	127	21	fold	fold	VERB
admet-352	127	22	more	more	ADV
admet-352	127	23	potent	potent	ADJ
admet-352	127	24	against	against	ADP
admet-352	127	25	eml4	eml4	PROPN
admet-352	127	26	-	-	PUNCT
admet-352	127	27	alk	alk	PROPN
admet-352	127	28	l1196	l1196	NOUN
admet-352	127	29	m	m	VERB
admet-352	127	30	compared	compare	VERB
admet-352	127	31	with	with	ADP
admet-352	127	32	crizotinib	crizotinib	NOUN
admet-352	127	33	[	[	X
admet-352	127	34	54	54	NUM
admet-352	127	35	]	]	PUNCT
admet-352	127	36	.	.	PUNCT
admet-352	128	1	importantly	importantly	ADV
admet-352	128	2	,	,	PUNCT
admet-352	128	3	lorlatinib	lorlatinib	NOUN
admet-352	128	4	has	have	AUX
admet-352	128	5	demonstrated	demonstrate	VERB
admet-352	128	6	activity	activity	NOUN
admet-352	128	7	in	in	ADP
admet-352	128	8	patients	patient	NOUN
admet-352	128	9	whose	whose	DET
admet-352	128	10	tumors	tumor	NOUN
admet-352	128	11	harbor	harbor	VERB
admet-352	128	12	the	the	DET
admet-352	128	13	highly	highly	ADV
admet-352	128	14	resistant	resistant	ADJ
admet-352	128	15	mutation	mutation	NOUN
admet-352	128	16	alk	alk	NOUN
admet-352	128	17	g1202r	g1202r	NOUN
admet-352	128	18	.	.	PUNCT
admet-352	129	1	this	this	DET
admet-352	129	2	mutation	mutation	NOUN
admet-352	129	3	confers	confer	VERB
admet-352	129	4	resistance	resistance	NOUN
admet-352	129	5	m.	m.	NOUN
admet-352	129	6	mendez	mendez	PROPN
admet-352	129	7	et	et	PROPN
admet-352	129	8	al	al	PROPN
admet-352	129	9	.	.	PROPN
admet-352	129	10	admet	admet	PROPN
admet-352	129	11	&	&	CCONJ
admet-352	129	12	dmpk	dmpk	PROPN
admet-352	129	13	5(1	5(1	NUM
admet-352	129	14	)	)	PUNCT
admet-352	129	15	(	(	PUNCT
admet-352	129	16	2017	2017	NUM
admet-352	129	17	)	)	PUNCT
admet-352	129	18	1	1	NUM
admet-352	129	19	-	-	SYM
admet-352	129	20	8	8	NUM
admet-352	129	21	6	6	NUM
admet-352	129	22	to	to	ADP
admet-352	129	23	other	other	ADJ
admet-352	129	24	next	next	ADJ
admet-352	129	25	-	-	PUNCT
admet-352	129	26	generation	generation	NOUN
admet-352	129	27	alk	alk	NOUN
admet-352	129	28	inhibitors	inhibitor	NOUN
admet-352	129	29	.	.	PUNCT
admet-352	130	1	other	other	ADJ
admet-352	130	2	drugs	drug	NOUN
admet-352	130	3	for	for	ADP
admet-352	130	4	crizotinib	crizotinib	ADJ
admet-352	130	5	resistant	resistant	ADJ
admet-352	130	6	tumor	tumor	NOUN
admet-352	130	7	asp3026	asp3026	NOUN
admet-352	130	8	this	this	PRON
admet-352	130	9	is	be	AUX
admet-352	130	10	an	an	DET
admet-352	130	11	alk	alk	NOUN
admet-352	130	12	inhibitor	inhibitor	NOUN
admet-352	130	13	active	active	ADJ
admet-352	130	14	against	against	ADP
admet-352	130	15	crizotinib	crizotinib	NOUN
admet-352	130	16	-	-	PUNCT
admet-352	130	17	resistant	resistant	ADJ
admet-352	130	18	alk	alk	VERB
admet-352	130	19	-	-	PUNCT
admet-352	130	20	positive	positive	ADJ
admet-352	130	21	advanced	advanced	ADJ
admet-352	130	22	tumors	tumor	NOUN
admet-352	130	23	[	[	X
admet-352	130	24	55	55	NUM
admet-352	130	25	]	]	PUNCT
admet-352	130	26	.	.	PUNCT
admet-352	131	1	x-376	x-376	PROPN
admet-352	131	2	and	and	CCONJ
admet-352	131	3	x-396	x-396	PUNCT
admet-352	132	1	(	(	PUNCT
admet-352	132	2	xcovery	xcovery	PROPN
admet-352	132	3	)	)	PUNCT
admet-352	132	4	these	these	PRON
admet-352	132	5	are	be	AUX
admet-352	132	6	more	more	ADV
admet-352	132	7	potent	potent	ADJ
admet-352	132	8	inhibitors	inhibitor	NOUN
admet-352	132	9	of	of	ADP
admet-352	132	10	alk	alk	NOUN
admet-352	132	11	but	but	CCONJ
admet-352	132	12	less	less	ADV
admet-352	132	13	potent	potent	ADJ
admet-352	132	14	inhibitors	inhibitor	NOUN
admet-352	132	15	of	of	ADP
admet-352	132	16	met	meet	VERB
admet-352	132	17	compared	compare	VERB
admet-352	132	18	to	to	ADP
admet-352	132	19	crizotinib	crizotinib	VERB
admet-352	132	20	.	.	PUNCT
admet-352	133	1	moreover	moreover	ADV
admet-352	133	2	,	,	PUNCT
admet-352	133	3	x-396	x-396	PUNCT
admet-352	133	4	could	could	AUX
admet-352	133	5	potently	potently	ADV
admet-352	133	6	inhibit	inhibit	VERB
admet-352	133	7	alk	alk	NOUN
admet-352	133	8	with	with	ADP
admet-352	133	9	two	two	NUM
admet-352	133	10	point	point	NOUN
admet-352	133	11	mutations	mutation	NOUN
admet-352	133	12	(	(	PUNCT
admet-352	133	13	l1196	l1196	NOUN
admet-352	133	14	m	m	NOUN
admet-352	133	15	and	and	CCONJ
admet-352	133	16	c1156y	c1156y	NOUN
admet-352	133	17	)	)	PUNCT
admet-352	133	18	associated	associate	VERB
admet-352	133	19	with	with	ADP
admet-352	133	20	acquired	acquire	VERB
admet-352	133	21	resistance	resistance	NOUN
admet-352	133	22	to	to	PART
admet-352	133	23	crizotinib	crizotinib	VERB
admet-352	133	24	and	and	CCONJ
admet-352	133	25	there	there	PRON
admet-352	133	26	is	be	VERB
admet-352	133	27	preclinical	preclinical	ADJ
admet-352	133	28	data	datum	NOUN
admet-352	133	29	about	about	ADP
admet-352	133	30	cns	cns	NOUN
admet-352	133	31	penetration	penetration	NOUN
admet-352	133	32	[	[	X
admet-352	133	33	56	56	NUM
admet-352	133	34	]	]	PUNCT
admet-352	133	35	.	.	PUNCT
admet-352	134	1	cep-28122	cep-28122	PROPN
admet-352	134	2	cep-29122	cep-29122	PROPN
admet-352	134	3	is	be	AUX
admet-352	134	4	a	a	DET
admet-352	134	5	potent	potent	ADJ
admet-352	134	6	and	and	CCONJ
admet-352	134	7	selective	selective	ADJ
admet-352	134	8	alk	alk	NOUN
admet-352	134	9	inhibitor	inhibitor	NOUN
admet-352	134	10	which	which	PRON
admet-352	134	11	showed	show	VERB
admet-352	134	12	selectivity	selectivity	NOUN
admet-352	134	13	in	in	ADP
admet-352	134	14	preclinical	preclinical	ADJ
admet-352	134	15	studies	study	NOUN
admet-352	134	16	against	against	ADP
admet-352	134	17	alk	alk	PROPN
admet-352	134	18	compared	compare	VERB
admet-352	134	19	to	to	ADP
admet-352	134	20	various	various	ADJ
admet-352	134	21	types	type	NOUN
admet-352	134	22	of	of	ADP
admet-352	134	23	tyrosine	tyrosine	NOUN
admet-352	134	24	kinases	kinase	NOUN
admet-352	134	25	,	,	PUNCT
admet-352	134	26	including	include	VERB
admet-352	134	27	insr	insr	NOUN
admet-352	134	28	,	,	PUNCT
admet-352	134	29	igf	igf	PROPN
admet-352	134	30	-	-	ADJ
admet-352	134	31	r1	r1	PROPN
admet-352	134	32	and	and	CCONJ
admet-352	134	33	c	c	AUX
admet-352	134	34	-	-	PUNCT
admet-352	134	35	met	meet	VERB
admet-352	134	36	.	.	PUNCT
admet-352	135	1	cep37440	cep37440	PROPN
admet-352	135	2	is	be	AUX
admet-352	135	3	an	an	DET
admet-352	135	4	alk	alk	NOUN
admet-352	135	5	inhibitor	inhibitor	NOUN
admet-352	135	6	and	and	CCONJ
admet-352	135	7	focal	focal	ADJ
admet-352	135	8	adhesion	adhesion	NOUN
admet-352	135	9	kinase	kinase	NOUN
admet-352	135	10	(	(	PUNCT
admet-352	135	11	fak	fak	PROPN
admet-352	135	12	)	)	PUNCT
admet-352	136	1	[	[	X
admet-352	136	2	57	57	NUM
admet-352	136	3	-	-	SYM
admet-352	136	4	58	58	NUM
admet-352	136	5	]	]	PUNCT
admet-352	136	6	.	.	PUNCT
admet-352	137	1	hsp90	hsp90	ADJ
admet-352	137	2	inhibitors	inhibitor	NOUN
admet-352	137	3	another	another	DET
admet-352	137	4	possibility	possibility	NOUN
admet-352	137	5	to	to	PART
admet-352	137	6	overcome	overcome	VERB
admet-352	137	7	resistance	resistance	NOUN
admet-352	137	8	to	to	PART
admet-352	137	9	alk	alk	VERB
admet-352	137	10	inhibitors	inhibitor	NOUN
admet-352	137	11	includes	include	VERB
admet-352	137	12	the	the	DET
admet-352	137	13	combination	combination	NOUN
admet-352	137	14	with	with	ADP
admet-352	137	15	hsp90	hsp90	ADJ
admet-352	137	16	inhibitors	inhibitor	NOUN
admet-352	137	17	such	such	ADJ
admet-352	137	18	as	as	ADP
admet-352	137	19	retaspimycin	retaspimycin	PROPN
admet-352	137	20	hydrochloride	hydrochloride	NOUN
admet-352	137	21	(	(	PUNCT
admet-352	137	22	ipi-504	ipi-504	NOUN
admet-352	137	23	)	)	PUNCT
admet-352	137	24	and	and	CCONJ
admet-352	137	25	ganetespib	ganetespib	ADJ
admet-352	137	26	(	(	PUNCT
admet-352	137	27	sta-9090	sta-9090	NOUN
admet-352	137	28	)	)	PUNCT
admet-352	137	29	that	that	PRON
admet-352	137	30	have	have	AUX
admet-352	137	31	demonstrated	demonstrate	VERB
admet-352	137	32	clinical	clinical	ADJ
admet-352	137	33	activity	activity	NOUN
admet-352	137	34	in	in	ADP
admet-352	137	35	alk+	alk+	NOUN
admet-352	137	36	nsclc	nsclc	NOUN
admet-352	137	37	patients	patient	NOUN
admet-352	137	38	[	[	X
admet-352	137	39	60	60	NUM
admet-352	137	40	-	-	SYM
admet-352	137	41	62	62	NUM
admet-352	137	42	]	]	PUNCT
admet-352	137	43	.	.	PUNCT
admet-352	138	1	several	several	ADJ
admet-352	138	2	clinical	clinical	ADJ
admet-352	138	3	trials	trial	NOUN
admet-352	138	4	are	be	AUX
admet-352	138	5	evaluating	evaluate	VERB
admet-352	138	6	hsp90	hsp90	ADJ
admet-352	138	7	inhibitors	inhibitor	NOUN
admet-352	138	8	in	in	ADP
admet-352	138	9	combination	combination	NOUN
admet-352	138	10	with	with	ADP
admet-352	138	11	alk	alk	NOUN
admet-352	138	12	inhibitors	inhibitor	NOUN
admet-352	138	13	.	.	PUNCT
admet-352	139	1	crizotinib	crizotinib	PROPN
admet-352	139	2	is	be	AUX
admet-352	139	3	combined	combine	VERB
admet-352	139	4	with	with	ADP
admet-352	139	5	ganetespib	ganetespib	ADJ
admet-352	139	6	in	in	ADP
admet-352	139	7	crizotinib	crizotinib	ADJ
admet-352	139	8	-	-	ADJ
admet-352	139	9	naive	naive	ADJ
admet-352	139	10	patients	patient	NOUN
admet-352	139	11	and	and	CCONJ
admet-352	139	12	in	in	ADP
admet-352	139	13	crizotinib	crizotinib	ADJ
admet-352	139	14	-	-	PUNCT
admet-352	139	15	resistant	resistant	ADJ
admet-352	139	16	disease	disease	NOUN
admet-352	139	17	.	.	PUNCT
admet-352	140	1	in	in	ADP
admet-352	140	2	other	other	ADJ
admet-352	140	3	studies	study	NOUN
admet-352	140	4	crizotinib	crizotinib	VERB
admet-352	140	5	is	be	AUX
admet-352	140	6	combined	combine	VERB
admet-352	140	7	with	with	ADP
admet-352	140	8	onalespib	onalespib	ADJ
admet-352	140	9	(	(	PUNCT
admet-352	140	10	at13387	at13387	NOUN
admet-352	140	11	)	)	PUNCT
admet-352	140	12	,	,	PUNCT
admet-352	140	13	while	while	SCONJ
admet-352	140	14	ceritinib	ceritinib	NOUN
admet-352	140	15	is	be	AUX
admet-352	140	16	combined	combine	VERB
admet-352	140	17	with	with	ADP
admet-352	140	18	auy922	auy922	PROPN
admet-352	140	19	.	.	PROPN
admet-352	140	20	table	table	NOUN
admet-352	140	21	1	1	NUM
admet-352	140	22	.	.	X
admet-352	140	23	main	main	ADJ
admet-352	140	24	molecular	molecular	ADJ
admet-352	140	25	characteristics	characteristic	NOUN
admet-352	140	26	of	of	ADP
admet-352	140	27	second	second	ADJ
admet-352	140	28	and	and	CCONJ
admet-352	140	29	third	third	ADJ
admet-352	140	30	-	-	PUNCT
admet-352	140	31	generation	generation	NOUN
admet-352	140	32	alk	alk	NOUN
admet-352	140	33	inhibitors	inhibitor	NOUN
admet-352	140	34	.	.	PUNCT
admet-352	141	1	drug	drug	NOUN
admet-352	141	2	targets	target	NOUN
admet-352	141	3	other	other	ADJ
admet-352	141	4	than	than	ADP
admet-352	141	5	alk	alk	VERB
admet-352	141	6	l1196	l1196	PROPN
admet-352	141	7	m	m	PROPN
admet-352	141	8	resistance	resistance	NOUN
admet-352	141	9	mutation	mutation	NOUN
admet-352	141	10	c1156y	c1156y	PROPN
admet-352	141	11	resistance	resistance	NOUN
admet-352	141	12	mutation	mutation	NOUN
admet-352	141	13	g1202r	g1202r	PROPN
admet-352	141	14	resistance	resistance	NOUN
admet-352	141	15	mutation	mutation	NOUN
admet-352	141	16	ceritinib	ceritinib	VERB
admet-352	141	17	igf	igf	PROPN
admet-352	141	18	-	-	PUNCT
admet-352	141	19	r1	r1	PROPN
admet-352	141	20	,	,	PUNCT
admet-352	141	21	insr	insr	NOUN
admet-352	141	22	,	,	PUNCT
admet-352	141	23	ros1	ros1	PROPN
admet-352	141	24	sens	sens	PROPN
admet-352	141	25	.	.	PROPN
admet-352	141	26	res	re	NOUN
admet-352	141	27	.	.	PUNCT
admet-352	142	1	res	re	NOUN
admet-352	142	2	.	.	PUNCT
admet-352	142	3	alectinib	alectinib	PROPN
admet-352	142	4	ltk	ltk	PROPN
admet-352	142	5	,	,	PUNCT
admet-352	142	6	gak	gak	PROPN
admet-352	142	7	sens	sens	PROPN
admet-352	142	8	.	.	PROPN
admet-352	142	9	sens	sens	PROPN
admet-352	142	10	.	.	PROPN
admet-352	142	11	res	res	PROPN
admet-352	142	12	.	.	PROPN
admet-352	142	13	brigatinib	brigatinib	PROPN
admet-352	142	14	ros1	ros1	PROPN
admet-352	142	15	,	,	PUNCT
admet-352	142	16	egfr	egfr	PROPN
admet-352	142	17	sens	sens	PROPN
admet-352	142	18	.	.	PROPN
admet-352	142	19	sens	sens	PROPN
admet-352	142	20	.	.	PROPN
admet-352	142	21	sens	sens	PROPN
admet-352	142	22	.	.	PROPN
admet-352	142	23	entrectinib	entrectinib	PROPN
admet-352	142	24	trka	trka	NOUN
admet-352	142	25	,	,	PUNCT
admet-352	142	26	trkb	trkb	NOUN
admet-352	142	27	,	,	PUNCT
admet-352	142	28	trkc	trkc	NOUN
admet-352	142	29	,	,	PUNCT
admet-352	142	30	ros1	ros1	PROPN
admet-352	142	31	sens	sens	PROPN
admet-352	142	32	.	.	PROPN
admet-352	142	33	sens	sens	PROPN
admet-352	142	34	.	.	PROPN
admet-352	142	35	nd	nd	NUM
admet-352	142	36	lorlatinib	lorlatinib	PROPN
admet-352	142	37	ros1	ros1	PROPN
admet-352	142	38	sens	sens	PROPN
admet-352	142	39	.	.	PROPN
admet-352	142	40	nd	nd	NUM
admet-352	142	41	sens	sens	PROPN
admet-352	142	42	.	.	PROPN
admet-352	142	43	tsr-011	tsr-011	PROPN
admet-352	142	44	trka	trka	PROPN
admet-352	142	45	,	,	PUNCT
admet-352	142	46	trkb	trkb	NOUN
admet-352	142	47	,	,	PUNCT
admet-352	142	48	trkc	trkc	PROPN
admet-352	142	49	sens	sens	PROPN
admet-352	142	50	.	.	PROPN
admet-352	142	51	nd	nd	PRON
admet-352	142	52	nd	nd	NOUN
admet-352	142	53	asp3026	asp3026	PROPN
admet-352	142	54	ros1	ros1	PROPN
admet-352	142	55	,	,	PUNCT
admet-352	142	56	ack	ack	PROPN
admet-352	142	57	sens	sen	NOUN
admet-352	142	58	.	.	PROPN
admet-352	142	59	nd	nd	PROPN
admet-352	142	60	nd	nd	PROPN
admet-352	142	61	x-396	x-396	PROPN
admet-352	142	62	met	meet	VERB
admet-352	142	63	sens	sen	NOUN
admet-352	142	64	.	.	PROPN
admet-352	142	65	sens	sens	PROPN
admet-352	142	66	.	.	PROPN
admet-352	142	67	nd	nd	PROPN
admet-352	142	68	conclusions	conclusion	VERB
admet-352	142	69	current	current	ADJ
admet-352	142	70	knowledge	knowledge	NOUN
admet-352	142	71	of	of	ADP
admet-352	142	72	the	the	DET
admet-352	142	73	biology	biology	NOUN
admet-352	142	74	of	of	ADP
admet-352	142	75	nsclc	nsclc	NOUN
admet-352	142	76	,	,	PUNCT
admet-352	142	77	allows	allow	VERB
admet-352	142	78	the	the	DET
admet-352	142	79	development	development	NOUN
admet-352	142	80	of	of	ADP
admet-352	142	81	new	new	ADJ
admet-352	142	82	molecules	molecule	NOUN
admet-352	142	83	that	that	PRON
admet-352	142	84	are	be	AUX
admet-352	142	85	able	able	ADJ
admet-352	142	86	to	to	PART
admet-352	142	87	control	control	VERB
admet-352	142	88	the	the	DET
admet-352	142	89	disease	disease	NOUN
admet-352	142	90	and	and	CCONJ
admet-352	142	91	have	have	VERB
admet-352	142	92	an	an	DET
admet-352	142	93	impact	impact	NOUN
admet-352	142	94	on	on	ADP
admet-352	142	95	disease	disease	NOUN
admet-352	142	96	control	control	NOUN
admet-352	142	97	,	,	PUNCT
admet-352	142	98	survival	survival	NOUN
admet-352	142	99	and	and	CCONJ
admet-352	142	100	quality	quality	NOUN
admet-352	142	101	of	of	ADP
admet-352	142	102	life	life	NOUN
admet-352	142	103	.	.	PUNCT
admet-352	143	1	the	the	DET
admet-352	143	2	new	new	ADJ
admet-352	143	3	thirdgeneration	thirdgeneration	NOUN
admet-352	143	4	egfr	egfr	VERB
admet-352	143	5	tkis	tkis	PROPN
admet-352	143	6	demonstrate	demonstrate	PROPN
admet-352	143	7	efficacy	efficacy	NOUN
admet-352	143	8	in	in	ADP
admet-352	143	9	patients	patient	NOUN
admet-352	143	10	with	with	ADP
admet-352	143	11	egfr	egfr	ADJ
admet-352	143	12	resistance	resistance	NOUN
admet-352	143	13	mutations	mutation	NOUN
admet-352	143	14	patients	patient	NOUN
admet-352	143	15	while	while	SCONJ
admet-352	143	16	the	the	DET
admet-352	143	17	new	new	ADJ
admet-352	143	18	alk	alk	NOUN
admet-352	143	19	inhibitors	inhibitor	NOUN
admet-352	143	20	show	show	VERB
admet-352	143	21	activity	activity	NOUN
admet-352	143	22	in	in	ADP
admet-352	143	23	patients	patient	NOUN
admet-352	143	24	with	with	ADP
admet-352	143	25	alk	alk	NOUN
admet-352	143	26	rearrangements	rearrangement	NOUN
admet-352	143	27	and	and	CCONJ
admet-352	143	28	mutations	mutation	NOUN
admet-352	143	29	.	.	PUNCT
admet-352	144	1	these	these	DET
admet-352	144	2	benefits	benefit	NOUN
admet-352	144	3	alone	alone	ADV
admet-352	144	4	have	have	AUX
admet-352	144	5	already	already	ADV
admet-352	144	6	allowed	allow	VERB
admet-352	144	7	the	the	DET
admet-352	144	8	registration	registration	NOUN
admet-352	144	9	of	of	ADP
admet-352	144	10	some	some	PRON
admet-352	144	11	of	of	ADP
admet-352	144	12	them	they	PRON
admet-352	144	13	.	.	PUNCT
admet-352	145	1	results	result	NOUN
admet-352	145	2	from	from	ADP
admet-352	145	3	other	other	ADJ
admet-352	145	4	studies	study	NOUN
admet-352	145	5	are	be	AUX
admet-352	145	6	pending	pende	VERB
admet-352	145	7	,	,	PUNCT
admet-352	145	8	as	as	ADV
admet-352	145	9	well	well	ADV
admet-352	145	10	as	as	ADP
admet-352	145	11	those	those	PRON
admet-352	145	12	related	relate	VERB
admet-352	145	13	to	to	ADP
admet-352	145	14	combinations	combination	NOUN
admet-352	145	15	with	with	ADP
admet-352	145	16	other	other	ADJ
admet-352	145	17	drugs	drug	NOUN
admet-352	145	18	.	.	PUNCT
admet-352	146	1	admet	admet	PROPN
admet-352	146	2	&	&	CCONJ
admet-352	146	3	dmpk	dmpk	PROPN
admet-352	146	4	5(1	5(1	NUM
admet-352	146	5	)	)	PUNCT
admet-352	146	6	(	(	PUNCT
admet-352	146	7	2017	2017	NUM
admet-352	146	8	)	)	PUNCT
admet-352	146	9	1	1	NUM
admet-352	146	10	-	-	SYM
admet-352	146	11	8	8	NUM
admet-352	146	12	tkis	tkis	NOUN
admet-352	146	13	in	in	ADP
admet-352	146	14	non	non	ADJ
admet-352	146	15	-	-	ADJ
admet-352	146	16	small	small	ADJ
admet-352	146	17	cell	cell	NOUN
admet-352	146	18	lung	lung	NOUN
admet-352	146	19	cancer	cancer	NOUN
admet-352	146	20	doi	doi	NOUN
admet-352	146	21	:	:	PUNCT
admet-352	146	22	10.5599	10.5599	NUM
admet-352	146	23	/	/	SYM
admet-352	146	24	admet.5.1.352	admet.5.1.352	NOUN
admet-352	146	25	7	7	NUM
admet-352	146	26	references	reference	NOUN
admet-352	146	27	[	[	X
admet-352	146	28	1	1	NUM
admet-352	146	29	]	]	PUNCT
admet-352	146	30	r.	r.	PROPN
admet-352	146	31	siegel	siegel	PROPN
admet-352	146	32	,	,	PUNCT
admet-352	146	33	j.	j.	PROPN
admet-352	146	34	ma	ma	PROPN
admet-352	146	35	,	,	PUNCT
admet-352	146	36	z.	z.	PROPN
admet-352	146	37	zou	zou	PROPN
admet-352	146	38	,	,	PUNCT
admet-352	146	39	a.	a.	PROPN
admet-352	146	40	jemal	jemal	PROPN
admet-352	146	41	.	.	PUNCT
admet-352	147	1	ca	can	AUX
admet-352	147	2	cancer	cancer	PROPN
admet-352	147	3	j.	j.	PROPN
admet-352	147	4	clin	clin	PROPN
admet-352	147	5	.	.	PUNCT
admet-352	148	1	64(1	64(1	NUM
admet-352	148	2	)	)	PUNCT
admet-352	148	3	(	(	PUNCT
admet-352	148	4	2014	2014	NUM
admet-352	148	5	)	)	PUNCT
admet-352	148	6	9	9	NUM
admet-352	148	7	-	-	SYM
admet-352	148	8	29	29	NUM
admet-352	148	9	.	.	PUNCT
admet-352	149	1	[	[	X
admet-352	149	2	2	2	NUM
admet-352	149	3	]	]	X
admet-352	149	4	n.	n.	NOUN
admet-352	149	5	lindeman	lindeman	NOUN
admet-352	149	6	,	,	PUNCT
admet-352	149	7	p.	p.	PROPN
admet-352	149	8	cagle	cagle	PROPN
admet-352	149	9	,	,	PUNCT
admet-352	149	10	m.b	m.b	PROPN
admet-352	149	11	.	.	PROPN
admet-352	149	12	beasley	beasley	PROPN
admet-352	149	13	et	et	PROPN
admet-352	149	14	al	al	PROPN
admet-352	149	15	.	.	PROPN
admet-352	149	16	arch	arch	PROPN
admet-352	149	17	.	.	PUNCT
admet-352	150	1	pathol	pathol	NOUN
admet-352	150	2	.	.	PUNCT
admet-352	151	1	lab	lab	AUX
admet-352	151	2	.	.	PUNCT
admet-352	151	3	med	med	PROPN
admet-352	151	4	.	.	PUNCT
admet-352	152	1	137(6	137(6	NUM
admet-352	152	2	)	)	PUNCT
admet-352	152	3	(	(	PUNCT
admet-352	152	4	2013	2013	NUM
admet-352	152	5	)	)	PUNCT
admet-352	152	6	828–860	828–860	NUM
admet-352	152	7	.	.	PUNCT
admet-352	153	1	[	[	X
admet-352	153	2	3	3	X
admet-352	153	3	]	]	X
admet-352	153	4	t.j	t.j	PROPN
admet-352	153	5	.	.	PROPN
admet-352	153	6	lynch	lynch	PROPN
admet-352	153	7	,	,	PUNCT
admet-352	153	8	d.w	d.w	PROPN
admet-352	153	9	.	.	PROPN
admet-352	153	10	bell	bell	PROPN
admet-352	153	11	,	,	PUNCT
admet-352	153	12	r.	r.	PROPN
admet-352	153	13	sordella	sordella	PROPN
admet-352	153	14	,	,	PUNCT
admet-352	153	15	et	et	PROPN
admet-352	153	16	al	al	PROPN
admet-352	153	17	.	.	PUNCT
admet-352	153	18	n.	n.	PROPN
admet-352	153	19	engl	engl	PROPN
admet-352	153	20	.	.	PUNCT
admet-352	154	1	j.	j.	PROPN
admet-352	154	2	med	med	PROPN
admet-352	154	3	.	.	PUNCT
admet-352	155	1	350(21	350(21	NUM
admet-352	155	2	)	)	PUNCT
admet-352	155	3	(	(	PUNCT
admet-352	155	4	2004	2004	NUM
admet-352	155	5	)	)	PUNCT
admet-352	155	6	2129	2129	NUM
admet-352	155	7	-	-	SYM
admet-352	155	8	2139	2139	NUM
admet-352	155	9	.	.	PUNCT
admet-352	156	1	[	[	X
admet-352	156	2	4	4	NUM
admet-352	156	3	]	]	X
admet-352	156	4	e.l	e.l	PROPN
admet-352	156	5	.	.	PROPN
admet-352	156	6	kwak	kwak	PROPN
admet-352	156	7	,	,	PUNCT
admet-352	156	8	y.j	y.j	PROPN
admet-352	156	9	.	.	PROPN
admet-352	156	10	bang	bang	PROPN
admet-352	156	11	,	,	PUNCT
admet-352	156	12	d.r	d.r	PROPN
admet-352	156	13	.	.	PROPN
admet-352	156	14	camidge	camidge	PROPN
admet-352	156	15	,	,	PUNCT
admet-352	156	16	et	et	PROPN
admet-352	156	17	al	al	PROPN
admet-352	156	18	.	.	PUNCT
admet-352	156	19	n.	n.	PROPN
admet-352	156	20	engl	engl	PROPN
admet-352	156	21	.	.	PUNCT
admet-352	157	1	j.	j.	PROPN
admet-352	157	2	med	med	PROPN
admet-352	157	3	.	.	PUNCT
admet-352	158	1	363(18	363(18	NUM
admet-352	158	2	)	)	PUNCT
admet-352	158	3	(	(	PUNCT
admet-352	158	4	2010	2010	NUM
admet-352	158	5	)	)	PUNCT
admet-352	158	6	1693	1693	NUM
admet-352	158	7	-	-	SYM
admet-352	158	8	1703	1703	NUM
admet-352	158	9	.	.	PUNCT
admet-352	159	1	[	[	X
admet-352	159	2	5	5	NUM
admet-352	159	3	]	]	PUNCT
admet-352	159	4	r.	r.	PROPN
admet-352	159	5	rosell	rosell	PROPN
admet-352	159	6	,	,	PUNCT
admet-352	159	7	e.	e.	PROPN
admet-352	159	8	carcereny	carcereny	PROPN
admet-352	159	9	,	,	PUNCT
admet-352	159	10	r.	r.	PROPN
admet-352	159	11	gervais	gervais	PROPN
admet-352	159	12	,	,	PUNCT
admet-352	159	13	et	et	PROPN
admet-352	159	14	al	al	PROPN
admet-352	159	15	.	.	PUNCT
admet-352	160	1	lancet	lancet	PROPN
admet-352	160	2	oncol	oncol	PROPN
admet-352	160	3	.	.	PUNCT
admet-352	161	1	13(3	13(3	NUM
admet-352	161	2	)	)	PUNCT
admet-352	161	3	(	(	PUNCT
admet-352	161	4	2012	2012	NUM
admet-352	161	5	)	)	PUNCT
admet-352	162	1	239–246	239–246	NUM
admet-352	162	2	.	.	PUNCT
admet-352	163	1	[	[	X
admet-352	163	2	6	6	NUM
admet-352	163	3	]	]	PUNCT
admet-352	163	4	f.-y	f.-y	NOUN
admet-352	163	5	.	.	PUNCT
admet-352	164	1	niu	niu	PROPN
admet-352	164	2	,	,	PUNCT
admet-352	164	3	y.-l.wu	y.-l.wu	PROPN
admet-352	164	4	.	.	PUNCT
admet-352	164	5	exp	exp	PROPN
admet-352	164	6	.	.	PUNCT
admet-352	164	7	hematol	hematol	NOUN
admet-352	164	8	.	.	PUNCT
admet-352	165	1	oncol	oncol	ADJ
admet-352	165	2	.	.	PUNCT
admet-352	166	1	3(1	3(1	NUM
admet-352	166	2	)	)	PUNCT
admet-352	166	3	(	(	PUNCT
admet-352	166	4	2014	2014	NUM
admet-352	166	5	)	)	PUNCT
admet-352	167	1	2	2	NUM
admet-352	167	2	.	.	PUNCT
admet-352	168	1	[	[	X
admet-352	168	2	7	7	X
admet-352	168	3	]	]	X
admet-352	168	4	n.b	n.b	PROPN
admet-352	168	5	.	.	PROPN
admet-352	168	6	leighl	leighl	PROPN
admet-352	168	7	,	,	PUNCT
admet-352	168	8	n.	n.	PROPN
admet-352	168	9	rekhtman	rekhtman	PROPN
admet-352	168	10	,	,	PUNCT
admet-352	168	11	w.a	w.a	PROPN
admet-352	168	12	.	.	PROPN
admet-352	168	13	biermann	biermann	PROPN
admet-352	168	14	,	,	PUNCT
admet-352	168	15	et	et	PROPN
admet-352	168	16	al	al	PROPN
admet-352	168	17	.	.	PUNCT
admet-352	169	1	j.	j.	PROPN
admet-352	169	2	clin	clin	PROPN
admet-352	169	3	.	.	PUNCT
admet-352	170	1	oncol	oncol	ADJ
admet-352	170	2	.	.	PUNCT
admet-352	171	1	32(32	32(32	NUM
admet-352	171	2	)	)	PUNCT
admet-352	171	3	(	(	PUNCT
admet-352	171	4	2014	2014	NUM
admet-352	171	5	)	)	PUNCT
admet-352	171	6	3673	3673	NUM
admet-352	171	7	.	.	PUNCT
admet-352	172	1	[	[	X
admet-352	172	2	8	8	NUM
admet-352	172	3	]	]	PUNCT
admet-352	172	4	a.	a.	NOUN
admet-352	172	5	chi	chi	PROPN
admet-352	172	6	,	,	PUNCT
admet-352	172	7	s.	s.	PROPN
admet-352	172	8	remick	remick	PROPN
admet-352	172	9	,	,	PUNCT
admet-352	172	10	w.	w.	PROPN
admet-352	172	11	tse	tse	PROPN
admet-352	172	12	.	.	PROPN
admet-352	172	13	biomark	biomark	PROPN
admet-352	172	14	.	.	PUNCT
admet-352	173	1	res	re	NOUN
admet-352	173	2	.	.	PROPN
admet-352	173	3	1(1	1(1	NUM
admet-352	173	4	)	)	PUNCT
admet-352	173	5	(	(	PUNCT
admet-352	173	6	2013	2013	NUM
admet-352	173	7	)	)	PUNCT
admet-352	173	8	2	2	NUM
admet-352	173	9	.	.	PUNCT
admet-352	174	1	[	[	X
admet-352	174	2	9	9	NUM
admet-352	174	3	]	]	X
admet-352	174	4	c.k	c.k	PROPN
admet-352	174	5	.	.	PROPN
admet-352	174	6	lee	lee	PROPN
admet-352	174	7	,	,	PUNCT
admet-352	174	8	y.-l	y.-l	PROPN
admet-352	174	9	.	.	PUNCT
admet-352	175	1	wu	wu	PROPN
admet-352	175	2	,	,	PUNCT
admet-352	175	3	p.n	p.n	PROPN
admet-352	175	4	.	.	PROPN
admet-352	175	5	ding	ding	PROPN
admet-352	175	6	,	,	PUNCT
admet-352	175	7	et	et	PROPN
admet-352	175	8	al	al	PROPN
admet-352	175	9	.	.	PUNCT
admet-352	176	1	j.	j.	PROPN
admet-352	176	2	clin	clin	PROPN
admet-352	176	3	.	.	PUNCT
admet-352	177	1	oncol	oncol	ADJ
admet-352	177	2	.	.	PUNCT
admet-352	178	1	33(17	33(17	NUM
admet-352	178	2	)	)	PUNCT
admet-352	178	3	(	(	PUNCT
admet-352	178	4	2015	2015	NUM
admet-352	178	5	)	)	PUNCT
admet-352	178	6	1958–1965	1958–1965	NUM
admet-352	178	7	.	.	PUNCT
admet-352	179	1	[	[	X
admet-352	179	2	10	10	NUM
admet-352	179	3	]	]	X
admet-352	179	4	a.o	a.o	PROPN
admet-352	179	5	.	.	PROPN
admet-352	179	6	walter	walter	PROPN
admet-352	179	7	,	,	PUNCT
admet-352	179	8	r.t	r.t	PROPN
admet-352	179	9	.	.	PROPN
admet-352	179	10	sjin	sjin	PROPN
admet-352	179	11	,	,	PUNCT
admet-352	179	12	h.j	h.j	PROPN
admet-352	179	13	.	.	PROPN
admet-352	179	14	haringsma	haringsma	PROPN
admet-352	179	15	,	,	PUNCT
admet-352	179	16	et	et	PROPN
admet-352	179	17	al	al	PROPN
admet-352	179	18	.	.	PUNCT
admet-352	179	19	cancer	cancer	NOUN
admet-352	179	20	discov	discov	PROPN
admet-352	179	21	.	.	PUNCT
admet-352	180	1	3(12	3(12	NUM
admet-352	180	2	)	)	PUNCT
admet-352	180	3	(	(	PUNCT
admet-352	180	4	2013	2013	NUM
admet-352	180	5	)	)	PUNCT
admet-352	180	6	1404–1415	1404–1415	NUM
admet-352	180	7	.	.	PUNCT
admet-352	181	1	[	[	X
admet-352	181	2	11	11	NUM
admet-352	181	3	]	]	X
admet-352	181	4	d.a	d.a	PROPN
admet-352	181	5	.	.	PROPN
admet-352	181	6	cross	cross	PROPN
admet-352	181	7	,	,	PUNCT
admet-352	181	8	s.e	s.e	PROPN
admet-352	181	9	.	.	PROPN
admet-352	181	10	ashton	ashton	PROPN
admet-352	181	11	,	,	PUNCT
admet-352	181	12	s.	s.	PROPN
admet-352	181	13	ghiorghiu	ghiorghiu	PROPN
admet-352	181	14	,	,	PUNCT
admet-352	181	15	et	et	PROPN
admet-352	181	16	al	al	PROPN
admet-352	181	17	.	.	PUNCT
admet-352	181	18	cancer	cancer	NOUN
admet-352	181	19	discov	discov	PROPN
admet-352	181	20	.	.	PUNCT
admet-352	182	1	4(9	4(9	NUM
admet-352	182	2	)	)	PUNCT
admet-352	183	1	(	(	PUNCT
admet-352	183	2	2014	2014	NUM
admet-352	183	3	)	)	PUNCT
admet-352	183	4	1046–1061	1046–1061	NUM
admet-352	183	5	.	.	PUNCT
admet-352	184	1	[	[	X
admet-352	184	2	12	12	NUM
admet-352	184	3	]	]	PUNCT
admet-352	184	4	s.	s.	PROPN
admet-352	184	5	kobayashi	kobayashi	PROPN
admet-352	184	6	,	,	PUNCT
admet-352	184	7	t.j	t.j	PROPN
admet-352	184	8	.	.	PROPN
admet-352	184	9	boggon	boggon	PROPN
admet-352	184	10	,	,	PUNCT
admet-352	184	11	t.	t.	PROPN
admet-352	184	12	dayaram	dayaram	PROPN
admet-352	184	13	,	,	PUNCT
admet-352	184	14	et	et	PROPN
admet-352	184	15	al	al	PROPN
admet-352	184	16	.	.	PUNCT
admet-352	184	17	n.	n.	PROPN
admet-352	184	18	engl	engl	PROPN
admet-352	184	19	.	.	PUNCT
admet-352	185	1	j.	j.	PROPN
admet-352	185	2	med	med	PROPN
admet-352	185	3	.	.	PUNCT
admet-352	186	1	352	352	NUM
admet-352	186	2	(	(	PUNCT
admet-352	186	3	2005	2005	NUM
admet-352	186	4	)	)	PUNCT
admet-352	187	1	786–792	786–792	NUM
admet-352	187	2	.	.	PUNCT
admet-352	188	1	[	[	X
admet-352	188	2	13	13	NUM
admet-352	188	3	]	]	X
admet-352	188	4	j.a	j.a	PROPN
admet-352	188	5	.	.	PROPN
admet-352	188	6	engelman	engelman	PROPN
admet-352	188	7	,	,	PUNCT
admet-352	188	8	k.	k.	PROPN
admet-352	188	9	zejnullahu	zejnullahu	PROPN
admet-352	188	10	,	,	PUNCT
admet-352	188	11	t.	t.	PROPN
admet-352	188	12	mitsudomi	mitsudomi	PROPN
admet-352	188	13	,	,	PUNCT
admet-352	188	14	et	et	PROPN
admet-352	188	15	al	al	PROPN
admet-352	188	16	.	.	PROPN
admet-352	188	17	science	science	PROPN
admet-352	188	18	316	316	NUM
admet-352	188	19	(	(	PUNCT
admet-352	188	20	2007	2007	NUM
admet-352	188	21	)	)	PUNCT
admet-352	188	22	1039–1043	1039–1043	NUM
admet-352	188	23	.	.	PUNCT
admet-352	189	1	[	[	X
admet-352	189	2	14	14	NUM
admet-352	189	3	]	]	PUNCT
admet-352	189	4	k.	k.	PROPN
admet-352	189	5	takezawa	takezawa	PROPN
admet-352	189	6	,	,	PUNCT
admet-352	189	7	v.	v.	ADP
admet-352	189	8	pirazzoli	pirazzoli	NOUN
admet-352	189	9	,	,	PUNCT
admet-352	189	10	m.e	m.e	PROPN
admet-352	189	11	.	.	PROPN
admet-352	189	12	arcila	arcila	PROPN
admet-352	189	13	,	,	PUNCT
admet-352	189	14	et	et	PROPN
admet-352	189	15	al	al	PROPN
admet-352	189	16	.	.	PUNCT
admet-352	189	17	cancer	cancer	NOUN
admet-352	189	18	discov	discov	NOUN
admet-352	189	19	.	.	PUNCT
admet-352	190	1	2	2	NUM
admet-352	190	2	(	(	PUNCT
admet-352	190	3	2012	2012	NUM
admet-352	190	4	)	)	PUNCT
admet-352	191	1	922–933	922–933	NUM
admet-352	191	2	.	.	PUNCT
admet-352	192	1	[	[	X
admet-352	192	2	15	15	NUM
admet-352	192	3	]	]	X
admet-352	192	4	t.m	t.m	PROPN
admet-352	192	5	.	.	PROPN
admet-352	192	6	kim	kim	PROPN
admet-352	192	7	,	,	PUNCT
admet-352	192	8	a.	a.	NOUN
admet-352	192	9	song	song	NOUN
admet-352	192	10	,	,	PUNCT
admet-352	192	11	d.-w	d.-w	PROPN
admet-352	192	12	.	.	PUNCT
admet-352	193	1	kim	kim	PROPN
admet-352	193	2	,	,	PUNCT
admet-352	193	3	et	et	PROPN
admet-352	193	4	al	al	PROPN
admet-352	193	5	.	.	PUNCT
admet-352	194	1	j.	j.	PROPN
admet-352	194	2	thorac	thorac	PROPN
admet-352	194	3	.	.	PUNCT
admet-352	195	1	oncol	oncol	ADJ
admet-352	195	2	.	.	PUNCT
admet-352	196	1	10	10	NUM
admet-352	196	2	(	(	PUNCT
admet-352	196	3	2015	2015	NUM
admet-352	196	4	)	)	PUNCT
admet-352	196	5	1736–1744	1736–1744	NUM
admet-352	196	6	.	.	PUNCT
admet-352	197	1	[	[	X
admet-352	197	2	16	16	NUM
admet-352	197	3	]	]	X
admet-352	197	4	p.a	p.a	PROPN
admet-352	197	5	.	.	PROPN
admet-352	197	6	jänne	jänne	PROPN
admet-352	197	7	,	,	PUNCT
admet-352	197	8	j.c	j.c	PROPN
admet-352	197	9	.	.	PROPN
admet-352	197	10	yang	yang	PROPN
admet-352	197	11	,	,	PUNCT
admet-352	197	12	d.w	d.w	PROPN
admet-352	197	13	.	.	PUNCT
admet-352	198	1	kim	kim	PROPN
admet-352	198	2	,	,	PUNCT
admet-352	198	3	et	et	PROPN
admet-352	198	4	al	al	PROPN
admet-352	198	5	.	.	PUNCT
admet-352	198	6	n.	n.	PROPN
admet-352	198	7	engl	engl	PROPN
admet-352	198	8	.	.	PUNCT
admet-352	199	1	j.	j.	PROPN
admet-352	199	2	med	med	PROPN
admet-352	199	3	.	.	PUNCT
admet-352	200	1	372(18	372(18	NUM
admet-352	200	2	)	)	PUNCT
admet-352	200	3	(	(	PUNCT
admet-352	200	4	2015	2015	NUM
admet-352	200	5	)	)	PUNCT
admet-352	200	6	1689	1689	NUM
admet-352	200	7	.	.	PUNCT
admet-352	201	1	[	[	X
admet-352	201	2	17	17	NUM
admet-352	201	3	]	]	X
admet-352	201	4	s.s	s.s	PROPN
admet-352	201	5	.	.	PROPN
admet-352	201	6	ramalingam	ramalingam	PROPN
admet-352	201	7	,	,	PUNCT
admet-352	201	8	j.	j.	PROPN
admet-352	201	9	yang	yang	PROPN
admet-352	201	10	,	,	PUNCT
admet-352	201	11	c.	c.	PROPN
admet-352	201	12	lee	lee	PROPN
admet-352	201	13	,	,	PUNCT
admet-352	201	14	et	et	PROPN
admet-352	201	15	al	al	PROPN
admet-352	201	16	.	.	PUNCT
admet-352	201	17	j.	j.	PROPN
admet-352	201	18	thoracic	thoracic	PROPN
admet-352	201	19	.	.	PUNCT
admet-352	202	1	oncol	oncol	ADJ
admet-352	202	2	.	.	PUNCT
admet-352	203	1	10(9_suppl	10(9_suppl	NUM
admet-352	203	2	2	2	NUM
admet-352	203	3	)	)	PUNCT
admet-352	203	4	(	(	PUNCT
admet-352	203	5	2015	2015	NUM
admet-352	203	6	)	)	PUNCT
admet-352	204	1	s319	s319	PROPN
admet-352	204	2	.	.	PUNCT
admet-352	205	1	[	[	X
admet-352	205	2	18	18	NUM
admet-352	205	3	]	]	X
admet-352	205	4	c.a	c.a	PROPN
admet-352	205	5	.	.	PROPN
admet-352	205	6	eberlein	eberlein	PROPN
admet-352	205	7	,	,	PUNCT
admet-352	205	8	d.	d.	PROPN
admet-352	205	9	stetson	stetson	PROPN
admet-352	205	10	,	,	PUNCT
admet-352	205	11	a.a	a.a	PROPN
admet-352	205	12	.	.	PROPN
admet-352	205	13	markovets	markovet	NOUN
admet-352	205	14	,	,	PUNCT
admet-352	205	15	et	et	PROPN
admet-352	205	16	al	al	PROPN
admet-352	205	17	.	.	PUNCT
admet-352	205	18	cancer	cancer	NOUN
admet-352	205	19	res	re	NOUN
admet-352	205	20	.	.	PUNCT
admet-352	206	1	75(12	75(12	NUM
admet-352	206	2	)	)	PUNCT
admet-352	206	3	(	(	PUNCT
admet-352	206	4	2015	2015	NUM
admet-352	206	5	)	)	PUNCT
admet-352	206	6	2489–500	2489–500	NOUN
admet-352	206	7	.	.	PUNCT
admet-352	207	1	[	[	X
admet-352	207	2	19	19	NUM
admet-352	207	3	]	]	X
admet-352	207	4	a.o	a.o	PROPN
admet-352	207	5	.	.	PROPN
admet-352	207	6	walter	walter	PROPN
admet-352	207	7	,	,	PUNCT
admet-352	207	8	r.t	r.t	PROPN
admet-352	207	9	.	.	PROPN
admet-352	207	10	sjin	sjin	PROPN
admet-352	207	11	,	,	PUNCT
admet-352	207	12	h.j	h.j	PROPN
admet-352	207	13	.	.	PROPN
admet-352	207	14	haringsma	haringsma	PROPN
admet-352	207	15	,	,	PUNCT
admet-352	207	16	et	et	PROPN
admet-352	207	17	al	al	PROPN
admet-352	207	18	.	.	PUNCT
admet-352	207	19	cancer	cancer	NOUN
admet-352	207	20	discov	discov	NOUN
admet-352	207	21	.	.	PUNCT
admet-352	208	1	3	3	NUM
admet-352	208	2	(	(	PUNCT
admet-352	208	3	2013	2013	NUM
admet-352	208	4	)	)	PUNCT
admet-352	208	5	1404	1404	NUM
admet-352	208	6	-	-	SYM
admet-352	208	7	1415	1415	NUM
admet-352	208	8	.	.	PUNCT
admet-352	209	1	[	[	X
admet-352	209	2	20	20	NUM
admet-352	209	3	]	]	X
admet-352	209	4	l.v	l.v	PROPN
admet-352	209	5	.	.	PROPN
admet-352	209	6	sequist	sequist	PROPN
admet-352	209	7	,	,	PUNCT
admet-352	209	8	j.c	j.c	PROPN
admet-352	209	9	.	.	PROPN
admet-352	209	10	soria	soria	PROPN
admet-352	209	11	,	,	PUNCT
admet-352	209	12	j.w	j.w	PROPN
admet-352	209	13	.	.	PROPN
admet-352	209	14	goldman	goldman	PROPN
admet-352	209	15	,	,	PUNCT
admet-352	209	16	et	et	PROPN
admet-352	209	17	al	al	PROPN
admet-352	209	18	.	.	PUNCT
admet-352	209	19	n.	n.	PROPN
admet-352	209	20	engl	engl	PROPN
admet-352	209	21	.	.	PUNCT
admet-352	210	1	j.	j.	PROPN
admet-352	210	2	med	med	PROPN
admet-352	210	3	.	.	PUNCT
admet-352	211	1	372(18	372(18	NUM
admet-352	211	2	)	)	PUNCT
admet-352	211	3	(	(	PUNCT
admet-352	211	4	2015	2015	NUM
admet-352	211	5	)	)	PUNCT
admet-352	211	6	1700–1709	1700–1709	NUM
admet-352	211	7	.	.	PUNCT
admet-352	212	1	[	[	X
admet-352	212	2	21	21	NUM
admet-352	212	3	]	]	X
admet-352	212	4	j.c	j.c	PROPN
admet-352	212	5	.	.	PROPN
admet-352	212	6	soria	soria	PROPN
admet-352	212	7	,	,	PUNCT
admet-352	212	8	d.r	d.r	PROPN
admet-352	212	9	.	.	PROPN
admet-352	212	10	camidge	camidge	NOUN
admet-352	212	11	.	.	PUNCT
admet-352	213	1	n.	n.	PROPN
admet-352	213	2	engl	engl	PROPN
admet-352	213	3	.	.	PUNCT
admet-352	214	1	j.	j.	PROPN
admet-352	214	2	med	med	PROPN
admet-352	214	3	.	.	PUNCT
admet-352	215	1	374	374	NUM
admet-352	215	2	(	(	PUNCT
admet-352	215	3	2016	2016	NUM
admet-352	215	4	)	)	PUNCT
admet-352	215	5	2296	2296	NUM
admet-352	215	6	-	-	SYM
admet-352	215	7	2297	2297	NUM
admet-352	215	8	[	[	X
admet-352	215	9	22	22	NUM
admet-352	215	10	]	]	X
admet-352	215	11	fda	fda	PROPN
admet-352	215	12	briefing	briefing	PROPN
admet-352	215	13	document	document	NOUN
admet-352	215	14	oncologic	oncologic	ADJ
admet-352	215	15	drugs	drug	NOUN
admet-352	215	16	advisory	advisory	ADJ
admet-352	215	17	committee	committee	NOUN
admet-352	215	18	meeting	meeting	NOUN
admet-352	215	19	.	.	PUNCT
admet-352	216	1	nda	nda	PROPN
admet-352	216	2	208542	208542	NUM
admet-352	216	3	rociletinib	rociletinib	NOUN
admet-352	216	4	.	.	PUNCT
admet-352	217	1	april	april	PROPN
admet-352	217	2	12	12	NUM
admet-352	217	3	,	,	PUNCT
admet-352	217	4	2016	2016	NUM
admet-352	218	1	[	[	X
admet-352	218	2	23	23	NUM
admet-352	218	3	]	]	PUNCT
admet-352	218	4	k.-o	k.-o	NOUN
admet-352	218	5	.	.	PUNCT
admet-352	219	1	lee	lee	PROPN
admet-352	219	2	,	,	PUNCT
admet-352	219	3	m.y	m.y	PROPN
admet-352	219	4	.	.	PROPN
admet-352	219	5	cha	cha	PROPN
admet-352	219	6	,	,	PUNCT
admet-352	219	7	m.	m.	PROPN
admet-352	219	8	kim	kim	PROPN
admet-352	219	9	,	,	PUNCT
admet-352	219	10	et	et	PROPN
admet-352	219	11	al	al	PROPN
admet-352	219	12	.	.	PUNCT
admet-352	219	13	cancer	cancer	NOUN
admet-352	219	14	res	re	NOUN
admet-352	219	15	.	.	PUNCT
admet-352	220	1	74(19	74(19	NUM
admet-352	220	2	)	)	PUNCT
admet-352	220	3	(	(	PUNCT
admet-352	220	4	2014	2014	NUM
admet-352	220	5	)	)	PUNCT
admet-352	220	6	lb-100	lb-100	PROPN
admet-352	220	7	.	.	PUNCT
admet-352	221	1	[	[	X
admet-352	221	2	24	24	NUM
admet-352	221	3	]	]	X
admet-352	221	4	h.	h.	PROPN
admet-352	221	5	sakagami	sakagami	PROPN
admet-352	221	6	,	,	PUNCT
admet-352	221	7	s.	s.	PROPN
admet-352	221	8	konagai	konagai	PROPN
admet-352	221	9	,	,	PUNCT
admet-352	221	10	h.	h.	PROPN
admet-352	221	11	yamamoto	yamamoto	PROPN
admet-352	221	12	,	,	PUNCT
admet-352	221	13	et	et	PROPN
admet-352	221	14	al	al	PROPN
admet-352	221	15	.	.	PUNCT
admet-352	222	1	cancer	cancer	NOUN
admet-352	222	2	res	re	NOUN
admet-352	222	3	.	.	PUNCT
admet-352	223	1	74(19	74(19	NUM
admet-352	223	2	supplement	supplement	NOUN
admet-352	223	3	)	)	PUNCT
admet-352	223	4	(	(	PUNCT
admet-352	223	5	2014	2014	NUM
admet-352	223	6	)	)	PUNCT
admet-352	223	7	1728	1728	NUM
admet-352	223	8	.	.	PUNCT
admet-352	224	1	[	[	X
admet-352	224	2	25	25	NUM
admet-352	224	3	]	]	X
admet-352	224	4	y.	y.	PROPN
admet-352	224	5	jia	jia	PROPN
admet-352	224	6	,	,	PUNCT
admet-352	224	7	j.	j.	PROPN
admet-352	224	8	juarez	juarez	PROPN
admet-352	224	9	,	,	PUNCT
admet-352	224	10	m.	m.	NOUN
admet-352	224	11	manuia	manuia	PROPN
admet-352	224	12	,	,	PUNCT
admet-352	224	13	g.	g.	PROPN
admet-352	224	14	lelais	lelais	PROPN
admet-352	224	15	,	,	PUNCT
admet-352	224	16	et	et	PROPN
admet-352	224	17	al	al	PROPN
admet-352	224	18	.	.	PUNCT
admet-352	224	19	cancer	cancer	NOUN
admet-352	224	20	res	re	NOUN
admet-352	224	21	.	.	PUNCT
admet-352	225	1	74(19	74(19	NUM
admet-352	225	2	supplement	supplement	NOUN
admet-352	225	3	)	)	PUNCT
admet-352	225	4	(	(	PUNCT
admet-352	225	5	2014	2014	NUM
admet-352	225	6	)	)	PUNCT
admet-352	225	7	1734	1734	NUM
admet-352	225	8	.	.	PUNCT
admet-352	226	1	[	[	X
admet-352	226	2	26	26	NUM
admet-352	226	3	]	]	X
admet-352	226	4	s.	s.	PROPN
admet-352	226	5	kasibhatla	kasibhatla	PROPN
admet-352	226	6	,	,	PUNCT
admet-352	226	7	j.	j.	PROPN
admet-352	226	8	li	li	PROPN
admet-352	226	9	,	,	PUNCT
admet-352	226	10	c.	c.	PROPN
admet-352	226	11	tompkins	tompkins	PROPN
admet-352	226	12	,	,	PUNCT
admet-352	226	13	et	et	PROPN
admet-352	226	14	al	al	PROPN
admet-352	226	15	.	.	PUNCT
admet-352	226	16	cancer	cancer	NOUN
admet-352	226	17	res	re	NOUN
admet-352	226	18	.	.	PUNCT
admet-352	227	1	74(19	74(19	NUM
admet-352	227	2	supplement	supplement	NOUN
admet-352	227	3	)	)	PUNCT
admet-352	227	4	(	(	PUNCT
admet-352	227	5	2014	2014	NUM
admet-352	227	6	)	)	PUNCT
admet-352	227	7	1733	1733	NUM
admet-352	227	8	.	.	PUNCT
admet-352	228	1	[	[	X
admet-352	228	2	27	27	NUM
admet-352	228	3	]	]	X
admet-352	228	4	y.	y.	PROPN
admet-352	228	5	goto	goto	PROPN
admet-352	228	6	,	,	PUNCT
admet-352	228	7	h.	h.	PROPN
admet-352	228	8	nokihara	nokihara	PROPN
admet-352	228	9	,	,	PUNCT
admet-352	228	10	h.	h.	PROPN
admet-352	228	11	murakami	murakami	PROPN
admet-352	228	12	,	,	PUNCT
admet-352	228	13	et	et	PROPN
admet-352	228	14	al	al	PROPN
admet-352	228	15	.	.	PROPN
admet-352	228	16	asco	asco	PROPN
admet-352	228	17	meet	meet	VERB
admet-352	228	18	abstr	abstr	PROPN
admet-352	228	19	.	.	PUNCT
admet-352	229	1	33(15_suppl	33(15_suppl	NUM
admet-352	229	2	)	)	PUNCT
admet-352	229	3	(	(	PUNCT
admet-352	229	4	2015	2015	NUM
admet-352	229	5	)	)	PUNCT
admet-352	229	6	8014	8014	NUM
admet-352	229	7	.	.	PUNCT
admet-352	230	1	[	[	X
admet-352	230	2	28	28	NUM
admet-352	230	3	]	]	X
admet-352	230	4	g.	g.	PROPN
admet-352	230	5	lelais	lelais	PROPN
admet-352	230	6	,	,	PUNCT
admet-352	230	7	r.	r.	PROPN
admet-352	230	8	epple	epple	PROPN
admet-352	230	9	,	,	PUNCT
admet-352	230	10	p.-y	p.-y	NOUN
admet-352	230	11	.	.	PUNCT
admet-352	231	1	michellys	michellys	PROPN
admet-352	231	2	,	,	PUNCT
admet-352	231	3	et	et	PROPN
admet-352	231	4	al	al	PROPN
admet-352	231	5	.	.	PUNCT
admet-352	231	6	cancer	cancer	NOUN
admet-352	231	7	res	re	NOUN
admet-352	231	8	.	.	PUNCT
admet-352	232	1	75(15	75(15	NUM
admet-352	232	2	supplement	supplement	NOUN
admet-352	232	3	)	)	PUNCT
admet-352	232	4	(	(	PUNCT
admet-352	232	5	2015	2015	NUM
admet-352	232	6	)	)	PUNCT
admet-352	232	7	2585	2585	NUM
admet-352	232	8	.	.	PUNCT
admet-352	233	1	[	[	X
admet-352	233	2	29	29	NUM
admet-352	233	3	]	]	PUNCT
admet-352	233	4	study	study	NOUN
admet-352	233	5	for	for	ADP
admet-352	233	6	patients	patient	NOUN
admet-352	233	7	with	with	ADP
admet-352	233	8	nsclc	nsclc	NOUN
admet-352	233	9	egfr	egfr	NOUN
admet-352	233	10	mutations	mutation	NOUN
admet-352	233	11	(	(	PUNCT
admet-352	233	12	del	del	PROPN
admet-352	233	13	19	19	NUM
admet-352	233	14	or	or	CCONJ
admet-352	233	15	l858r	l858r	NOUN
admet-352	233	16	+	+	PROPN
admet-352	233	17	/t790	/t790	NOUN
admet-352	233	18	m	m	NOUN
admet-352	233	19	)	)	PUNCT
admet-352	233	20	.	.	PUNCT
admet-352	234	1	clinicaltrials.gov	clinicaltrials.gov	NOUN
admet-352	234	2	identifier	identifier	NOUN
admet-352	234	3	:	:	PUNCT
admet-352	234	4	nct02349633	nct02349633	ADJ
admet-352	234	5	.	.	PUNCT
admet-352	235	1	[	[	X
admet-352	235	2	30	30	NUM
admet-352	235	3	]	]	PUNCT
admet-352	235	4	a.	a.	NOUN
admet-352	235	5	ullrich	ullrich	PROPN
admet-352	235	6	,	,	PUNCT
admet-352	235	7	j.	j.	PROPN
admet-352	235	8	schlessinger	schlessinger	PROPN
admet-352	235	9	.	.	PUNCT
admet-352	236	1	cell	cell	PROPN
admet-352	236	2	61(2	61(2	PROPN
admet-352	236	3	)	)	PUNCT
admet-352	236	4	(	(	PUNCT
admet-352	236	5	1990	1990	NUM
admet-352	236	6	)	)	PUNCT
admet-352	237	1	203–212	203–212	NUM
admet-352	237	2	.	.	PUNCT
admet-352	238	1	[	[	X
admet-352	238	2	31	31	NUM
admet-352	238	3	]	]	PUNCT
admet-352	238	4	d.	d.	PROPN
admet-352	238	5	camidge	camidge	PROPN
admet-352	238	6	,	,	PUNCT
admet-352	238	7	s.	s.	PROPN
admet-352	238	8	kono	kono	PROPN
admet-352	238	9	,	,	PUNCT
admet-352	238	10	a.	a.	NOUN
admet-352	238	11	flacco	flacco	PROPN
admet-352	238	12	,	,	PUNCT
admet-352	238	13	et	et	PROPN
admet-352	238	14	al	al	PROPN
admet-352	238	15	.	.	PUNCT
admet-352	238	16	clin	clin	PROPN
admet-352	238	17	.	.	PUNCT
admet-352	239	1	cancer	cancer	NOUN
admet-352	239	2	res	re	NOUN
admet-352	239	3	.	.	PUNCT
admet-352	240	1	16(22	16(22	NUM
admet-352	240	2	)	)	PUNCT
admet-352	240	3	(	(	PUNCT
admet-352	240	4	2010	2010	NUM
admet-352	240	5	)	)	PUNCT
admet-352	240	6	5581–5590	5581–5590	NUM
admet-352	240	7	.	.	PUNCT
admet-352	241	1	[	[	X
admet-352	241	2	32	32	NUM
admet-352	241	3	]	]	X
admet-352	241	4	j.j	j.j	PROPN
admet-352	241	5	.	.	PROPN
admet-352	241	6	cui	cui	PROPN
admet-352	241	7	,	,	PUNCT
admet-352	241	8	m.	m.	NOUN
admet-352	241	9	tran	tran	PROPN
admet-352	241	10	-	-	NOUN
admet-352	241	11	dubé	dubé	NOUN
admet-352	241	12	,	,	PUNCT
admet-352	241	13	h.	h.	PROPN
admet-352	241	14	shen	shen	PROPN
admet-352	241	15	,	,	PUNCT
admet-352	241	16	et	et	PROPN
admet-352	241	17	al	al	PROPN
admet-352	241	18	.	.	PUNCT
admet-352	241	19	j.	j.	PROPN
admet-352	241	20	med	med	PROPN
admet-352	241	21	.	.	PROPN
admet-352	241	22	chem	chem	PROPN
admet-352	241	23	.	.	PUNCT
admet-352	242	1	54(18	54(18	NUM
admet-352	242	2	)	)	PUNCT
admet-352	242	3	(	(	PUNCT
admet-352	242	4	2011	2011	NUM
admet-352	242	5	)	)	PUNCT
admet-352	242	6	6342–6363	6342–6363	NUM
admet-352	242	7	.	.	PUNCT
admet-352	243	1	[	[	X
admet-352	243	2	33	33	NUM
admet-352	243	3	]	]	X
admet-352	243	4	a.t	a.t	PROPN
admet-352	243	5	.	.	PROPN
admet-352	243	6	shaw	shaw	PROPN
admet-352	243	7	,	,	PUNCT
admet-352	243	8	s.h	s.h	PROPN
admet-352	243	9	.	.	PROPN
admet-352	243	10	ou	ou	PROPN
admet-352	243	11	,	,	PUNCT
admet-352	243	12	y.j	y.j	PROPN
admet-352	243	13	.	.	PROPN
admet-352	243	14	bang	bang	PROPN
admet-352	243	15	,	,	PUNCT
admet-352	243	16	et	et	PROPN
admet-352	243	17	al	al	PROPN
admet-352	243	18	.	.	PUNCT
admet-352	243	19	n.	n.	PROPN
admet-352	243	20	engl	engl	PROPN
admet-352	243	21	.	.	PUNCT
admet-352	244	1	j.	j.	PROPN
admet-352	244	2	med	med	PROPN
admet-352	244	3	.	.	PUNCT
admet-352	245	1	371(21	371(21	NUM
admet-352	245	2	)	)	PUNCT
admet-352	245	3	(	(	PUNCT
admet-352	245	4	2014	2014	NUM
admet-352	245	5	)	)	PUNCT
admet-352	245	6	1963–1971	1963–1971	NUM
admet-352	245	7	.	.	PUNCT
admet-352	246	1	[	[	X
admet-352	246	2	34	34	NUM
admet-352	246	3	]	]	X
admet-352	246	4	b.j	b.j	PROPN
admet-352	246	5	.	.	PROPN
admet-352	246	6	solomon	solomon	PROPN
admet-352	246	7	,	,	PUNCT
admet-352	246	8	t.	t.	PROPN
admet-352	246	9	mok	mok	PROPN
admet-352	246	10	,	,	PUNCT
admet-352	246	11	d.w	d.w	PROPN
admet-352	246	12	.	.	PUNCT
admet-352	247	1	kim	kim	PROPN
admet-352	247	2	,	,	PUNCT
admet-352	247	3	et	et	PROPN
admet-352	247	4	al	al	PROPN
admet-352	247	5	.	.	PUNCT
admet-352	247	6	n.	n.	PROPN
admet-352	247	7	engl	engl	PROPN
admet-352	247	8	.	.	PUNCT
admet-352	248	1	j.	j.	PROPN
admet-352	248	2	med	med	PROPN
admet-352	248	3	.	.	PUNCT
admet-352	249	1	371(23	371(23	NOUN
admet-352	249	2	)	)	PUNCT
admet-352	249	3	(	(	PUNCT
admet-352	249	4	2014	2014	NUM
admet-352	249	5	)	)	PUNCT
admet-352	249	6	2167–2177	2167–2177	NUM
admet-352	249	7	.	.	PUNCT
admet-352	250	1	[	[	X
admet-352	250	2	35	35	NUM
admet-352	250	3	]	]	PUNCT
admet-352	250	4	e.	e.	PROPN
admet-352	250	5	felip	felip	PROPN
admet-352	250	6	,	,	PUNCT
admet-352	250	7	s.	s.	PROPN
admet-352	250	8	orlov	orlov	PROPN
admet-352	250	9	,	,	PUNCT
admet-352	250	10	k.	k.	PROPN
admet-352	250	11	park	park	PROPN
admet-352	250	12	,	,	PUNCT
admet-352	250	13	et	et	PROPN
admet-352	250	14	al	al	PROPN
admet-352	250	15	.	.	PUNCT
admet-352	251	1	j.	j.	PROPN
admet-352	251	2	clin	clin	PROPN
admet-352	251	3	.	.	PUNCT
admet-352	252	1	oncol	oncol	ADJ
admet-352	252	2	.	.	PUNCT
admet-352	253	1	33	33	NUM
admet-352	253	2	(	(	PUNCT
admet-352	253	3	2015	2015	NUM
admet-352	253	4	)	)	PUNCT
admet-352	253	5	8060	8060	NUM
admet-352	253	6	.	.	PUNCT
admet-352	254	1	[	[	X
admet-352	254	2	36	36	NUM
admet-352	254	3	]	]	X
admet-352	254	4	j.m	j.m	PROPN
admet-352	254	5	.	.	PROPN
admet-352	254	6	heuckmann	heuckmann	PROPN
admet-352	254	7	,	,	PUNCT
admet-352	254	8	h.	h.	PROPN
admet-352	254	9	balke	balke	PROPN
admet-352	254	10	-	-	PUNCT
admet-352	254	11	want	want	PROPN
admet-352	254	12	,	,	PUNCT
admet-352	254	13	f.	f.	PROPN
admet-352	254	14	malchers	malchers	PROPN
admet-352	254	15	,	,	PUNCT
admet-352	254	16	et	et	PROPN
admet-352	254	17	al	al	PROPN
admet-352	254	18	.	.	PUNCT
admet-352	254	19	clin	clin	PROPN
admet-352	254	20	.	.	PUNCT
admet-352	255	1	cancer	cancer	NOUN
admet-352	255	2	res	re	NOUN
admet-352	255	3	.	.	PUNCT
admet-352	256	1	18(17	18(17	NUM
admet-352	256	2	)	)	PUNCT
admet-352	256	3	(	(	PUNCT
admet-352	256	4	2012	2012	NUM
admet-352	256	5	)	)	PUNCT
admet-352	256	6	4682–4690	4682–4690	NOUN
admet-352	256	7	.	.	PUNCT
admet-352	257	1	[	[	X
admet-352	257	2	37	37	NUM
admet-352	257	3	]	]	X
admet-352	257	4	y.l	y.l	PROPN
admet-352	257	5	.	.	PROPN
admet-352	257	6	choi	choi	PROPN
admet-352	257	7	,	,	PUNCT
admet-352	257	8	m.	m.	NOUN
admet-352	257	9	soda	soda	NOUN
admet-352	257	10	,	,	PUNCT
admet-352	257	11	y.	y.	PROPN
admet-352	257	12	yamashita	yamashita	PROPN
admet-352	257	13	,	,	PUNCT
admet-352	257	14	et	et	PROPN
admet-352	257	15	al	al	PROPN
admet-352	257	16	.	.	PUNCT
admet-352	257	17	n.	n.	PROPN
admet-352	257	18	engl	engl	PROPN
admet-352	257	19	.	.	PUNCT
admet-352	258	1	j.	j.	PROPN
admet-352	258	2	med	med	PROPN
admet-352	258	3	.	.	PUNCT
admet-352	259	1	363(18	363(18	NUM
admet-352	259	2	)	)	PUNCT
admet-352	259	3	(	(	PUNCT
admet-352	259	4	2010	2010	NUM
admet-352	259	5	)	)	PUNCT
admet-352	259	6	1734–1739	1734–1739	NUM
admet-352	259	7	.	.	PUNCT
admet-352	260	1	[	[	X
admet-352	260	2	38	38	NUM
admet-352	260	3	]	]	PUNCT
admet-352	260	4	r.	r.	PROPN
admet-352	260	5	katayama	katayama	PROPN
admet-352	260	6	,	,	PUNCT
admet-352	260	7	a.t	a.t	PROPN
admet-352	260	8	.	.	PROPN
admet-352	260	9	shaw	shaw	PROPN
admet-352	260	10	,	,	PUNCT
admet-352	260	11	t.m	t.m	PROPN
admet-352	260	12	.	.	PROPN
admet-352	260	13	khan	khan	PROPN
admet-352	260	14	et	et	PROPN
admet-352	260	15	al	al	PROPN
admet-352	260	16	.	.	PUNCT
admet-352	260	17	sci	sci	PROPN
admet-352	260	18	.	.	PROPN
admet-352	260	19	transl	transl	PROPN
admet-352	260	20	.	.	PUNCT
admet-352	261	1	med	med	PROPN
admet-352	261	2	.	.	PUNCT
admet-352	262	1	4(120	4(120	NUM
admet-352	262	2	)	)	PUNCT
admet-352	262	3	(	(	PUNCT
admet-352	262	4	2012	2012	NUM
admet-352	262	5	)	)	PUNCT
admet-352	262	6	120ra17	120ra17	NOUN
admet-352	262	7	.	.	PUNCT
admet-352	263	1	[	[	X
admet-352	263	2	39	39	NUM
admet-352	263	3	]	]	PUNCT
admet-352	263	4	j.	j.	PROPN
admet-352	263	5	gainor	gainor	PROPN
admet-352	263	6	,	,	PUNCT
admet-352	263	7	s.h	s.h	PROPN
admet-352	263	8	.	.	PROPN
admet-352	263	9	ou	ou	PROPN
admet-352	263	10	,	,	PUNCT
admet-352	263	11	j.	j.	PROPN
admet-352	263	12	logan	logan	PROPN
admet-352	263	13	,	,	PUNCT
admet-352	263	14	l.f	l.f	PROPN
admet-352	263	15	.	.	PROPN
admet-352	263	16	borges	borges	PROPN
admet-352	263	17	,	,	PUNCT
admet-352	263	18	a.t	a.t	PROPN
admet-352	263	19	.	.	PROPN
admet-352	263	20	sahw	sahw	PROPN
admet-352	263	21	.	.	PUNCT
admet-352	264	1	j.	j.	PROPN
admet-352	264	2	thorac	thorac	PROPN
admet-352	264	3	.	.	PUNCT
admet-352	265	1	oncol	oncol	ADJ
admet-352	265	2	.	.	PUNCT
admet-352	266	1	8(12	8(12	NUM
admet-352	266	2	)	)	PUNCT
admet-352	266	3	(	(	PUNCT
admet-352	266	4	2013	2013	NUM
admet-352	266	5	)	)	PUNCT
admet-352	266	6	1570–1573	1570–1573	NUM
admet-352	266	7	.	.	PUNCT
admet-352	267	1	[	[	X
admet-352	267	2	40	40	NUM
admet-352	267	3	]	]	X
admet-352	267	4	d.	d.	PROPN
admet-352	267	5	costa	costa	PROPN
admet-352	267	6	,	,	PUNCT
admet-352	267	7	a.t	a.t	PROPN
admet-352	267	8	.	.	PROPN
admet-352	267	9	shaw	shaw	PROPN
admet-352	267	10	,	,	PUNCT
admet-352	267	11	s.h	s.h	PROPN
admet-352	267	12	.	.	PROPN
admet-352	267	13	ou	ou	PROPN
admet-352	267	14	,	,	PUNCT
admet-352	267	15	et	et	PROPN
admet-352	267	16	al	al	PROPN
admet-352	267	17	.	.	PUNCT
admet-352	268	1	j.	j.	PROPN
admet-352	268	2	clin	clin	PROPN
admet-352	268	3	.	.	PUNCT
admet-352	269	1	oncol	oncol	ADJ
admet-352	269	2	.	.	PUNCT
admet-352	270	1	33(17	33(17	NUM
admet-352	270	2	)	)	PUNCT
admet-352	270	3	(	(	PUNCT
admet-352	270	4	2015	2015	NUM
admet-352	270	5	)	)	PUNCT
admet-352	270	6	1881–88	1881–88	NUM
admet-352	270	7	.	.	PUNCT
admet-352	271	1	[	[	X
admet-352	271	2	41	41	NUM
admet-352	271	3	]	]	PUNCT
admet-352	271	4	r.	r.	PROPN
admet-352	271	5	doebele	doebele	PROPN
admet-352	271	6	,	,	PUNCT
admet-352	271	7	a.	a.	PROPN
admet-352	271	8	pilling	pilling	NOUN
admet-352	271	9	,	,	PUNCT
admet-352	271	10	d.	d.	PROPN
admet-352	271	11	aisner	aisner	PROPN
admet-352	271	12	,	,	PUNCT
admet-352	271	13	et	et	PROPN
admet-352	271	14	al	al	PROPN
admet-352	271	15	.	.	PUNCT
admet-352	272	1	clin	clin	PROPN
admet-352	272	2	.	.	PUNCT
admet-352	273	1	cancer	cancer	NOUN
admet-352	273	2	res	re	NOUN
admet-352	273	3	.	.	PUNCT
admet-352	274	1	18(5	18(5	NUM
admet-352	274	2	)	)	PUNCT
admet-352	274	3	(	(	PUNCT
admet-352	274	4	2012	2012	NUM
admet-352	274	5	)	)	PUNCT
admet-352	275	1	1472–1482	1472–1482	NUM
admet-352	275	2	.	.	PUNCT
admet-352	275	3	m.	m.	PROPN
admet-352	275	4	mendez	mendez	PROPN
admet-352	275	5	et	et	PROPN
admet-352	275	6	al	al	PROPN
admet-352	275	7	.	.	PROPN
admet-352	275	8	admet	admet	PROPN
admet-352	275	9	&	&	CCONJ
admet-352	275	10	dmpk	dmpk	PROPN
admet-352	275	11	5(1	5(1	NUM
admet-352	275	12	)	)	PUNCT
admet-352	275	13	(	(	PUNCT
admet-352	275	14	2017	2017	NUM
admet-352	275	15	)	)	PUNCT
admet-352	275	16	1	1	NUM
admet-352	275	17	-	-	SYM
admet-352	275	18	8	8	NUM
admet-352	275	19	8	8	NUM
admet-352	275	20	[	[	X
admet-352	275	21	42	42	NUM
admet-352	275	22	]	]	PUNCT
admet-352	275	23	l.	l.	PROPN
admet-352	275	24	friboulet	friboulet	PROPN
admet-352	275	25	,	,	PUNCT
admet-352	275	26	n.	n.	PROPN
admet-352	275	27	li	li	PROPN
admet-352	275	28	,	,	PUNCT
admet-352	275	29	r.	r.	PROPN
admet-352	275	30	katayama	katayama	PROPN
admet-352	275	31	,	,	PUNCT
admet-352	275	32	et	et	PROPN
admet-352	275	33	al	al	PROPN
admet-352	275	34	.	.	PUNCT
admet-352	275	35	cancer	cancer	NOUN
admet-352	275	36	discov	discov	PROPN
admet-352	275	37	.	.	PUNCT
admet-352	276	1	4(6	4(6	NUM
admet-352	276	2	)	)	PUNCT
admet-352	277	1	(	(	PUNCT
admet-352	277	2	2014	2014	NUM
admet-352	277	3	)	)	PUNCT
admet-352	277	4	662–673	662–673	NUM
admet-352	277	5	.	.	PUNCT
admet-352	278	1	[	[	X
admet-352	278	2	43	43	NUM
admet-352	278	3	]	]	PUNCT
admet-352	278	4	k.	k.	PROPN
admet-352	278	5	kinoshita	kinoshita	PROPN
admet-352	278	6	,	,	PUNCT
admet-352	278	7	k.	k.	PROPN
admet-352	278	8	asoh	asoh	PROPN
admet-352	278	9	,	,	PUNCT
admet-352	278	10	n.	n.	PROPN
admet-352	278	11	furuchi	furuchi	PROPN
admet-352	278	12	,	,	PUNCT
admet-352	278	13	et	et	PROPN
admet-352	278	14	al	al	PROPN
admet-352	278	15	bioorg	bioorg	PROPN
admet-352	278	16	.	.	PUNCT
admet-352	279	1	med	med	PROPN
admet-352	279	2	.	.	PUNCT
admet-352	279	3	chem	chem	PROPN
admet-352	279	4	.	.	PUNCT
admet-352	280	1	20(3	20(3	NOUN
admet-352	280	2	)	)	PUNCT
admet-352	280	3	(	(	PUNCT
admet-352	280	4	2012	2012	NUM
admet-352	280	5	)	)	PUNCT
admet-352	280	6	1271–1280	1271–1280	NUM
admet-352	280	7	.	.	PUNCT
admet-352	281	1	[	[	X
admet-352	281	2	44	44	NUM
admet-352	281	3	]	]	PUNCT
admet-352	281	4	t.	t.	PROPN
admet-352	281	5	seto	seto	PROPN
admet-352	281	6	,	,	PUNCT
admet-352	281	7	k.	k.	PROPN
admet-352	281	8	kiura	kiura	PROPN
admet-352	281	9	,	,	PUNCT
admet-352	281	10	m.	m.	NOUN
admet-352	281	11	nishio	nishio	PROPN
admet-352	281	12	,	,	PUNCT
admet-352	281	13	et	et	PROPN
admet-352	281	14	al	al	PROPN
admet-352	281	15	.	.	PUNCT
admet-352	282	1	lancet	lancet	PROPN
admet-352	282	2	oncol	oncol	PROPN
admet-352	282	3	.	.	PUNCT
admet-352	283	1	14(7	14(7	NUM
admet-352	283	2	)	)	PUNCT
admet-352	283	3	(	(	PUNCT
admet-352	283	4	2013	2013	NUM
admet-352	283	5	)	)	PUNCT
admet-352	283	6	590	590	NUM
admet-352	283	7	-	-	SYM
admet-352	283	8	598	598	NUM
admet-352	283	9	.	.	PUNCT
admet-352	284	1	[	[	X
admet-352	284	2	45	45	NUM
admet-352	284	3	]	]	PUNCT
admet-352	284	4	t.	t.	PROPN
admet-352	284	5	tamura	tamura	PROPN
admet-352	284	6	,	,	PUNCT
admet-352	284	7	t.	t.	PROPN
admet-352	284	8	seto	seto	PROPN
admet-352	284	9	,	,	PUNCT
admet-352	284	10	k.	k.	PROPN
admet-352	284	11	nakagawa	nakagawa	PROPN
admet-352	284	12	,	,	PUNCT
admet-352	284	13	et	et	PROPN
admet-352	284	14	al	al	PROPN
admet-352	284	15	.	.	PROPN
admet-352	284	16	radiat	radiat	PROPN
admet-352	284	17	.	.	PUNCT
admet-352	285	1	oncol	oncol	ADJ
admet-352	285	2	.	.	PUNCT
admet-352	286	1	90	90	NUM
admet-352	286	2	(	(	PUNCT
admet-352	286	3	2014	2014	NUM
admet-352	286	4	)	)	PUNCT
admet-352	286	5	s6	s6	PROPN
admet-352	286	6	.	.	PUNCT
admet-352	287	1	[	[	X
admet-352	287	2	46	46	NUM
admet-352	287	3	]	]	X
admet-352	287	4	s.	s.	PROPN
admet-352	287	5	gadgeel	gadgeel	PROPN
admet-352	287	6	,	,	PUNCT
admet-352	287	7	l.	l.	PROPN
admet-352	287	8	gandhi	gandhi	PROPN
admet-352	287	9	,	,	PUNCT
admet-352	287	10	g.	g.	PROPN
admet-352	287	11	riely	riely	PROPN
admet-352	287	12	,	,	PUNCT
admet-352	287	13	et	et	PROPN
admet-352	287	14	al	al	PROPN
admet-352	287	15	.	.	PUNCT
admet-352	288	1	lancet	lancet	PROPN
admet-352	288	2	oncol	oncol	PROPN
admet-352	288	3	.	.	PUNCT
admet-352	289	1	15	15	NUM
admet-352	289	2	(	(	PUNCT
admet-352	289	3	2014	2014	NUM
admet-352	289	4	)	)	PUNCT
admet-352	289	5	1119–1128	1119–1128	NOUN
admet-352	289	6	.	.	PUNCT
admet-352	290	1	[	[	X
admet-352	290	2	47	47	NUM
admet-352	290	3	]	]	PUNCT
admet-352	290	4	j.	j.	PROPN
admet-352	290	5	wu	wu	PROPN
admet-352	290	6	,	,	PUNCT
admet-352	290	7	j.	j.	PROPN
admet-352	290	8	savooji	savooji	PROPN
admet-352	290	9	,	,	PUNCT
admet-352	290	10	d.	d.	PROPN
admet-352	290	11	liu	liu	PROPN
admet-352	290	12	.	.	PUNCT
admet-352	291	1	j.	j.	PROPN
admet-352	291	2	hematol	hematol	PROPN
admet-352	291	3	.	.	PUNCT
admet-352	292	1	oncol	oncol	ADJ
admet-352	292	2	.	.	PUNCT
admet-352	293	1	9	9	NUM
admet-352	293	2	(	(	PUNCT
admet-352	293	3	2016	2016	NUM
admet-352	293	4	)	)	PUNCT
admet-352	293	5	9	9	NUM
admet-352	293	6	.	.	PUNCT
admet-352	294	1	[	[	X
admet-352	294	2	48	48	NUM
admet-352	294	3	]	]	PUNCT
admet-352	294	4	r.	r.	PROPN
admet-352	294	5	squillace	squillace	PROPN
admet-352	294	6	,	,	PUNCT
admet-352	294	7	r.	r.	PROPN
admet-352	294	8	anjum	anjum	PROPN
admet-352	294	9	,	,	PUNCT
admet-352	294	10	d.	d.	PROPN
admet-352	294	11	miller	miller	PROPN
admet-352	294	12	,	,	PUNCT
admet-352	294	13	et	et	PROPN
admet-352	294	14	al	al	PROPN
admet-352	294	15	.	.	PUNCT
admet-352	294	16	cancer	cancer	NOUN
admet-352	294	17	res	re	NOUN
admet-352	294	18	.	.	PUNCT
admet-352	294	19	73(8	73(8	NOUN
admet-352	294	20	suppl	suppl	NOUN
admet-352	294	21	)	)	PUNCT
admet-352	294	22	(	(	PUNCT
admet-352	294	23	2013	2013	NUM
admet-352	294	24	)	)	PUNCT
admet-352	294	25	abstract	abstract	ADJ
admet-352	294	26	#	#	SYM
admet-352	294	27	5655	5655	NUM
admet-352	294	28	.	.	PUNCT
admet-352	295	1	[	[	X
admet-352	295	2	49	49	X
admet-352	295	3	]	]	PUNCT
admet-352	295	4	v.	v.	ADP
admet-352	295	5	rivera	rivera	PROPN
admet-352	295	6	,	,	PUNCT
admet-352	295	7	f.	f.	PROPN
admet-352	295	8	wang	wang	PROPN
admet-352	295	9	,	,	PUNCT
admet-352	295	10	r.	r.	PROPN
admet-352	295	11	anjum	anjum	PROPN
admet-352	295	12	,	,	PUNCT
admet-352	295	13	et	et	PROPN
admet-352	295	14	al	al	PROPN
admet-352	295	15	.	.	PUNCT
admet-352	295	16	cancer	cancer	NOUN
admet-352	295	17	res	re	NOUN
admet-352	295	18	.	.	PUNCT
admet-352	296	1	72(8	72(8	NUM
admet-352	296	2	suppl	suppl	ADJ
admet-352	296	3	)	)	PUNCT
admet-352	296	4	(	(	PUNCT
admet-352	296	5	2012	2012	NUM
admet-352	296	6	)	)	PUNCT
admet-352	296	7	abstract	abstract	ADJ
admet-352	296	8	#	#	SYM
admet-352	296	9	1794	1794	NUM
admet-352	296	10	.	.	PUNCT
admet-352	297	1	[	[	X
admet-352	297	2	50	50	NUM
admet-352	297	3	]	]	PUNCT
admet-352	297	4	d.	d.	PROPN
admet-352	297	5	camidge	camidge	PROPN
admet-352	297	6	,	,	PUNCT
admet-352	297	7	l.	l.	PROPN
admet-352	297	8	bazhenova	bazhenova	PROPN
admet-352	297	9	,	,	PUNCT
admet-352	297	10	r.	r.	PROPN
admet-352	297	11	salgia	salgia	PROPN
admet-352	297	12	,	,	PUNCT
admet-352	297	13	et	et	PROPN
admet-352	297	14	al	al	PROPN
admet-352	297	15	.	.	PUNCT
admet-352	298	1	j.	j.	PROPN
admet-352	298	2	clin	clin	PROPN
admet-352	298	3	.	.	PUNCT
admet-352	299	1	oncol	oncol	ADJ
admet-352	299	2	.	.	PUNCT
admet-352	300	1	33	33	NUM
admet-352	300	2	(	(	PUNCT
admet-352	300	3	2015	2015	NUM
admet-352	300	4	)	)	PUNCT
admet-352	300	5	8062	8062	NUM
admet-352	300	6	.	.	PUNCT
admet-352	301	1	[	[	X
admet-352	301	2	51	51	NUM
admet-352	301	3	]	]	PUNCT
admet-352	301	4	a.	a.	NOUN
admet-352	301	5	vaishnavi	vaishnavi	PROPN
admet-352	301	6	,	,	PUNCT
admet-352	301	7	m.	m.	PROPN
admet-352	301	8	capelletti	capelletti	PROPN
admet-352	301	9	,	,	PUNCT
admet-352	301	10	a.t	a.t	PROPN
admet-352	301	11	.	.	PROPN
admet-352	301	12	le	le	PROPN
admet-352	301	13	,	,	PUNCT
admet-352	301	14	et	et	PROPN
admet-352	301	15	al	al	PROPN
admet-352	301	16	.	.	PUNCT
admet-352	302	1	nat	nat	PROPN
admet-352	302	2	.	.	PUNCT
admet-352	303	1	med	med	PROPN
admet-352	303	2	.	.	PUNCT
admet-352	304	1	19(11	19(11	NUM
admet-352	304	2	)	)	PUNCT
admet-352	304	3	(	(	PUNCT
admet-352	304	4	2013	2013	NUM
admet-352	304	5	)	)	PUNCT
admet-352	304	6	1469–1472	1469–1472	NUM
admet-352	304	7	.	.	PUNCT
admet-352	305	1	[	[	X
admet-352	305	2	52	52	NUM
admet-352	305	3	]	]	PUNCT
admet-352	305	4	e.	e.	PROPN
admet-352	305	5	ardini	ardini	PROPN
admet-352	305	6	,	,	PUNCT
admet-352	305	7	m.	m.	PROPN
admet-352	305	8	menichincheri	menichincheri	PROPN
admet-352	305	9	,	,	PUNCT
admet-352	305	10	c.	c.	PROPN
admet-352	305	11	de	de	X
admet-352	305	12	ponti	ponti	PROPN
admet-352	305	13	,	,	PUNCT
admet-352	305	14	et	et	PROPN
admet-352	305	15	al	al	PROPN
admet-352	305	16	.	.	PROPN
admet-352	305	17	mol	mol	PROPN
admet-352	305	18	.	.	PUNCT
admet-352	305	19	cancer	cancer	NOUN
admet-352	305	20	ther	ther	PROPN
admet-352	305	21	.	.	PUNCT
admet-352	306	1	8(12	8(12	NUM
admet-352	306	2	suppl	suppl	ADJ
admet-352	306	3	)	)	PUNCT
admet-352	306	4	(	(	PUNCT
admet-352	306	5	2009	2009	NUM
admet-352	306	6	)	)	PUNCT
admet-352	306	7	a243	a243	PROPN
admet-352	306	8	.	.	PUNCT
admet-352	307	1	[	[	X
admet-352	307	2	53	53	NUM
admet-352	307	3	]	]	PUNCT
admet-352	307	4	m.	m.	NOUN
admet-352	307	5	patel	patel	PROPN
admet-352	307	6	,	,	PUNCT
admet-352	307	7	t.	t.	PROPN
admet-352	307	8	bauer	bauer	PROPN
admet-352	307	9	,	,	PUNCT
admet-352	307	10	s.	s.	PROPN
admet-352	307	11	liu	liu	PROPN
admet-352	307	12	,	,	PUNCT
admet-352	307	13	et	et	PROPN
admet-352	307	14	al	al	PROPN
admet-352	307	15	.	.	PUNCT
admet-352	308	1	j.	j.	PROPN
admet-352	308	2	clin	clin	PROPN
admet-352	308	3	.	.	PUNCT
admet-352	309	1	oncol	oncol	ADJ
admet-352	309	2	.	.	PUNCT
admet-352	310	1	33	33	NUM
admet-352	310	2	(	(	PUNCT
admet-352	310	3	2015	2015	NUM
admet-352	310	4	)	)	PUNCT
admet-352	310	5	2596	2596	NUM
admet-352	310	6	.	.	PUNCT
admet-352	311	1	[	[	X
admet-352	311	2	54	54	NUM
admet-352	311	3	]	]	PUNCT
admet-352	311	4	t.	t.	PROPN
admet-352	311	5	johnson	johnson	PROPN
admet-352	311	6	,	,	PUNCT
admet-352	311	7	p.	p.	PROPN
admet-352	311	8	richardson	richardson	PROPN
admet-352	311	9	,	,	PUNCT
admet-352	311	10	s.	s.	PROPN
admet-352	311	11	bailey	bailey	PROPN
admet-352	311	12	,	,	PUNCT
admet-352	311	13	et	et	PROPN
admet-352	311	14	al	al	PROPN
admet-352	311	15	.	.	PUNCT
admet-352	312	1	j.	j.	PROPN
admet-352	312	2	med	med	PROPN
admet-352	312	3	.	.	PROPN
admet-352	312	4	chem	chem	PROPN
admet-352	312	5	.	.	PUNCT
admet-352	313	1	57(11	57(11	NUM
admet-352	313	2	)	)	PUNCT
admet-352	313	3	(	(	PUNCT
admet-352	313	4	2014	2014	NUM
admet-352	313	5	)	)	PUNCT
admet-352	313	6	4720–4744	4720–4744	NUM
admet-352	313	7	.	.	PUNCT
admet-352	314	1	[	[	X
admet-352	314	2	55	55	NUM
admet-352	314	3	]	]	PUNCT
admet-352	314	4	t.	t.	PROPN
admet-352	314	5	li	li	PROPN
admet-352	314	6	,	,	PUNCT
admet-352	314	7	p.	p.	PROPN
admet-352	314	8	lorusso	lorusso	PROPN
admet-352	314	9	,	,	PUNCT
admet-352	314	10	m.	m.	PROPN
admet-352	314	11	maitland	maitland	PROPN
admet-352	314	12	,	,	PUNCT
admet-352	314	13	et	et	PROPN
admet-352	314	14	al	al	PROPN
admet-352	314	15	.	.	PUNCT
admet-352	315	1	j.	j.	PROPN
admet-352	315	2	hematol	hematol	PROPN
admet-352	315	3	.	.	PUNCT
admet-352	316	1	oncol	oncol	ADJ
admet-352	316	2	.	.	PUNCT
admet-352	317	1	9	9	NUM
admet-352	317	2	(	(	PUNCT
admet-352	317	3	2016	2016	NUM
admet-352	317	4	)	)	PUNCT
admet-352	317	5	23	23	NUM
admet-352	317	6	.	.	PUNCT
admet-352	318	1	[	[	X
admet-352	318	2	56	56	NUM
admet-352	318	3	]	]	X
admet-352	318	4	c.	c.	PROPN
admet-352	318	5	lovly	lovly	PROPN
admet-352	318	6	,	,	PUNCT
admet-352	318	7	j.	j.	PROPN
admet-352	318	8	heuckmann	heuckmann	PROPN
admet-352	318	9	,	,	PUNCT
admet-352	318	10	e.	e.	PROPN
admet-352	318	11	de	de	PROPN
admet-352	318	12	stanchina	stanchina	PROPN
admet-352	318	13	,	,	PUNCT
admet-352	318	14	et	et	PROPN
admet-352	318	15	al	al	PROPN
admet-352	318	16	.	.	PUNCT
admet-352	318	17	cancer	cancer	NOUN
admet-352	318	18	res	re	NOUN
admet-352	318	19	.	.	PUNCT
admet-352	319	1	71(14	71(14	NOUN
admet-352	319	2	)	)	PUNCT
admet-352	319	3	(	(	PUNCT
admet-352	319	4	2011	2011	NUM
admet-352	319	5	)	)	PUNCT
admet-352	319	6	4920–4931	4920–4931	NUM
admet-352	319	7	.	.	PUNCT
admet-352	320	1	[	[	X
admet-352	320	2	57	57	NUM
admet-352	320	3	]	]	PUNCT
admet-352	320	4	m.	m.	NOUN
admet-352	320	5	cheng	cheng	PROPN
admet-352	320	6	,	,	PUNCT
admet-352	320	7	m.	m.	NOUN
admet-352	320	8	quail	quail	PROPN
admet-352	320	9	,	,	PUNCT
admet-352	320	10	d.	d.	PROPN
admet-352	320	11	girgrich	girgrich	PROPN
admet-352	320	12	,	,	PUNCT
admet-352	320	13	et	et	PROPN
admet-352	320	14	al	al	PROPN
admet-352	320	15	.	.	PROPN
admet-352	320	16	mol	mol	PROPN
admet-352	320	17	.	.	PUNCT
admet-352	320	18	cancer	cancer	NOUN
admet-352	320	19	ther	ther	PROPN
admet-352	320	20	.	.	PUNCT
admet-352	321	1	11	11	NUM
admet-352	321	2	(	(	PUNCT
admet-352	321	3	2012	2012	NUM
admet-352	321	4	)	)	PUNCT
admet-352	322	1	670–679	670–679	NUM
admet-352	322	2	.	.	PUNCT
admet-352	323	1	[	[	X
admet-352	323	2	58	58	NUM
admet-352	323	3	]	]	X
admet-352	323	4	i.	i.	PROPN
admet-352	323	5	sullivan	sullivan	PROPN
admet-352	323	6	,	,	PUNCT
admet-352	323	7	d.	d.	PROPN
admet-352	323	8	planchard	planchard	PROPN
admet-352	323	9	.	.	PUNCT
admet-352	324	1	ther	ther	INTJ
admet-352	324	2	.	.	PUNCT
admet-352	325	1	adv	adv	AUX
admet-352	325	2	.	.	PUNCT
admet-352	325	3	med	med	PROPN
admet-352	325	4	.	.	PUNCT
admet-352	325	5	oncol	oncol	PROPN
admet-352	325	6	.	.	PUNCT
admet-352	326	1	8(1	8(1	NOUN
admet-352	326	2	)	)	PUNCT
admet-352	326	3	(	(	PUNCT
admet-352	326	4	2016	2016	NUM
admet-352	326	5	)	)	PUNCT
admet-352	326	6	32–47	32–47	NUM
admet-352	326	7	.	.	PUNCT
admet-352	327	1	[	[	X
admet-352	327	2	59	59	NUM
admet-352	327	3	]	]	PUNCT
admet-352	327	4	l.	l.	PROPN
admet-352	327	5	sequist	sequist	PROPN
admet-352	327	6	,	,	PUNCT
admet-352	327	7	s.	s.	PROPN
admet-352	327	8	gettinger	gettinger	PROPN
admet-352	327	9	,	,	PUNCT
admet-352	327	10	n.	n.	NOUN
admet-352	327	11	sanzer	sanzer	NOUN
admet-352	327	12	,	,	PUNCT
admet-352	327	13	et	et	PROPN
admet-352	327	14	al	al	PROPN
admet-352	327	15	.	.	PUNCT
admet-352	328	1	j.	j.	PROPN
admet-352	328	2	clin	clin	PROPN
admet-352	328	3	.	.	PUNCT
admet-352	329	1	oncol	oncol	ADJ
admet-352	329	2	.	.	PUNCT
admet-352	330	1	28(33	28(33	NUM
admet-352	330	2	)	)	PUNCT
admet-352	330	3	(	(	PUNCT
admet-352	330	4	2010	2010	NUM
admet-352	330	5	)	)	PUNCT
admet-352	330	6	4953–4960	4953–4960	NUM
admet-352	330	7	.	.	PUNCT
admet-352	331	1	[	[	X
admet-352	331	2	60	60	NUM
admet-352	331	3	]	]	X
admet-352	331	4	e.	e.	PROPN
admet-352	331	5	normant	normant	PROPN
admet-352	331	6	,	,	PUNCT
admet-352	331	7	g.	g.	PROPN
admet-352	331	8	paez	paez	PROPN
admet-352	331	9	,	,	PUNCT
admet-352	331	10	k.	k.	PROPN
admet-352	331	11	west	west	PROPN
admet-352	331	12	,	,	PUNCT
admet-352	331	13	et	et	PROPN
admet-352	331	14	al	al	PROPN
admet-352	331	15	.	.	PUNCT
admet-352	332	1	oncogene	oncogene	PROPN
admet-352	332	2	30(22	30(22	PROPN
admet-352	332	3	)	)	PUNCT
admet-352	332	4	(	(	PUNCT
admet-352	332	5	2011	2011	NUM
admet-352	332	6	)	)	PUNCT
admet-352	332	7	2581–2586	2581–2586	NUM
admet-352	332	8	.	.	PUNCT
admet-352	333	1	[	[	X
admet-352	333	2	61	61	NUM
admet-352	333	3	]	]	PUNCT
admet-352	333	4	m.	m.	NOUN
admet-352	333	5	socinski	socinski	PROPN
admet-352	333	6	,	,	PUNCT
admet-352	333	7	j.	j.	PROPN
admet-352	333	8	goldman	goldman	PROPN
admet-352	333	9	,	,	PUNCT
admet-352	333	10	i.	i.	PROPN
admet-352	333	11	el	el	PROPN
admet-352	333	12	-	-	PROPN
admet-352	333	13	harary	harary	NOUN
admet-352	333	14	,	,	PUNCT
admet-352	333	15	et	et	PROPN
admet-352	333	16	al	al	PROPN
admet-352	333	17	.	.	PUNCT
admet-352	334	1	clin	clin	PROPN
admet-352	334	2	.	.	PUNCT
admet-352	335	1	cancer	cancer	NOUN
admet-352	335	2	res	re	NOUN
admet-352	335	3	.	.	PUNCT
admet-352	336	1	19(11	19(11	NUM
admet-352	336	2	)	)	PUNCT
admet-352	336	3	(	(	PUNCT
admet-352	336	4	2013	2013	NUM
admet-352	336	5	)	)	PUNCT
admet-352	336	6	3068–3077	3068–3077	NUM
admet-352	336	7	.	.	PUNCT
admet-352	337	1	©	©	PROPN
admet-352	337	2	2017	2017	NUM
admet-352	337	3	by	by	ADP
admet-352	337	4	the	the	DET
admet-352	337	5	authors	author	NOUN
admet-352	337	6	;	;	PUNCT
admet-352	337	7	licensee	licensee	PROPN
admet-352	337	8	iapc	iapc	PROPN
admet-352	337	9	,	,	PUNCT
admet-352	337	10	zagreb	zagreb	PROPN
admet-352	337	11	,	,	PUNCT
admet-352	337	12	croatia	croatia	PROPN
admet-352	337	13	.	.	PUNCT
admet-352	338	1	this	this	DET
admet-352	338	2	article	article	NOUN
admet-352	338	3	is	be	AUX
admet-352	338	4	an	an	DET
admet-352	338	5	open	open	ADJ
admet-352	338	6	-	-	PUNCT
admet-352	338	7	access	access	NOUN
admet-352	338	8	article	article	NOUN
admet-352	338	9	distributed	distribute	VERB
admet-352	338	10	under	under	ADP
admet-352	338	11	the	the	DET
admet-352	338	12	terms	term	NOUN
admet-352	338	13	and	and	CCONJ
admet-352	338	14	conditions	condition	NOUN
admet-352	338	15	of	of	ADP
admet-352	338	16	the	the	DET
admet-352	338	17	creative	creative	ADJ
admet-352	338	18	commons	common	NOUN
admet-352	338	19	attribution	attribution	NOUN
admet-352	338	20	license	license	NOUN
admet-352	338	21	(	(	PUNCT
admet-352	338	22	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN
admet-352	338	23	)	)	PUNCT
admet-352	338	24	.	.	PUNCT
admet-352	339	1	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN